
<html lang="en"     class="pb-page"  data-request-id="a3a788cf-2ef3-42c9-82ff-f08048f779ac"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-9;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b01336;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology" /></meta><meta name="dc.Creator" content="Marialuisa  Moccia" /></meta><meta name="dc.Creator" content="Brendan  Frett" /></meta><meta name="dc.Creator" content="Lingtian  Zhang" /></meta><meta name="dc.Creator" content="Naga Rajiv  Lakkaniga" /></meta><meta name="dc.Creator" content="David C.  Briggs" /></meta><meta name="dc.Creator" content="Rakhee  Chauhan" /></meta><meta name="dc.Creator" content="Annalisa  Brescia" /></meta><meta name="dc.Creator" content="Giorgia  Federico" /></meta><meta name="dc.Creator" content="Wei  Yan" /></meta><meta name="dc.Creator" content="Massimo  Santoro" /></meta><meta name="dc.Creator" content="Neil Q.  McDonald" /></meta><meta name="dc.Creator" content="Hong-yu  Li" /></meta><meta name="dc.Creator" content="Francesca  Carlomagno" /></meta><meta name="dc.Description" content="RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key in vivo metabolite of Pz-1 is its les..." /></meta><meta name="Description" content="RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key in vivo metabolite of Pz-1 is its les..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 16, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01336" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01336" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01336" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01336" /></link>
        
    
    

<title>Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01336" /></meta><meta property="og:title" content="Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0007.jpeg" /></meta><meta property="og:description" content="RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key in vivo metabolite of Pz-1 is its less active demethylated pyrazole analogue. Using bioisosteric substitution methods, here, we report the identification of NPA101.3, lacking the structural liability for demethylation. NPA101.3 showed a selective inhibitory profile and an inhibitory concentration 50 (IC50) of &lt;0.003 μM for both RET and VEGFR2. NPA101.3 inhibited phosphorylation of all tested RET oncoproteins as well as VEGFR2 and proliferation of cells transformed by RET. Oral administration of NPA101.3 (10 mg/kg/day) completely prevented formation of tumors induced by RET/C634Y-transformed cells, while it weakened, but did not abrogate, formation of tumors induced by a control oncogene (HRAS/G12V). The balanced synchronous inhibition of both RET and VEGFR2, as well the resistance to demethylation, renders NPA101.3 a potential clinical candidate for RET-driven cancers." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01336"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01336">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01336&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01336&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01336&amp;href=/doi/10.1021/acs.jmedchem.9b01336" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4506-4516</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01937" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01392" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Marialuisa Moccia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marialuisa Moccia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marialuisa++Moccia">Marialuisa Moccia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brendan Frett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brendan Frett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div><div class="loa-info-affiliations-info">Synactix Pharmaceuticals, Inc., Tucson, Arizona 85718, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brendan++Frett">Brendan Frett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lingtian Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lingtian Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lingtian++Zhang">Lingtian Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Naga Rajiv Lakkaniga</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naga Rajiv Lakkaniga</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naga+Rajiv++Lakkaniga">Naga Rajiv Lakkaniga</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8370-2224" title="Orcid link">http://orcid.org/0000-0001-8370-2224</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David C. Briggs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David C. Briggs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Signalling and Structural Biology Laboratory, The Francis Crick Institute, London NW1 1AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+C.++Briggs">David C. Briggs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rakhee Chauhan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rakhee Chauhan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Signalling and Structural Biology Laboratory, The Francis Crick Institute, London NW1 1AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rakhee++Chauhan">Rakhee Chauhan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Annalisa Brescia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Annalisa Brescia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Annalisa++Brescia">Annalisa Brescia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Giorgia Federico</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giorgia Federico</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giorgia++Federico">Giorgia Federico</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Yan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Yan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Yan">Wei Yan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Massimo Santoro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Massimo Santoro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Massimo++Santoro">Massimo Santoro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil Q. McDonald</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil Q. McDonald</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Signalling and Structural Biology Laboratory, The Francis Crick Institute, London NW1 1AT, U.K.</div><div class="loa-info-affiliations-info">Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, London WC1E 7HX, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil+Q.++McDonald">Neil Q. McDonald</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong-yu Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong-yu Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</div><div class="loa-info-affiliations-info">Synactix Pharmaceuticals, Inc., Tucson, Arizona 85718, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205. Phone: (501) 296-1154. Email: <a href="/cdn-cgi/l/email-protection#430b0f2a710336222e306d262736"><span class="__cf_email__" data-cfemail="743c381d4634011519075a111001">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong-yu++Li">Hong-yu Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9212-2010" title="Orcid link">http://orcid.org/0000-0001-9212-2010</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Francesca Carlomagno</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesca Carlomagno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</div><div class="loa-info-affiliations-info">Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, 80131 Napoli, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, via S. Pansini 5, 80131 Napoli, Italy. Phone: +390815455561. Fax: +390817462685. Email: <a href="/cdn-cgi/l/email-protection#335541525d50564050521d5052415f5c5e52545d5c73465d5a5d521d5a47"><span class="__cf_email__" data-cfemail="4e283c2f202d2b3d2d2f602d2f3c2221232f2920210e3b2027202f60273a">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Carlomagno">Francesca Carlomagno</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1483-4677" title="Orcid link">http://orcid.org/0000-0002-1483-4677</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01336&amp;href=/doi/10.1021%2Facs.jmedchem.9b01336" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4506–4516</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 16, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 August 2019</li><li><span class="item_label"><b>Published</b> online</span>16 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01336" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01336</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01336"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1631</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01336" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Marialuisa&quot;,&quot;last_name&quot;:&quot;Moccia&quot;},{&quot;first_name&quot;:&quot;Brendan&quot;,&quot;last_name&quot;:&quot;Frett&quot;},{&quot;first_name&quot;:&quot;Lingtian&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Naga&quot;,&quot;last_name&quot;:&quot;Rajiv Lakkaniga&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;C. Briggs&quot;},{&quot;first_name&quot;:&quot;Rakhee&quot;,&quot;last_name&quot;:&quot;Chauhan&quot;},{&quot;first_name&quot;:&quot;Annalisa&quot;,&quot;last_name&quot;:&quot;Brescia&quot;},{&quot;first_name&quot;:&quot;Giorgia&quot;,&quot;last_name&quot;:&quot;Federico&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Massimo&quot;,&quot;last_name&quot;:&quot;Santoro&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Q. McDonald&quot;},{&quot;first_name&quot;:&quot;Hong-yu&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Carlomagno&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;4506-4516&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01336&quot;},&quot;abstract&quot;:&quot;RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key in vivo metabolite of Pz-1 is its less active demethylated pyrazole analogue. Using bioisosteric substitution methods, here, we report the identification of NPA101.3, lacking the structural liability for demethylation. NPA101.3 showed a selective inhibitory profile and an inhibitory concentration 50 (IC50) of &lt;0.003 μM for both RET and VEGFR2. NPA101.3 inhibited phosphorylation of all tested RET oncoproteins as well as VEGFR2 and proliferation of cells transformed by RET. Oral administration of NPA101.3 (10 mg/kg/day) completely prevented formation of tumors induced by RET/C634Y-transformed cells, while it weakened, but did not abrogate, formation of tumors induced by a control oncogene (HRAS/G12V). The balanced synchronous inhibition of both RET and VEGFR2, as well the resistance to demethylation, renders NPA101.3 a potential clinical candidate for RE&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01336&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01336" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01336&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01336" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01336&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01336" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01336&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01336&amp;href=/doi/10.1021/acs.jmedchem.9b01336" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01336" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01336" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01336%26sid%3Dliteratum%253Aachs%26pmid%3D32298114%26genre%3Darticle%26aulast%3DMoccia%26date%3D2020%26atitle%3DBioisosteric%2BDiscovery%2Bof%2BNPA101.3%252C%2Ba%2BSecond-Generation%2BRET%252FVEGFR2%2BInhibitor%2BOptimized%2Bfor%2BSingle-Agent%2BPolypharmacology%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D9%26spage%3D4506%26epage%3D4516%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/jmcmar.2020.63.issue-9/20200514/jmcmar.2020.63.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key <i>in vivo</i> metabolite of Pz-1 is its less active demethylated pyrazole analogue. Using bioisosteric substitution methods, here, we report the identification of NPA101.3, lacking the structural liability for demethylation. NPA101.3 showed a selective inhibitory profile and an inhibitory concentration 50 (IC<sub>50</sub>) of <0.003 μM for both RET and VEGFR2. NPA101.3 inhibited phosphorylation of all tested RET oncoproteins as well as VEGFR2 and proliferation of cells transformed by RET. Oral administration of NPA101.3 (10 mg/kg/day) completely prevented formation of tumors induced by RET/C634Y-transformed cells, while it weakened, but did not abrogate, formation of tumors induced by a control oncogene (HRAS/G12V). The balanced synchronous inhibition of both RET and VEGFR2, as well the resistance to demethylation, renders NPA101.3 a potential clinical candidate for RET-driven cancers.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">RET (rearranged during transfection) is the receptor tyrosine kinase (RTK) for neurotrophic factors of the GDNF (glial cell line-derived neurotrophic factor) family.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In several human cancers, RET rearrangements lead to the formation of chimeric oncoproteins, containing the RET tyrosine kinase (TK) domain fused to the N-terminal region of heterologous proteins. These include papillary thyroid carcinoma (PTC),<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> medullary thyroid carcinoma (MTC),<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> lung adenocarcinoma,<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> chronic myeloproliferative disorders,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Spitz melanoma,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and colon,<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> breast,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and salivary duct<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> carcinomas. CCDC6 (coiled-coil domain containing 6)-RET rearrangement has also been found in EGFR (epidermal growth factor receptor) mutant lung adenocarcinoma patients who had progressed upon EGFR TKI treatment.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In addition, various types of germline point mutations activating the RET kinase are the causative event of hereditary MTC, in the frame of multiple endocrine neoplasia type 2 (MEN2A and MEN2B) syndromes. Somatic RET mutations, mostly RET/M918T, are commonly associated (∼50% of cases) to sporadic MTC.<a onclick="showRef(event, 'ref1 ref15'); return false;" href="javascript:void(0);" class="ref ref1 ref15">(1,15)</a> Finally, RET is overexpressed in several malignancies, including breast<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> and pancreatic<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> carcinoma.</div><div class="NLM_p">RET targeting with tyrosine kinase inhibitors (TKIs) has emerged as a promising molecular approach for the treatment of cancer.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Two TKIs, Vandetanib and Cabozantinib, were found to exhibit VEGFR2 (vascular endothelial growth factor receptor 2) and RET activity.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> These two drugs have been approved to treat MTC because of their capability to prolong progression-free survival.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> In addition, Sorafenib and Lenvatinib, two multikinase inhibitors with activity against RET, have been approved for the treatment of radioiodine-refractory differentiated thyroid cancer.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Novel TKIs, BLU-667, LOXO-292, and RXDX-105, have recently demonstrated promising clinical activity in RET-driven cancers.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a></div><div class="NLM_p">Toxicity, due to on- or off-targets effects, and resistance formation may limit the efficacy of TKIs in clinical practice. We sought to set up a fragment-based chemical screen to identify novel RET inhibitors. This approach led to the clinical candidate Pz-1, a type 2 TKI directed against RET and VEGFR2.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p last"><i>In vivo</i> stability is a critical factor that directly determines efficacy.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Through completion of investigative new drug (IND) studies, a demethylated less active metabolite of Pz-1 was identified. Here, by applying bioisosteric substitution of the Pz-1 site susceptible to demethylation, we report the identification of NPA101.3 as a novel clinical TKI candidate and its characterization through <i>in vitro</i> and <i>in vivo</i> assays.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Discovery of NPA101.3</h3><div class="NLM_p">During IND studies of Pz-1, a series of <i>in vivo</i> metabolites were identified; via phase 1 metabolic systems, Pz-1 is oxidized, hydrolyzed, or demethylated, generating a less active derivative (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and data not shown). Hydrolysis and initial oxidation occur in the selectivity region, which is the region of Pz-1 that enters the allosteric pocket of both RET and VEGFR2. Any modification to slow metabolism in this region can alter selectivity and inhibitory profiles and, therefore, is likely to alter the optimized RET/VEGFR2 inhibitory profile. Another major, metabolic pathway of Pz-1 is initiated via the phase 1 demethylation of methylpyrazole to generate Pz-1a. In turn, Pz-1a is further biotransformed via oxidation (to Pz-1b) or oxidation and sugar conjugation through phase 2 systems (to Pz-1c). Interestingly, the methylpyrazole substituent of Pz-1 is oriented toward the solvent and is not expected to contribute significantly to selectivity profiles<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Metabolism of Pz-1 and bioisosteric replacement methods. Pz-1 is hydrolyzed, oxidized, or demethylated via phase 1 metabolic systems. Hydrolysis and oxidation occur in the selectivity region for binding to RET and VEGFR2, while demethylation occurs at the solvent front for both kinases. Bioisosteric replacement at the solvent front was performed by replacing methylpyrazole with (methylsulfonyl)benzene, generating NPA101.3. VEGFR2 DFG-out crystal structure (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OH4">2OH4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Bioisosteric replacement of the methylpyrazole of Pz-1 was investigated to generate an alternative clinical candidate with a similar polypharmacological profile but resistance to demethylation. In both RET and VEGFR2, the methylpyrazole binds to solvent-exposed regions, which can accommodate a variety of substituents. SAR (structure–activity relationship) studies have shown that replacement of methylpyrazole with various five-membered ring systems decreases inhibitory activity.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Therefore, substitution with polar, electron-deficient (methylsulfonyl)benzene was investigated. The methylsulfonyl group occupies the same chemical space as the methyl pyrazole and has the same hydrogen binding pattern at the computer modeling (data not shown); therefore, it is expected not to affect the pharmacological activity of the drug as compared to methylpyrazole. Importantly, analogues containing (methylsulfonyl)benzene do not carry the structural liability of demethylation. Therefore, the (methylsulfonyl)benzene was chosen as an appropriate bioisosteric replacement for methylpyrazole, to obtain the novel compound designated NPA101.3 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The chemical synthesis of NPA101.3 is described in the <a class="ref internalNav" href="#notes2" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Computational Modeling of NPA101.3</h3><div class="NLM_p">NPA101.3 was modeled in the RET kinase DFG [aspartic acid (D892), phenylalanine (F893), glycine (G894)]-out computational model as previously described (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The model suggested that NPA101.3 binds to RET kinase in its inactive (DFG-out) conformation, as it is characteristic of type 2 TKIs.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The benzimidazole moiety acts as the “warhead”, making a key hydrogen bond with A807 at the RET ATP binding site (hinge region). The benzimidazole also forms two π–π stacking interactions with Y806. The <i>p</i>-sulfone substituent displays an orientation toward the solvent and engages K728 through a cation−π interaction. The amide region interacts with D892 from the DFG motif through a hydrogen bond. This interaction opens a novel lipophilic pocket, which is effectively filled by <i>tert</i>-butyl isoxazole. The modeling predicted NPA101.3 to bind RET with high affinity and with a projected Δ<i>G</i> of −11.9 kcal/mol. Moreover, the model indicated that binding of NPA101.3 was not influenced by substitutions of V804, which is the gatekeeper residue whose replacement with a methionine or a leucine confers resistance to Vandetanib, Cabozantinib, and several other inhibitors (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref internalNav" href="#notes2" aria-label="Table S1">Table S1</a>).<a onclick="showRef(event, 'ref29 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref29 ref34 ref35 ref36">(29,34−36)</a> NPA101.3 was also predicted to bind VEGFR2 with comparable high affinity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Indeed, similar to Pz-1, the free rotation of the methylene linker permits a tailored orientation of the isoxazole in the allosteric pocket of both RET and VEGFR2, enabling balanced inhibition of both kinases.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Computational modeling of NPA101.3. (A) NPA101.3 computationally modeled in a RET DFG-out homology model. The model shows the hydrogen bond at the ATP binding site with A807, a hydrogen bond network at the DFG motif, and interaction with Y806 via π–π stacking. The model also shows that <i>p</i>-sulfone of NPA101.3 is solvent-exposed. Hydrogen bonds are shown with blue dotted lines. (B) NPA101.3 computationally modeled in a RET/V804M DFG-out homology model. NPA101.3 can accommodate bulky mutations at the gatekeeper residue. (C) NPA101.3 computationally modeled in the VEGFR2 kinase. The binding mode is nearly identical to the binding mode in RET, with the exception of the isoxazole orientation in the allosteric pocket. Flexibility at the methylene linker is predicted to permit the balanced affinity of NPA101.3 for RET and VEGFR2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To further address the type of binding, we docked sorafenib in the RET model and compared docking poses between the RET–sorafenib and VEGFR2–sorafenib (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3WZE">3WZE</a>) complexes. The poses were nearly identical, further suggesting NPA101.3 is a type 2 inhibitor (<a class="ref internalNav" href="#notes2" aria-label="Figure S1">Figure S1</a>).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Kinase Inhibitory Activity of NPA101.3</h3><div class="NLM_p">We tested the ability of NPA101.3 to inhibit RET, the RET/V804M mutant, and VEGFR2 in an <i>in vitro</i> kinase assay. To determine if NPA101.3 tightly bound the kinase, we used a high concentration of ATP (190 μM). Such a high concentration is orders of magnitude greater than the <i>K</i><sub>m</sub> for either RET or VEGFR2 and reflects the high intracellular concentration of ATP (1–10 mM). NPA101.3 exhibited an inhibitory concentration 50 (IC<sub>50</sub>) of 0.001 μM for RET, 0.008 μM for RET/V804M, and 0.003 μM for VEGFR2. Thus, NPA101.3 represents a novel RET/VEGFR2 dual inhibitor with a pharmacological profile similar to that of Pz-1.</div><div class="NLM_p">To further investigate the binding of NPA101.3 to RET, a thermal shift assay was performed to monitor the protein melting temperature. This assay determines the drug-induced increase in the melting temperature (Δ<i>T</i><sub>m</sub>) of the isolated RET kinase domain, which reflects the stability of the kinase–ligand complex<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> and correlates with the inhibitor IC<sub>50</sub>.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Addition of NPA101.3 increased the thermal stability of active and phosphorylated RET by a dramatic Δ<i>T</i><sub>m</sub> of 16 ± 1.1 °C, over a time course of 240 min (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C; a representative experiment is reported in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). This was consistent with values seen for type 2 inhibitors, such as Sorafenib, stabilizing a DFG-out inactive conformer.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> We observed the same magnitude of thermal shift by NPA101.3 for the wild type and V804M mutant (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), confirming that the compound is insensitive to gatekeeper mutation. In contrast, a substantially smaller Δ<i>T</i><sub>m</sub> shift of 6.1 ± 3.3 °C was observed with the type 1 compound PP1 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C), consistent with our previously published data.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> As expected, the type 1 inhibitor PP1 was sensitive to gatekeeper mutation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). We conclude that NPA101.3 binds tightly to both wild type and V804M RET kinase domains in a type 2 binding mode.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Thermal shift assay determination of the type 2 binding mode of NPA101.3. (A) Representative experiment of binding of NPA101.3 to the wild type RET core kinase domain monitored by the change in thermal stability. The melting temperature (<i>T</i><sub>m</sub>) is obtained from the first derivative of the change in fluorescence (−d<i>F</i>/d<i>t</i>) taken from the top of the peak in the derivative plot. (B) Plot of the derivative of the change in fluorescence (−d<i>F</i>/d<i>t</i>) for the wild type protein or V804M mutant in the presence of NPA101.3 (red) or buffer (blue) for a representative experiment. The compound binds equally well to either RET protein. (C) Tabulated average melting temperature differences (Δ<i>T</i><sub>m</sub>) from four independent experiments after the addition of NPA101.3, PP1 (a known type 1 inhibitor), or Sorafenib (a known type 2 inhibitor). The respective SD errors are shown for each drug.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition, NPA101.3, at a concentration of 100 nM, was subjected to a kinome scan against a 96-kinase panel representing major kinome clusters (<a class="ref internalNav" href="#notes2" aria-label="Table S2">Table S2</a>). The compound featured good selectivity, displaying strong binding activity (>90% bound) for only seven additional kinases [CSF1R (colony stimulating factor 1 receptor), FRK (fyn-related Src family tyrosine kinase), HCK (HCK proto-oncogene, Src family tyrosine kinase), LYN (lyn proto-oncogene, Src family tyrosine kinase), MKNK2 (MAPK-interacting serine/threonine kinase 2), TRKA (neurotrophic receptor tyrosine kinase 1), and TRKC (neurotrophic receptor tyrosine kinase 3)] and weak binding (>10–35% bound) for six other kinases (<a class="ref internalNav" href="#notes2" aria-label="Table S2 and Figure S2">Table S2 and Figure S2</a>). It is important to note that the measurement of binding affinity, which is based on control ligand displacement (<i>K</i><sub>d</sub>), is more sensitive than the <i>in vitro</i> kinase assay. Among the seven kinases with >90% binding, TRKA and CSF1R were selected for an <i>in vitro</i> kinase assay. NPA101.3 was active against TRKA and CSF1R with IC<sub>50</sub> values of 32 and 46 nM, respectively (<a class="ref internalNav" href="#notes2" aria-label="Figure S3">Figure S3</a>). Finally, we verified the ability of NPA101.3 to interfere with hERG (potassium voltage-gated channel subfamily H member 2) conductibility via a patch-clamp assay. As shown in <a class="ref internalNav" href="#notes2" aria-label="Table S4">Table S4</a>, the IC<sub>50</sub> dose of NPA101.3 for hERG was 7.57 μM (while it was 0.027 μM in the case of the positive control E-4031), thereby >7000-fold higher than that for RET (1 nM) (<a class="ref internalNav" href="#notes2" aria-label="Table S3">Table S3</a>).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> NPA101.3-Mediated Inhibition of RET and VEGFR2 Phosphorylation and Signaling</h3><div class="NLM_p">Fibroblasts transfected with RET/C634R were treated with increasing doses of NPA101.3, ranging from 0.1 to 10.0 nM. RET autophosphorylation was assessed by Western blotting using two different antibodies that can recognize phosphorylated Y905, located in the RET kinase activation loop, or Y1062, a multidocking site involved in RET downstream signaling.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, RET phosphorylation started to be inhibited at 0.3 nM and was almost completely blocked at 3.0 nM. NPA101.3 also inhibited other MTC-associated RET oncogenic point mutants, including RET/M918T, RET/A883F, and RET/V804L/M (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Rearranged RET oncoproteins (CCDC6-RET, NCOA4-RET, and FGFR1OP-RET) were highly sensitive to NPA101.3 inhibition, as well (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Finally, 1.0 nM NPA101.3 reduced the level of ligand-induced VEGFR2 autophosphorylation; inhibition was virtually total at 10.0 nM, indicating that NPA101.3 has a similar inhibitory activity for VEGFR2 and RET (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. NPA101.3-mediated inhibition of phosphorylation and signaling of oncogenic RET mutants and VEGFR2 in intact cells. Serum-starved RAT1 cells exogenously expressing the (A and B) indicated RET point mutants or (C) NIH3T3 cells exogenously expressing the indicated RET rearranged mutants were treated for 2 h with the indicated concentrations of the compound. Total cell lysates (50 μg) were subjected to immunoblotting with anti-phospho-Y1062 (αp1062) and anti-phospho-Y905 (αp905) RET antibodies. The blots were normalized using the anti-RET (αRET) antibody. (D) HEK293 cells were transiently transfected with human VEGFR2; 36 h after transfection, cells were serum starved for 12 h. The indicated doses of the compound or vehicle (NT) were added for 2 h, and then VEGFA (100 ng/mL) stimulation was applied for 15 min. Cell lysates were immunoblotted with the anti-phospho-VEGFR2 (αpVEGFR2) antibody. The blot was normalized using the anti-VEGFR2 (αVEGFR2) antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">NPA101.3 inhibited RET autophosphorylation and signaling along the SHC/MAPK pathway in human cancer cell lines endogenously expressing RET oncogenic variants, including MTC cell lines, TT (RET/C634W) and MZ-CRC-1 (RET/M918T), and PTC cell line TPC-1 (CCDC6-RET); in the lung adenocarcinoma cell line Lc-2/ad (CCDC6-RET), only RET and SHC (but not MAPK) dephosphorylation was detectable (<a class="ref internalNav" href="#notes2" aria-label="Figure S4">Figure S4</a>). Virtually no effect on SHC/MAPK signaling was identified in control cell lines lacking RET oncogenes, including Nthy-ori-3.1 thyroid follicular cells, BCPAP and 8505-C, derived from thyroid cancers negative for RET oncogenes, and PC-9, A549, and CALU-1, derived from lung adenocarcinomas negative for RET oncogenes (<a class="ref internalNav" href="#notes2" aria-label="Figure S5">Figure S5</a>).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> NPA101.3-Mediated Inhibition of RET-Driven Cell Proliferation</h3><div class="NLM_p">The murine pro-B cell line Ba/F3 requires IL-3 (interleukin 3) for proliferation and survival; this dependency is bypassed by active tyrosine kinases. Therefore, the Ba/F3 cell line is a standard cell culture model for determining the activity and drug-mediated inhibition of tyrosine kinases.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Accordingly, stable transfection of RET/C634R, RET/M918T, and CCDC6-RET oncoproteins promotes IL-3-independent growth (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Treatment with NPA101.3 blunted RET-driven (IC<sub>50</sub> values of 1.6–3.1 nM) but not IL-3-driven parental Ba/F3 cell proliferation (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), parallel to inhibition of RET phosphorylation (<a class="ref internalNav" href="#notes2" aria-label="Figure S6">Figure S6</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. NPA101.3-mediated inhibition of proliferation of RET-transformed Ba/F3 cells. Parental and RET/C634R-, RET M918T-, and NCOA4-RET-transfected Ba/F3 cells were incubated with vehicle (NT, not treated) or the indicated concentrations of NPA101.3 and counted at the indicated time points. Parental cells were supplemented with IL-3 (10 ng/mL). Data are the mean ± SD of a single experiment performed in triplicate. Growth inhibition IC<sub>50</sub> doses of the compound for the different cell lines are reported; 95% confidence intervals are indicated in brackets.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">NPA101.3 inhibited proliferation of RET mutant TT, MZ-CRC-1, TPC-1, and Lc-2/ad human cancer cells with an IC<sub>50</sub> of 0.67–3.6 nM (<a class="ref internalNav" href="#notes2" aria-label="Figure S7 and Table S4">Figure S7 and Table S4</a>). The IC<sub>50</sub> dose for all human RET-negative cells was >100.0 nM, confirming compound selectivity (<a class="ref internalNav" href="#notes2" aria-label="Figure S8 and Table S4">Figure S8 and Table S4</a>).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> NPA101.3 Inhibits Tumorigenicity of RET-Transformed Cells</h3><div class="NLM_p">The IC<sub>50</sub> dose for NPA101.3-mediated NIH3T3 RET/C634Y cell proliferation inhibition was 4.17 nM; virtually no effect was observed upon proliferation of NIH3T3 HRAS (Harvey rat sarcoma virus oncogene)/G12V cells up to 100.0 nM (<a class="ref internalNav" href="#notes2" aria-label="Figure S9">Figure S9</a>). At 10.0 nM, the compound almost completely inhibited phosphorylation of RET and SHC, and attenuated phosphorylation of MAPK, in NIH3T3 RET/C634Y cells, while virtually no effect could be detected in NIH3T3 HRAS/G12V cells up to a dose of 100.0 nM (<a class="ref internalNav" href="#notes2" aria-label="Figure S10">Figure S10</a>).</div><div class="NLM_p"><i>In vivo</i> target (RET and VEGFR2) inhibition was studied by treating animals grafted with NIH3T3 RET/C634Y cells at different doses (0.3, 1, or 3 mg/kg/day p.o.) of NPA101.3 for 2 days and then performing Western blot analysis on protein extracts. As shown in <a class="ref internalNav" href="#notes2" aria-label="Figure S11">Figure S11</a>, a 3 mg/kg/day dose of NPA101.3 strongly inhibited RET autophosphorylation and signaling as well as VEGFR2 phosphorylation. Then, to determine antitumorigenic activity and to better distinguish RET- and VEGFR2-mediated effects, we tested NPA101.3 in nude mice transplanted with NIH3T3 cells transformed by either RET/C634Y or HRAS/G12V. Before tumors appeared, animals were treated daily with NPA101.3 (1.0, 3.0, or 10.0 mg/kg/day) or left untreated. NPA101.3 preferentially inhibited RET compared to RAS-driven tumors. While 10.0 mg of compound/kg completely prevented tumor formation induced by oncogenic RET, the treatment reduced, but did not abrogate, formation of tumors driven by RAS; moreover, at lower doses, the compound significantly reduced the rate of growth of RET-driven, but not RAS-driven, tumors (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). At 1.0 mg/kg, NPA101.3 exhibited strong RET phosphorylation and signaling inhibition in NIH3T3 RET/C634Y tumors (<a class="ref internalNav" href="#notes2" aria-label="Figure S12">Figure S12</a>); in contrast, virtually no effect on RAS signaling (MAPK phosphorylation) was detected in NIH3T3 HRAS/G12V tumors. Still, VEGFR2 inhibition was detected also in RAS-driven tumors, an effect that might explain the, albeit reduced, effect of the drug on their growth (<a class="ref internalNav" href="#notes2" aria-label="Figure S13">Figure S13</a>). Importantly, as predicted, no trace of NPA101.3 demethyl metabolites was detected after 1 or 4 h from oral dosing in mice (<a class="ref internalNav" href="#notes2" aria-label="Figure S14">Figure S14</a>). Moreover, in terms of potential toxicity, no significant change in standard blood markers of organ damage was detected upon 7 days of oral dosing (10 mg/kg/day) of NPA101.3, indicating that at this dose the compound had no general toxicity (<a class="ref internalNav" href="#notes2" aria-label="Figure S15">Figure S15</a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of NPA101.3 on <i>in vivo</i> tumor growth. NIH3T3 cells transformed by RET/C634Y or HRAS/G12V were inoculated subcutaneously into nu/nu mice. After 4 days, animals were randomly assigned to receive for the indicated time periods the compound (1.0, 3.0, or 10 mg/kg/day) (24 mice; 8 mice/group for 1, 3, and 10 mg/kg doses) or vehicle (8 mice) by oral gavage. The average size of tumors is reported ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33387" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33387" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The drug efficacy of a clinical agent is determined by target inhibition and ADMET (adsorption, distribution, metabolism, excretion, and toxicity) profiles.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> During the IND study of the clinical TKI candidate Pz-1, we identified a major metabolic pathway initiated by phase 1 demethylation of the Pz-1 methylpyrazole substituent. Here, to generate secondary candidates with pharmacological profiles similar to that of Pz-1 but no propensity for demethylation, we replaced methylpyrazole with the metabolically resistant bioisostere (methylsulfonyl)benzene. This led to NPA101.3, a demethylation-resistant clinical candidate optimized for single-agent polypharmacology.</div><div class="NLM_p">Molecular modeling indicated that, similar to Pz-1, NPA101.3 binds the DFG-out “inactive” conformation of RET and VEGFR2, thus functioning as a bona fide type 2 TKI.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> This is supported experimentally by the relatively large thermal shift observed for the RET kinase–NPA101.3 complex. NPA101.3 exhibited IC<sub>50</sub> values of 0.001 μM for RET and 0.003 μM for VEGFR2. It is noteworthy that, similar to Pz-1, NPA101.3 was able to bind tightly to and inhibit (IC<sub>50</sub> = 0.008 μM) the RET mutant at the gatekeeper site (V804M), which is refractory to the clinical inhibitors Vandetanib and Cabozantinib.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> NPA101.3 featured excellent selectivity for RET and VEGFR2, exhibiting affinity for only a few other kinases such as TRKs (TRKA and TRKC), CSF1R, FRK, HCK, LYN, and MKNK2. Among them, TRKA and TRKC are well-known driver oncogenes, which expands the potential therapeutic application of NPA101.3 beyond RET-driven cancers.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_p last">In cell-based assays, NPA101.3 inhibited RET autophosphorylation and displayed a potent (IC<sub>50</sub> between 0.67 and 4.17 nM) growth inhibitory effect on different types of RET (either transfected or endogenously expressing) mutant cells with no detectable effect at doses of ≤100 nM in cells negative for RET oncogenes. Finally, NPA101.3 featured efficacy already at 1 mg/kg/day in RET-driven tumors in nude mice. At higher doses (10 mg/kg/day), NPA101.3 displayed activity also against RAS-driven tumors, likely mediated by VEGFR2 inhibition. Therefore, though in a therapeutic setting toxicity may be increased by hitting multiple targets, it is feasible that the activity of the NPA101.3 against RET-driven tumors may take advantage of a synergistic combination of cell autonomous (on tumor cell growth mediated by RET inhibition) and non-cell autonomous (on blood vessel formation mediated by VEGFR2 inhibition) effects, potentiating its effect and reducing the chances of resistance development. 	Several TKIs with anti-RET activity are available, and some are already registered for the treatment of different types of thyroid cancers. The lesson learned from the use of TKIs in various cancer types has shown that second-line inhibitors are clinically useful when first-line treatments are hampered by toxicity and/or resistance. On the basis of potency, selectivity, and balanced RET/VEGFR2 inhibition, we posit that NPA101.3 may represent a promising, demethylation-resistant type 2 TKI for the treatment of RET-driven tumors. Studies regarding the PK profile and metabolic stability will clarify in the future how NPA101.3 is metabolized <i>in vivo</i>. This notion will be crucial to proposing NPA101.3 as a clinical candidate.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74171" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74171" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> General Chemistry Procedures and Synthesis of NPA101.3</h3><div class="NLM_p last">All solvents were reagent grade or HPLC grade, and all starting materials were obtained from commercial sources and used without further purification. The purity of the final compounds was assessed using a Shimadzu ultra-high-throughput LC/MS system (SIL-20A, LC-20AD, LC-MS 2020, Phenomenex Onyx Monolithic C-18 Column) at variable wavelengths of 254 and 214 nm (Shimadzu PDA Detector, SPD-MN20A) and was >95%, unless otherwise noted. The HPLC mobile phase consisted of a water/acetonitrile gradient buffered with 0.1% formic acid. <sup>1</sup>H NMR spectra were recorded at 400 MHz, and <sup>13</sup>C NMR spectra were recorded at 100 MHz, both completed on a Varian 400 MHz instrument (model 4001S41ASP). All compounds were purified using silica gel (0.035–0.070 mm, 60 Å) flash chromatography, unless otherwise noted. Microwave-assisted reactions were completed in sealed vessels using a Biotage Initiator microwave synthesizer.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>In Vitro</i> Kinase Assays</h3><div class="NLM_p last">Kinase activity was measured by a microfluidic assay that monitors the separation of the phosphorylated product from the substrate.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The assay was run using a 12-sipper chip on a Caliper EZ Reader II (PerkinElmer, Waltham, MA) with separation buffer [100 mM HEPES, 10 mM EDTA, 0.015% Brij-35, and 0.1% CR-3 (PerkinElmer)]. In 96-well polypropylene plates (Greiner, Frickenhausen, Germany), compound stocks (20 mM in DMSO) were diluted into kinase buffer (50 mM HEPES, 0.075% Brij-35, 0.1% Tween 20, 2 mM DTT, 10 mM MgCl<sub>2</sub>, and 0.02% NaN<sub>3</sub>) in 12-point <sup>1</sup>/<sub>2</sub> log dilutions (2 mM to 6.32 nM). After, 1 μL was transferred into a 384-well polypropylene assay plate (Greiner). The enzymes (RET, RET/V804M, VEGFR2, TRKA, and CSF1R) (Invitrogen, Grand Island, NY) were diluted in kinase buffer to a concentration of 2 nM, and 5 μL of the enzyme mixture was transferred to the assay plate. Kinases were preincubated with the TKI or control buffer, with gentle shaking for 60 min to allow the inhibitor to trap the DFG-out conformation; indeed, it has been reported for the type 2 (DFG-out) p38 inhibitor, BIRB-796, that an increase in incubation time increases activity.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> A substrate mix was prepared containing ATP (Ambresco, Solon, OH) and the substrate peptide dissolved in kinase buffer, and 5 μL of the substrate mix was added to the assay plate. Running concentrations were as follows: 190 μM for ATP, 1.5 μM peptide, compound 12-point <sup>1</sup>/<sub>2</sub> log dilutions of 0.2 mM to 0.632 nM). For a positive control, no inhibitor was added. For a negative control, no enzyme was added. The plate was run until 10–20% conversion was reached, based on the positive control wells. The following separation conditions were utilized: upstream voltage, −500 V; downstream voltage, −1900 V; chip pressure, −0.8. The percent inhibition was measured for each well comparing starting peptide to phosphorylated product peaks relative to the baseline. Dose–response curves, spanning the IC<sub>50</sub> dose, were generated in GraphPad Prism 7 and fit to an exponential one-phase decay line; IC<sub>50</sub> values were obtained from the half-life value of the curve. IC<sub>50</sub> values were generated in triplicate.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Thermal Shift Assay</h3><div class="NLM_p last">Wild type and V804M mutant RET core kinase domain proteins were expressed in SF21 cells and purified using a GST affinity tag as previously described.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Subsequently, both proteins were purified and phosphorylated. The affinity tag was removed using HRV 3C protease. To determine the protein thermal shifts, 3 μM recombinant proteins were incubated with DMSO (vehicle control), NPA101.3, PP1 or Sorafenib (in 100% DMSO), with a final drug concentration of 40 μM, and a final DMSO concentration of 1% (v/v). Sypro-Orange dye (Life Technologies) was added to each drug treatment, and the thermal shift was measured in a QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems) over a temperature range of 25–90 °C. Subsequent analysis was performed using Protein Thermal Shift Software version 1.2 (Applied Biosystems).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Cell Cultures</h3><div class="NLM_p last">NPA101.3 was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 50 mM and stored at −80 °C. The final dosing solution was prepared on the day of use by dilution of the stock solution in cell growth media. RAT1 cells transformed by the various RET mutants<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> were a kind gift of M. Billaud and were cultured in DMEM with 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin (GIBCO). NIH3T3 cells transformed by RET/C634Y, HRAS/G12V, CCDC6-RET, NCOA4-RET, and FGFR1OP-RET were cultured in DMEM with 5% calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin (GIBCO). Parental NIH3T3 cells were grown in DMEM with 10% calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin (GIBCO). All of the RET constructs expressed in RAT1 or NIH3T3 cells encoded the short isoform of the RET protein (RET-9). Ba/F3 murine pro-B cells stably expressing NCOA4-RET, RET/C634R, and RET/M918T mutant proteins (all cloned in the long RET-51 isoform) were generated by electroporation. Parental and transformed Ba/F3 cells were cultured in RPMI supplemented with 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin (GIBCO), and in the case of parental cells supplemented with 10 ng/mL IL-3. CALU-1 cells, derived from a human lung adenocarcinoma, were grown in EMEM with 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin (GIBCO). PC-9, derived from a human lung adenocarcinoma, was grown in RPMI with 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin. Nthy-ori-3-1, derived from normal thyroid follicular tissue and immortalized by SV40 Large T, TPC-1, derived from a human PTC harboring CCDC6-RET,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> BCPAP, derived from human PTC, 8505-C, derived from a human undifferentiated thyroid cancer, and A549, derived from a human lung adenocarcinoma, were cultured in DMEM with 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin. TT, from a human MTC harboring RET/C634W,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and MZ-CRC-1, from a human MTC harboring RET/M918T (a kind gift of R. F. Gagel), were cultured in RPMI with 20% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin (GIBCO). Lc-2/ad cells, derived from human lung adenocarcinoma harboring CCDC6-RET,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> were grown in RPMI 1640/Ham’s F12 (1:1) with 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 100 units/mL penicillin-streptomycin (GIBCO). All of the human cell lines were SNP authenticated in 2017.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Immunoblotting</h3><div class="NLM_p last">Protein lysates were prepared according to standard procedures. Briefly, cells were lysed in a buffer containing 50 mM <i>N</i>-2-hydroxyethylpiperazine-<i>N</i>′-2-ethanesulfonic acid (HEPES; pH 7.5), 1% (v/v) Triton X-100, 150 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM sodium vanadate, 2 mM phenylmethanesulfonyl fluoride (PMSF), and 1 μg/mL aprotinin. Lysates were clarified by centrifugation at 10000<i>g</i> for 15 min. Lysates containing comparable amounts of proteins, estimated by a modified Bradford assay (Bio-Rad, Munich, Germany), were subjected to direct Western blotting. Immune complexes were detected with the enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Little Chalfont, U.K.). Anti-phospho-SHC (#Y317), which recognizes SHC protein when phosphorylated on Y317, was from Upstate Biotechnology Inc. (Lake Placid, NY). Anti-SHC (H-108) was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-MAPK (9101) and anti-phospho-MAPK (9102), specific for p42/44MAPK (ERK1/2) phosphorylated on Thr202/Tyr204, antibodies were from Cell Signaling Technologies (Danvers, MA). Anti-phospho-VEGFR2/KDR (2478), specific for VEGFR2/KDR phosphorylated on Tyr1175, and anti-VEGFR2/KDR (2479) were from Cell Signaling Technologies. Anti-phospho-p70S6K (9234), specific for p70S6K phosphorylated on Thr389, and anti-p70S6K (2708) were from Cell Signaling Technologies. Anti-RET is a polyclonal antibody raised against the tyrosine kinase protein fragment of human RET; anti-phospho-905 is a phospho-specific polyclonal antibody recognizing RET proteins phosphorylated at Y905, and anti-phospho-1062 is a phospho-specific polyclonal antibody recognizing RET proteins phosphorylated at Y1062.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Secondary antibodies coupled to horseradish peroxidase were from Santa Cruz Biotechnology.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Cell Growth Curves</h3><div class="NLM_p last">Nthy-ory-3-1 (10000 per well), TPC-1 (10000 per well), MZ-CRC-1 (100000 per well), TT (200000 per well), Lc-2/ad (100000 per well), BCPAP (10000 per well), 8505-C (10000 per well), PC-9 (10000 per well), A549 (10000 per well), CALU-1 (10000 per well), NIH3T3 RET/C634Y (10000 per well), and NIH3T3 HRAS/G12V (10000 per well) were seeded in six-well tissue culture plates. Cells were kept in 2% (TPC-1), 5% (Nthy-ori-3-1), or 10% (BCPAP, 8505-C, CALU-1, A549, PC-9, TT, MZ-CRC-1, and Lc-2/ad) fetal calf serum or in 2% (NIH3T3 RET/C634Y and HRAS/G12V) calf serum. Ba/F3 cells (200000 per well in 2 mL) were seeded in six-well tissue culture plates and kept in 10% fetal calf serum. The day after plating, different concentrations of the drug or vehicle were added to the medium and changed every 2–3 days. Cells were counted every day (Ba/F3), every 2 days (fibroblasts), or every 2–3 days (human cell lines). To compare cell growth, we performed an unpaired Student’s <i>t</i> test using the Instat software program (Graphpad Software Inc.). All <i>P</i> values were two-sided, and differences were considered to be statistically significant at <i>P</i> < 0.02. IC<sub>50</sub> doses were calculated through a curve fitting analysis from last day of growth curves using the PRISM software program (Graphpad Software Inc.).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Mouse Xenograft Experiments</h3><div class="NLM_p last">NPA101.3 was dissolved in 80% H<sub>2</sub>O, 19.875% Tween 20, and 0.125% xanthan gum. The formulation was stored at room temperature and vortexed prior to administration. NIH3T3 RET/C634Y (200000) or NIH3T3 HRAS/G12V (50000) cells were inoculated subcutaneously into the dorsal portion (both sides) of 6-week-old female BALB/c nu/nu mice (32 mice/cell line) (Jackson Laboratories, Bar Harbor, ME). After 4 days, before tumors had appeared, animals were randomly assigned to receive NPA101.3 (1.0, 3.0, or 10 mg/kg/day) (8 mice/group) or vehicle control (8 mice) by oral gavage. Tumor diameters were measured with caliper every 2–3 days. Tumor volumes (<i>V</i>) were calculated by the rotational ellipsoid formula <i>V</i> = <i>A</i> × <i>B</i><sup>2</sup>/2 (<i>A</i> is the axial diameter, and <i>B</i> is the rotational diameter). No mouse showed signs of wasting or other signs of toxicity. Animals were fed <i>ad libitum</i> on an autoclaved diet and tap water and maintained at the Dipartimento di Medicina Molecolare e Biotecnologie Mediche Animal Facility. All manipulations were performed while the animals were under isoflurane gas anesthesia. Animal studies were conducted in accordance with Italian regulations for experimentation on animals and approved by the Italian Ministry of Health (Authorization 1023/2015-PR). To compare tumor growth, an unpaired Student’s <i>t</i> test (InStat program, GraphPad Software) was used. <i>P</i> values were statistically significant at the <i>P</i> < 0.05 level.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01336" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00740" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00740" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01336?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01336</a>. <ul class="NLM_list-list_type-label"><li><p class="inline">Molecular formula string of NPA101.3 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Additional data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Supplementary Methods, Tables S1–S4, and Figures S1–S14 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_003.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_001.csv">jm9b01336_si_001.csv (0.33 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_002.pdb">jm9b01336_si_002.pdb (189.35 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_003.pdf">jm9b01336_si_003.pdf (1.25 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">VEGFR2 DFG-out crystal structure, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OH4">2OH4</a>; amino acid sequence of RET, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVU">2IVU</a>; Sorafenib in the VEGFR2 DFG-out crystal structure, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3WZE">3WZE</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01336" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong-yu Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Synactix
Pharmaceuticals, Inc., Tucson, Arizona 85718, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9212-2010" title="Orcid link">http://orcid.org/0000-0001-9212-2010</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8dc5c1e4bfcdf8ece0fea3e8e9f8"><span class="__cf_email__" data-cfemail="ace4e0c59eecd9cdc1df82c9c8d9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Carlomagno</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Istituto
di Endocrinologia ed Oncologia Sperimentale del CNR, 80131 Napoli, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1483-4677" title="Orcid link">http://orcid.org/0000-0002-1483-4677</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#244256454a47415747450a474556484b4945434a4b64514a4d4a450a4d50"><span class="__cf_email__" data-cfemail="1c7a6e7d727f796f7f7d327f7d6e7073717d7b72735c697275727d327568">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marialuisa Moccia</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brendan Frett</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Synactix
Pharmaceuticals, Inc., Tucson, Arizona 85718, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lingtian Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naga Rajiv Lakkaniga</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8370-2224" title="Orcid link">http://orcid.org/0000-0001-8370-2224</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David C. Briggs</span> - <span class="hlFld-Affiliation affiliation">Signalling
and Structural Biology Laboratory, The Francis
Crick Institute, London NW1 1AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rakhee Chauhan</span> - <span class="hlFld-Affiliation affiliation">Signalling
and Structural Biology Laboratory, The Francis
Crick Institute, London NW1 1AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Annalisa Brescia</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giorgia Federico</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Yan</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Massimo Santoro</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli “Federico II”, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Q. McDonald</span> - <span class="hlFld-Affiliation affiliation">Signalling
and Structural Biology Laboratory, The Francis
Crick Institute, London NW1 1AT, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Institute
of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, London WC1E 7HX, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.M. and B.F. contributed equally to this work. M.M., A.B., and G.F. performed the cell-based and animal-based experiments. B.F., L.Z., W.Y., and N.R.L. performed the synthesis, the modeling studies, and the in vitro kinase assays. D.C.B. and R.C. performed the thermal shift assay. M.S. and N.Q.M. participated in experiment planning and data analysis. H.L. and F.C. participated in experiment planning and data analysis and wrote the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This study was supported by NIH Grant 1R01CA197178-01A1R (to H.L.). In addition, H.L. was supported by NIH Grant 1R01CA194094-010 and University of Arkansas for Medical Sciences (UAMS) start-up funding. F.C. was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC). N.Q.M. was supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001115), the UK Medical Research Council (FC001115), and the Wellcome Trust (FC001115). R.C. was supported by a grant to NQM from the Association for Multiple Endocrine Neoplasia Disorders MTC Research Fund. This work was also supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant P20 GM109005, by the UAMS Seeds of Science cancer research grant, by a grant from the American Thyroid Association (ATA/Thyca), and by the POR Campania FESR 2014–2020 “SATIN” grant.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): B.F. and H.L. have ownership interest in Synactix Pharmaceuticals, Inc. F.C., B.F., M.S., and H.L. are inventors of patent WO/2015/187818. D.C.B., R.C., and N.Q.M. declare no potential conflicts of interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42675" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42675" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">MZ-CRC-1 cells and RAT1 cells expressing RET mutants were kindly donated by R. F. Gagel (M. D. Anderson Cancer Center) and by M. Billaud (Institut Albert Bonniot, Grenoble, France), respectively.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">A</td><td class="NLM_def"><p class="first last">alanine</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">adsorption, distribution, metabolism, excretion, and toxicity</p></td></tr><tr><td class="NLM_term">C</td><td class="NLM_def"><p class="first last">cysteine</p></td></tr><tr><td class="NLM_term">CCDC6</td><td class="NLM_def"><p class="first last">coiled-coil domain containing 6</p></td></tr><tr><td class="NLM_term">CSF1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">D</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">F</td><td class="NLM_def"><p class="first last">phenylalanine</p></td></tr><tr><td class="NLM_term">FGFR1OP</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 1 oncogene partner</p></td></tr><tr><td class="NLM_term">FRK</td><td class="NLM_def"><p class="first last">fyn-related Src family tyrosine kinase</p></td></tr><tr><td class="NLM_term">G</td><td class="NLM_def"><p class="first last">glycine</p></td></tr><tr><td class="NLM_term">GDNF</td><td class="NLM_def"><p class="first last">glial cell line-derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">HCK</td><td class="NLM_def"><p class="first last">HCK proto-oncogene, Src family tyrosine kinase</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">potassium voltage-gated channel subfamily H member 2</p></td></tr><tr><td class="NLM_term">HRAS</td><td class="NLM_def"><p class="first last">Harvey rat sarcoma virus oncogene</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">inhibitory concentration 50</p></td></tr><tr><td class="NLM_term">IL-3</td><td class="NLM_def"><p class="first last">interleukin 3</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigative new drug</p></td></tr><tr><td class="NLM_term">K</td><td class="NLM_def"><p class="first last">lysine</p></td></tr><tr><td class="NLM_term">L</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">LYN</td><td class="NLM_def"><p class="first last">LYN proto-oncogene, Src family tyrosine kinase</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">methionine</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MEN2</td><td class="NLM_def"><p class="first last">multiple endocrine neoplasia type 2</p></td></tr><tr><td class="NLM_term">MKNK2</td><td class="NLM_def"><p class="first last">MAPK-interacting serine/threonine kinase 2</p></td></tr><tr><td class="NLM_term">MTC</td><td class="NLM_def"><p class="first last">medullary thyroid carcinoma</p></td></tr><tr><td class="NLM_term">NCOA4</td><td class="NLM_def"><p class="first last">nuclear coactivator 4</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PTC</td><td class="NLM_def"><p class="first last">papillary thyroid carcinoma</p></td></tr><tr><td class="NLM_term">R</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SHC</td><td class="NLM_def"><p class="first last">SHC adaptor protein 1</p></td></tr><tr><td class="NLM_term">T</td><td class="NLM_def"><p class="first last">threonine</p></td></tr><tr><td class="NLM_term">TK</td><td class="NLM_def"><p class="first last">tyrosine kinase</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">TRKA</td><td class="NLM_def"><p class="first last">neurotrophic receptor tyrosine kinase 1</p></td></tr><tr><td class="NLM_term">TRKC</td><td class="NLM_def"><p class="first last">neurotrophic receptor tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">V</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr><tr><td class="NLM_term">W</td><td class="NLM_def"><p class="first last">tryptophan</p></td></tr><tr><td class="NLM_term">Y</td><td class="NLM_def"><p class="first last">tyrosine</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, L. M.</span></span> <span> </span><span class="NLM_article-title">RET Revisited: Expanding the Oncogenic Portfolio</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1038/nrc3680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnrc3680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24561444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=173-186&author=L.+M.+Mulligan&title=RET+Revisited%3A+Expanding+the+Oncogenic+Portfolio&doi=10.1038%2Fnrc3680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">RET revisited: expanding the oncogenic portfolio</span></div><div class="casAuthors">Mulligan, Lois M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-186</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RET receptor tyrosine kinase is crucial for normal development but also contributes to pathologies that reflect both the loss and the gain of RET function.  Activation of RET occurs via oncogenic mutations in familial and sporadic cancers - most notably, those of the thyroid and the lung.  RET has also recently been implicated in the progression of breast and pancreatic tumors, among others, which makes it an attractive target for small-mol. kinase inhibitors as therapeutics.  However, the complex roles of RET in homeostasis and survival of neural lineages and in tumor-assocd. inflammation might also suggest potential long-term pitfalls of broadly targeting RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohwDQSALnEwbVg90H21EOLACvtfcHk0lgbqkcC0bu0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D&md5=665dae74c8f7a1df0e413ca15ca86440</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc3680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3680%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26atitle%3DRET%2520Revisited%253A%2520Expanding%2520the%2520Oncogenic%2520Portfolio%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D173%26epage%3D186%26doi%3D10.1038%2Fnrc3680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, N.</span></span>; <span class="NLM_contrib-group">Cancer Genome Atlas Research Network</span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Integrated Genomic Characterization of Papillary Thyroid Carcinoma</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.09.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.cell.2014.09.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=25417114" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2014&pages=676-690&author=N.+Agrawalauthor=Cancer+Genome+Atlas+Research+Network&title=Integrated+Genomic+Characterization+of+Papillary+Thyroid+Carcinoma&doi=10.1016%2Fj.cell.2014.09.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.09.050%26sid%3Dliteratum%253Aachs%26aulast%3DAgrawal%26aufirst%3DN.%26aulast%3D%26atitle%3DIntegrated%2520Genomic%2520Characterization%2520of%2520Papillary%2520Thyroid%2520Carcinoma%26jtitle%3DCell%26date%3D2014%26volume%3D159%26spage%3D676%26epage%3D690%26doi%3D10.1016%2Fj.cell.2014.09.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grubbs, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busaidy, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrier, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waguespack, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, G. J.</span></span> <span> </span><span class="NLM_article-title">RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1210/jc.2014-4153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1210%2Fjc.2014-4153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=25546157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVGisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=788-793&author=E.+G.+Grubbsauthor=P.+K.+Ngauthor=J.+Buiauthor=N.+L.+Busaidyauthor=K.+Chenauthor=J.+E.+Leeauthor=X.+Luauthor=H.+Luauthor=F.+Meric-Bernstamauthor=G.+B.+Millsauthor=G.+Palmerauthor=N.+D.+Perrierauthor=K.+L.+Scottauthor=K.+R.+Shawauthor=S.+G.+Waguespackauthor=M.+D.+Williamsauthor=R.+Yelenskyauthor=G.+J.+Cote&title=RET+Fusion+as+a+Novel+Driver+of+Medullary+Thyroid+Carcinoma&doi=10.1210%2Fjc.2014-4153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">RET fusion as a novel driver of medullary thyroid carcinoma</span></div><div class="casAuthors">Grubbs, Elizabeth G.; Ng, Patrick Kwok-Shing; Bui, Jacquelin; Busaidy, Naifa L.; Chen, Ken; Lee, Jeffrey E.; Lu, Xinyan; Lu, Hengyu; Meric-Bernstam, Funda; Mills, Gordon B.; Palmer, Gary; Perrier, Nancy D.; Scott, Kenneth L.; Shaw, Kenna R.; Waguespack, Steven G.; Williams, Michelle D.; Yelensky, Roman; Cote, Gilbert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">788-793</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Introduction: Oncogenic RET tyrosine kinase gene fusions and activating mutations have recently been identified in lung cancers, prompting initiation of targeted therapy trials in this disease.  Although RET point mutation has been identified as a driver of tumorigenesis in medullary thyroid carcinoma (MTC), no fusions have been described to date.  Objective: We evaluated the role of RET fusion as an oncogenic driver in MTC.  Methods: We describe a patient who died from aggressive sporadic MTC < 10 mo after diagnosis.  Her tumor was evaluated by means of next-generation sequencing, including an intronic capture strategy.  Results: A reciprocal translocation involving RET intron 12 was identified.  The fusion was validated using a targeted break apart fluorescence in situ hybridization probe, and RNA sequencing confirmed the existence of an in-frame fusion transcript joining MYH13 exon 35 with RET exon 12.  Ectopic expression of fusion product in a murine Ba/F3 cell reporter model established strong oncogenicity.  Three tyrosine kinase inhibitors currently used to treat MTC in clin. practice blocked tumorigenic cell growth.  Conclusion: This finding represents the report of a novel RET fusion, the first of its kind described in MTC.  The finding of this potential novel oncogenic mechanism has clear implications for sporadic MTC, which in the majority of cases has no driver mutation identified.  The presence of a RET fusion also provides a plausible target for RET tyrosine kinase inhibitor therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI15Lf8n2UYrVg90H21EOLACvtfcHk0lgbqkcC0bu0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVGisb8%253D&md5=13a711308a94082ca23d5a190ad999ac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1210%2Fjc.2014-4153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2014-4153%26sid%3Dliteratum%253Aachs%26aulast%3DGrubbs%26aufirst%3DE.%2BG.%26aulast%3DNg%26aufirst%3DP.%2BK.%26aulast%3DBui%26aufirst%3DJ.%26aulast%3DBusaidy%26aufirst%3DN.%2BL.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DPalmer%26aufirst%3DG.%26aulast%3DPerrier%26aufirst%3DN.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BL.%26aulast%3DShaw%26aufirst%3DK.%2BR.%26aulast%3DWaguespack%26aufirst%3DS.%2BG.%26aulast%3DWilliams%26aufirst%3DM.%2BD.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DCote%26aufirst%3DG.%2BJ.%26atitle%3DRET%2520Fusion%2520as%2520a%2520Novel%2520Driver%2520of%2520Medullary%2520Thyroid%2520Carcinoma%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2015%26volume%3D100%26spage%3D788%26epage%3D793%26doi%3D10.1210%2Fjc.2014-4153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nammo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogiwara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oike, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schetter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaug, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiku, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span> <span> </span><span class="NLM_article-title">KIF5B-RET Fusions in Lung Adenocarcinoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1038/nm.2644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnm.2644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22327624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=375-377&author=T.+Kohnoauthor=H.+Ichikawaauthor=Y.+Totokiauthor=K.+Yasudaauthor=M.+Hiramotoauthor=T.+Nammoauthor=H.+Sakamotoauthor=K.+Tsutaauthor=K.+Furutaauthor=Y.+Shimadaauthor=R.+Iwakawaauthor=H.+Ogiwaraauthor=T.+Oikeauthor=M.+Enariauthor=A.+J.+Schetterauthor=H.+Okayamaauthor=A.+Haugenauthor=V.+Skaugauthor=S.+Chikuauthor=I.+Yamanakaauthor=Y.+Araiauthor=S.+Watanabeauthor=I.+Sekineauthor=S.+Ogawaauthor=C.+C.+Harrisauthor=H.+Tsudaauthor=T.+Yoshidaauthor=J.+Yokotaauthor=T.+Shibata&title=KIF5B-RET+Fusions+in+Lung+Adenocarcinoma&doi=10.1038%2Fnm.2644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">KIF5B-RET fusions in lung adenocarcinoma</span></div><div class="casAuthors">Kohno, Takashi; Ichikawa, Hitoshi; Totoki, Yasushi; Yasuda, Kazuki; Hiramoto, Masaki; Nammo, Takao; Sakamoto, Hiromi; Tsuta, Koji; Furuta, Koh; Shimada, Yoko; Iwakawa, Reika; Ogiwara, Hideaki; Oike, Takahiro; Enari, Masato; Schetter, Aaron J.; Okayama, Hirokazu; Haugen, Aage; Skaug, Vidar; Chiku, Suenori; Yamanaka, Itaru; Arai, Yasuhito; Watanabe, Shun-ichi; Sekine, Ikuo; Ogawa, Seishi; Harris, Curtis C.; Tsuda, Hitoshi; Yoshida, Teruhiko; Yokota, Jun; Shibata, Tatsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-377</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing.  The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHQqNYV3xGfbVg90H21EOLACvtfcHk0lg_Skdyacn39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaltb8%253D&md5=301f964ad413e020aba11122dff13054</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm.2644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2644%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DIchikawa%26aufirst%3DH.%26aulast%3DTotoki%26aufirst%3DY.%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DHiramoto%26aufirst%3DM.%26aulast%3DNammo%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DFuruta%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DIwakawa%26aufirst%3DR.%26aulast%3DOgiwara%26aufirst%3DH.%26aulast%3DOike%26aufirst%3DT.%26aulast%3DEnari%26aufirst%3DM.%26aulast%3DSchetter%26aufirst%3DA.%2BJ.%26aulast%3DOkayama%26aufirst%3DH.%26aulast%3DHaugen%26aufirst%3DA.%26aulast%3DSkaug%26aufirst%3DV.%26aulast%3DChiku%26aufirst%3DS.%26aulast%3DYamanaka%26aufirst%3DI.%26aulast%3DArai%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DSekine%26aufirst%3DI.%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DC.%2BC.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DYokota%26aufirst%3DJ.%26aulast%3DShibata%26aufirst%3DT.%26atitle%3DKIF5B-RET%2520Fusions%2520in%2520Lung%2520Adenocarcinoma%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D375%26epage%3D377%26doi%3D10.1038%2Fnm.2644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamanaka, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span> <span> </span><span class="NLM_article-title">RET, ROS1 and ALK Fusions in Lung Cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1038/nm.2658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnm.2658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22327623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=378-381&author=K.+Takeuchiauthor=M.+Sodaauthor=Y.+Togashiauthor=R.+Suzukiauthor=S.+Sakataauthor=S.+Hatanoauthor=R.+Asakaauthor=W.+Hamanakaauthor=H.+Ninomiyaauthor=H.+Ueharaauthor=Y.+Lim+Choiauthor=Y.+Satohauthor=S.+Okumuraauthor=K.+Nakagawaauthor=H.+Manoauthor=Y.+Ishikawa&title=RET%2C+ROS1+and+ALK+Fusions+in+Lung+Cancer&doi=10.1038%2Fnm.2658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">RET, ROS1 and ALK fusions in lung cancer</span></div><div class="casAuthors">Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki; Suzuki, Ritsuro; Sakata, Seiji; Hatano, Satoko; Asaka, Reimi; Hamanaka, Wakako; Ninomiya, Hironori; Uehara, Hirofumi; Lim Choi, Young; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Mano, Hiroyuki; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">378-381</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Through an integrated mol.- and histopathol.-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-pos. and 13 ROS1-fusion-pos. adenocarcinomas, including for unidentified fusion partners for ROS1.  In addn., we discovered previously unidentified kinase fusions that may be promising for mol.-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain contg. 6 (CCDC6)-RET, in 14 adenocarcinomas.  A multivariate anal. of 1,116 adenocarcinomas contg. these 71 kinase-fusion-pos. adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathol. stage and neg. kinase-fusion status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhJr0BIAnHWLVg90H21EOLACvtfcHk0lg_Skdyacn39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D&md5=986c7eba0992b29950756e129a395d60</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm.2658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2658%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DSakata%26aufirst%3DS.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DAsaka%26aufirst%3DR.%26aulast%3DHamanaka%26aufirst%3DW.%26aulast%3DNinomiya%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DLim%2BChoi%26aufirst%3DY.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DOkumura%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DRET%252C%2520ROS1%2520and%2520ALK%2520Fusions%2520in%2520Lung%2520Cancer%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D378%26epage%3D381%26doi%3D10.1038%2Fnm.2658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donahue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwirko, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peretz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nechushtan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan-Gutman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span> <span> </span><span class="NLM_article-title">Identification of New ALK and RET Gene Fusions from Colorectal and Lung Cancer Biopsies</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1038/nm.2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnm.2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22327622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFalsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=382-384&author=D.+Lipsonauthor=M.+Capellettiauthor=R.+Yelenskyauthor=G.+Ottoauthor=A.+Parkerauthor=M.+Jaroszauthor=J.+A.+Curranauthor=S.+Balasubramanianauthor=T.+Bloomauthor=K.+W.+Brennanauthor=A.+Donahueauthor=S.+R.+Downingauthor=G.+M.+Framptonauthor=L.+Garciaauthor=F.+Juhnauthor=K.+C.+Mitchellauthor=E.+Whiteauthor=J.+Whiteauthor=Z.+Zwirkoauthor=T.+Peretzauthor=H.+Nechushtanauthor=L.+Soussan-Gutmanauthor=J.+Kimauthor=H.+Sasakiauthor=H.+R.+Kimauthor=S.+I.+Parkauthor=D.+Ercanauthor=C.+E.+Sheehanauthor=J.+S.+Rossauthor=M.+T.+Croninauthor=P.+A.+J%C3%A4nneauthor=P.+J.+Stephens&title=Identification+of+New+ALK+and+RET+Gene+Fusions+from+Colorectal+and+Lung+Cancer+Biopsies&doi=10.1038%2Fnm.2673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies</span></div><div class="casAuthors">Lipson, Doron; Capelletti, Marzia; Yelensky, Roman; Otto, Geoff; Parker, Alex; Jarosz, Mirna; Curran, John A.; Balasubramanian, Sohail; Bloom, Troy; Brennan, Kristina W.; Donahue, Amy; Downing, Sean R.; Frampton, Garrett M.; Garcia, Lazaro; Juhn, Frank; Mitchell, Kathy C.; White, Emily; White, Jared; Zwirko, Zac; Peretz, Tamar; Nechushtan, Hovav; Soussan-Gutman, Lior; Kim, Jhingook; Sasaki, Hidefumi; Kim, Hyeong Ryul; Park, Seung-il; Ercan, Dalia; Sheehan, Christine E.; Ross, Jeffrey S.; Cronin, Maureen T.; Jaenne, Pasi A.; Stephens, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-384</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non-small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clin. relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma.  Further screening of 561 lung adenocarcinomas identified 11 addnl. tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8-3.1%).  Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9dSer699HbVg90H21EOLACvtfcHk0lg_Skdyacn39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFalsbk%253D&md5=9ab47602d1e1ed547cb852a34d29e5bb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnm.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2673%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DCurran%26aufirst%3DJ.%2BA.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DBloom%26aufirst%3DT.%26aulast%3DBrennan%26aufirst%3DK.%2BW.%26aulast%3DDonahue%26aufirst%3DA.%26aulast%3DDowning%26aufirst%3DS.%2BR.%26aulast%3DFrampton%26aufirst%3DG.%2BM.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DJuhn%26aufirst%3DF.%26aulast%3DMitchell%26aufirst%3DK.%2BC.%26aulast%3DWhite%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DZwirko%26aufirst%3DZ.%26aulast%3DPeretz%26aufirst%3DT.%26aulast%3DNechushtan%26aufirst%3DH.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DSheehan%26aufirst%3DC.%2BE.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26atitle%3DIdentification%2520of%2520New%2520ALK%2520and%2520RET%2520Gene%2520Fusions%2520from%2520Colorectal%2520and%2520Lung%2520Cancer%2520Biopsies%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D382%26epage%3D384%26doi%3D10.1038%2Fnm.2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballerini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prade, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toujani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deswarte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbelstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapillonne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pages, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansat-De Mas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadieu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastugue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broccardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabesse, E.</span></span> <span> </span><span class="NLM_article-title">RET Fusion Genes are Associated with Chronic Myelomonocytic Leukemia and Enhance Monocytic Differentiation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2384</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fleu.2012.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22513837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GiurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2384-2389&author=P.+Balleriniauthor=S.+Struskiauthor=C.+Cressonauthor=N.+Pradeauthor=S.+Toujaniauthor=C.+Deswarteauthor=S.+Dobbelsteinauthor=A.+Petitauthor=H.+Lapillonneauthor=E.+F.+Gautierauthor=C.+Demurauthor=E.+Lippertauthor=P.+Pagesauthor=V.+Mansat-De+Masauthor=J.+Donadieuauthor=F.+Huguetauthor=N.+Dastugueauthor=C.+Broccardoauthor=C.+Perotauthor=E.+Delabesse&title=RET+Fusion+Genes+are+Associated+with+Chronic+Myelomonocytic+Leukemia+and+Enhance+Monocytic+Differentiation&doi=10.1038%2Fleu.2012.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation</span></div><div class="casAuthors">Ballerini, P.; Struski, S.; Cresson, C.; Prade, N.; Toujani, S.; Deswarte, C.; Dobbelstein, S.; Petit, A.; Lapillonne, H.; Gautier, E.-F.; Demur, C.; Lippert, E.; Pages, P.; Mansat-De Mas, V.; Donadieu, J.; Huguet, F.; Dastugue, N.; Broccardo, C.; Perot, C.; Delabesse, E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2384-2389</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative neoplasms are frequently assocd. with aberrant constitutive tyrosine kinase (TK) activity resulting from chimeric fusion genes or point mutations such as BCR-ABL1 or JAK2 V617F.  We report here the cloning and functional characterization of two novel fusion genes BCR-RET and FGFR1OP-RET in chronic myelomonocytic leukemia (CMML) cases generated by two balanced translocations t(10;22)(q11;q11) and t(6;10)(q27;q11), resp.  The two RET fusion genes leading to the aberrant activation of RET, are able to transform hematopoietic cells and skew the hematopoietic differentiation program towards the monocytic/macrophage lineage.  The RET fusion genes seem to constitutively mimic the same signaling pathway as RAS mutations frequently involved in CMML.  One patient was treated with Sorafenib, a specific inhibitor of the RET TK function, and demonstrated cytol. and clin. remissions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpya3dQPOlhQLVg90H21EOLACvtfcHk0liZvwOeZga-ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GiurzE&md5=729bb3f8447df9949a9fc86623337150</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.109%26sid%3Dliteratum%253Aachs%26aulast%3DBallerini%26aufirst%3DP.%26aulast%3DStruski%26aufirst%3DS.%26aulast%3DCresson%26aufirst%3DC.%26aulast%3DPrade%26aufirst%3DN.%26aulast%3DToujani%26aufirst%3DS.%26aulast%3DDeswarte%26aufirst%3DC.%26aulast%3DDobbelstein%26aufirst%3DS.%26aulast%3DPetit%26aufirst%3DA.%26aulast%3DLapillonne%26aufirst%3DH.%26aulast%3DGautier%26aufirst%3DE.%2BF.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DLippert%26aufirst%3DE.%26aulast%3DPages%26aufirst%3DP.%26aulast%3DMansat-De%2BMas%26aufirst%3DV.%26aulast%3DDonadieu%26aufirst%3DJ.%26aulast%3DHuguet%26aufirst%3DF.%26aulast%3DDastugue%26aufirst%3DN.%26aulast%3DBroccardo%26aufirst%3DC.%26aulast%3DPerot%26aufirst%3DC.%26aulast%3DDelabesse%26aufirst%3DE.%26atitle%3DRET%2520Fusion%2520Genes%2520are%2520Associated%2520with%2520Chronic%2520Myelomonocytic%2520Leukemia%2520and%2520Enhance%2520Monocytic%2520Differentiation%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D2384%26epage%3D2389%26doi%3D10.1038%2Fleu.2012.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallavicini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruneri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trubia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviele, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anaganti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fiore, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span> <span> </span><span class="NLM_article-title">Functional Characterization of a Novel FGFR1OP-RET Rearrangement in Hematopoietic Malignancies</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2013.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.molonc.2013.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24315414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvF2rsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=221-231&author=D.+Bossiauthor=F.+Carlomagnoauthor=I.+Pallaviciniauthor=G.+Pruneriauthor=M.+Trubiaauthor=P.+R.+Ravieleauthor=A.+Marinelliauthor=S.+Anagantiauthor=M.+C.+Coxauthor=G.+Vialeauthor=M.+Santoroauthor=P.+P.+Di+Fioreauthor=S.+Minucci&title=Functional+Characterization+of+a+Novel+FGFR1OP-RET+Rearrangement+in+Hematopoietic+Malignancies&doi=10.1016%2Fj.molonc.2013.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies</span></div><div class="casAuthors">Bossi, Daniela; Carlomagno, Francesca; Pallavicini, Isabella; Pruneri, Giancarlo; Trubia, Maurizio; Raviele, Paola Rafaniello; Marinelli, Alessandra; Anaganti, Suresh; Cox, Maria Christina; Viale, Giuseppe; Santoro, Massimo; Di Fiore, Pier Paolo; Minucci, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-231</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The RET (REarranged during Transfection) receptor tyrosine kinase is targeted by oncogenic rearrangements in thyroid and lung adenocarcinoma.  Recently, a RET (exon 12) rearrangement with FGFR1OP [fibroblast growth factor receptor 1 (FGFR1) oncogene partner] (exon 12) was identified in one chronic myelomonocytic leukemia (CMML) patient.  We report the mol. cloning and functional characterization of a novel FGFR1OP (exon 11)-RET (exon 11) gene fusion event (named FGFR1OP-RET), mediated by a reciprocal translocation t(6; 10)(q27; q11), in a patient affected by primary myelofibrosis (PMF) with secondary acute myeloid leukemia (AML).  The FGFR1OP-RET fusion protein displayed constitutive tyrosine kinase and transforming activity in NIH3T3 fibroblasts, and induced IL3-independent growth and activation of PI3K/STAT signaling in hematopoietic Ba/F3 cells.  FGFR1OP-RET supported cytokine-independent growth, protection from stress and enhanced self-renewal of primary murine hematopoietic progenitor and stem cells in vitro.  In vivo, FGFR1OP-RET caused a spectrum of disease phenotypes, with >50% of mice showing a fatal myeloproliferative disorder (MPD).  Other phenotypes were leukemia transplantable in secondary recipients, dramatic expansion of the mast cell lineage, and redn. of repopulating activity upon lethal irradn.  In conclusion, FGFR1OP-RET chimeric oncogenes are endowed with leukemogenic potential and assocd. to myeloid neoplasms (CMML and PMF/AML).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprMnoS-3RcaLVg90H21EOLACvtfcHk0liZvwOeZga-ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvF2rsLfJ&md5=e2af92bdeccf6d132f9ecaea05ba1c98</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2013.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2013.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DD.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DPallavicini%26aufirst%3DI.%26aulast%3DPruneri%26aufirst%3DG.%26aulast%3DTrubia%26aufirst%3DM.%26aulast%3DRaviele%26aufirst%3DP.%2BR.%26aulast%3DMarinelli%26aufirst%3DA.%26aulast%3DAnaganti%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DDi%2BFiore%26aufirst%3DP.%2BP.%26aulast%3DMinucci%26aufirst%3DS.%26atitle%3DFunctional%2520Characterization%2520of%2520a%2520Novel%2520FGFR1OP-RET%2520Rearrangement%2520in%2520Hematopoietic%2520Malignancies%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D221%26epage%3D231%26doi%3D10.1016%2Fj.molonc.2013.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteve-Puig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparatta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerroni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busam, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutzner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, B. C.</span></span> <span> </span><span class="NLM_article-title">Kinase Fusions are Frequent in Spitz Tumours and Spitzoid Melanomas</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3116</span>, <span class="refDoi"> DOI: 10.1038/ncomms4116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fncomms4116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24445538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3116&author=T.+Wiesnerauthor=J.+Heauthor=R.+Yelenskyauthor=R.+Esteve-Puigauthor=T.+Bottonauthor=I.+Yehauthor=D.+Lipsonauthor=G.+Ottoauthor=K.+Brennanauthor=R.+Muraliauthor=M.+Garridoauthor=V.+A.+Millerauthor=J.+S.+Rossauthor=M.+F.+Bergerauthor=A.+Sparattaauthor=G.+Palmedoauthor=L.+Cerroniauthor=K.+J.+Busamauthor=H.+Kutznerauthor=M.+T.+Croninauthor=P.+J.+Stephensauthor=B.+C.+Bastian&title=Kinase+Fusions+are+Frequent+in+Spitz+Tumours+and+Spitzoid+Melanomas&doi=10.1038%2Fncomms4116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase fusions are frequent in Spitz tumours and spitzoid melanomas</span></div><div class="casAuthors">Wiesner Thomas; Murali Rajmohan; Berger Michael F; Busam Klaus J; Bastian Boris C; Wiesner Thomas; Cerroni Lorenzo; He Jie; Yelensky Roman; Lipson Doron; Otto Geoff; Brennan Kristina; Miller Vincent A; Ross Jeffrey S; Cronin Maureen T; Stephens Philip J; Esteve-Puig Rosaura; Botton Thomas; Yeh Iwei; Garrido Maria; Sparatta Alyssa; Bastian Boris C; Murali Rajmohan; Bastian Boris C; Palmedo Gabriele; Kutzner Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3116</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spitzoid neoplasms are a group of melanocytic tumours with distinctive histopathological features.  They include benign tumours (Spitz naevi), malignant tumours (spitzoid melanomas) and tumours with borderline histopathological features and uncertain clinical outcome (atypical Spitz tumours).  Their genetic underpinnings are poorly understood, and alterations in common melanoma-associated oncogenes are typically absent.  Here we show that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern.  The chimeric proteins are constitutively active, stimulate oncogenic signalling pathways, are tumourigenic and are found in the entire biologic spectrum of spitzoid neoplasms, including 55% of Spitz naevi, 56% of atypical Spitz tumours and 39% of spitzoid melanomas.  Kinase inhibitors suppress the oncogenic signalling of the fusion proteins in vitro.  In summary, kinase fusions account for the majority of oncogenic aberrations in spitzoid neoplasms and may serve as therapeutic targets for metastatic spitzoid melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRd1A4UrEIWolQKX3ooHxWjfW6udTcc2eYPncqNuvnHqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D&md5=c98dfce5cbc4b2c38e3898b9e0c4c4fa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fncomms4116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4116%26sid%3Dliteratum%253Aachs%26aulast%3DWiesner%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DEsteve-Puig%26aufirst%3DR.%26aulast%3DBotton%26aufirst%3DT.%26aulast%3DYeh%26aufirst%3DI.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DK.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DSparatta%26aufirst%3DA.%26aulast%3DPalmedo%26aufirst%3DG.%26aulast%3DCerroni%26aufirst%3DL.%26aulast%3DBusam%26aufirst%3DK.%2BJ.%26aulast%3DKutzner%26aufirst%3DH.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26atitle%3DKinase%2520Fusions%2520are%2520Frequent%2520in%2520Spitz%2520Tumours%2520and%2520Spitzoid%2520Melanomas%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3116%26doi%3D10.1038%2Fncomms4116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Rolle, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seery, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, V. K.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of RET Fusions in Advanced Colorectal Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">28929</span>– <span class="NLM_lpage">28937</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.18632%2Foncotarget.4325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=26078337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbjsl2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=28929-28937&author=A.+F.+Le%0ARolleauthor=S.+J.+Klempnerauthor=C.+R.+Garrettauthor=T.+Seeryauthor=E.+M.+Sanfordauthor=S.+Balasubramanianauthor=J.+S.+Rossauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Aliauthor=V.+K.+Chiu&title=Identification+and+Characterization+of+RET+Fusions+in+Advanced+Colorectal+Cancer&doi=10.18632%2Foncotarget.4325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of RET fusions in advanced colorectal cancer</span></div><div class="casAuthors">Le Rolle Anne-France; Klempner Samuel J; Seery Tara; Chiu Vi K; Le Rolle Anne-France; Klempner Samuel J; Seery Tara; Chiu Vi K; Garrett Christopher R; Sanford Eric M; Balasubramanian Sohail; Ross Jeffrey S; Stephens Philip J; Miller Vincent A; Ali Siraj M; Ross Jeffrey S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">28929-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is an unmet clinical need for molecularly directed therapies available for metastatic colorectal cancer.  Comprehensive genomic profiling has the potential to identify actionable genomic alterations in colorectal cancer.  Through comprehensive genomic profiling we prospectively identified 6 RET fusion kinases, including two novel fusions of CCDC6-RET and NCOA4-RET, in metastatic colorectal cancer (CRC) patients.  RET fusion kinases represent a novel class of oncogenic driver in CRC and occurred at a 0.2% frequency without concurrent driver mutations, including KRAS, NRAS, BRAF, PIK3CA or other fusion tyrosine kinases.  Multiple RET kinase inhibitors were cytotoxic to RET fusion kinase positive cancer cells and not RET fusion kinase negative CRC cells.  The presence of a RET fusion kinase may identify a subset of metastatic CRC patients with a high response rate to RET kinase inhibition.  This is the first characterization of RET fusions in CRC patients and highlights the therapeutic significance of prospective comprehensive genomic profiling in advanced CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwwUHokNNKkEbxh97K6Vt6fW6udTcc2eYPncqNuvnHqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbjsl2ksw%253D%253D&md5=224fa8b7f303111457f6cfa9862394c0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4325%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRolle%26aufirst%3DA.%2BF.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DSeery%26aufirst%3DT.%26aulast%3DSanford%26aufirst%3DE.%2BM.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DChiu%26aufirst%3DV.%2BK.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520RET%2520Fusions%2520in%2520Advanced%2520Colorectal%2520Cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D28929%26epage%3D28937%26doi%3D10.18632%2Foncotarget.4325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaeger, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma that are Preferentially Associated with Wild Type RAS/RAF</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-15-0392-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F1541-7786.MCR-15-0392-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=26660078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlajtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=296-301&author=J.+F.+Hechtmanauthor=A.+Zehirauthor=R.+D.+Yaegerauthor=L.+Wangauthor=S.+Middhaauthor=T.+Zhengauthor=D.+Hymanauthor=D.+Solitauthor=M.+E.+Arcilaauthor=L.+Borsuauthor=J.+Shiaauthor=E.+Vakianiauthor=L.+Saltzauthor=M.+Ladanyi&title=Identification+of+Targetable+Kinase+Alterations+in+Patients+with+Colorectal+Carcinoma+that+are+Preferentially+Associated+with+Wild+Type+RAS%2FRAF&doi=10.1158%2F1541-7786.MCR-15-0392-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF</span></div><div class="casAuthors">Hechtman, Jaclyn F.; Zehir, Ahmet; Yaeger, Rona; Wang, Lu; Middha, Sumit; Zheng, Tao; Hyman, David M.; Solit, David; Arcila, Maria E.; Borsu, Laetitia; Shia, Jinru; Vakiani, Efsevia; Saltz, Leonard; Ladanyi, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">296-301</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted therapy for metastatic colorectal carcinoma consists of anti-EGFR therapy for patients with RAS/RAF wild-type tumors.  However, the response rate remains low, suggesting the presence of alternative drivers possibly also representing potential therapeutic targets.  We investigated receptor tyrosine kinase (RTK) alterations and MAP2K1 (MEK1) mutations in a large cohort of colorectal carcinoma patients studied by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets and The Cancer Genome Atlas, focusing on amplifications, fusions, and hotspot mutations in RTK genes and MAP2K1.  RTK gene amplifications were confirmed with FISH and immunohistochem. (IHC) staining.  Among 751 colorectal carcinoma cases with next-generation sequencing data, 7% and 1% of colorectal carcinoma harbored RTK alterations and MAP2K1 hotspot mutations (n = 7), resp.  RTK-altered cases had fewer concurrent RAS/RAF mutations (P = 0.003) than RTK/MAP2K1 wild-type colorectal carcinoma.  MAP2K1-mutated colorectal carcinoma showed no RAS/RAF mutations.  ERBB2 (n = 32) and EGFR (n = 13) were the most frequently altered RTKs, both activated by amplification and/or hotspot mutations.  Three RTK fusions were identified: NCOA4-RET, ERBB2-GRB7, and ETV6-NTRK3.  Only 1 of 6 patients with an RTK or MAP2K1 alteration who received anti-EGFR and/or anti-ERBB2 therapy demonstrated stable disease; the rest progressed immediately.  Overall, RTK alterations and MAP2K1 mutations occur in approx. 8% of colorectal carcinoma.  In spite of the usual absence of RAS/RAF mutations, response to anti-EGFR and/or anti-ERBB2 therapy was poor in this limited group.  Larger studies are warranted to further define these kinase alterations as novel therapeutic targets in colorectal carcinoma and as neg. predictors of response to anti-EGFR therapy.  Implications: Targetable kinase alterations were identified in a subset of advanced colorectal carcinoma patients, preferentially assocd. with wild-type RAS/RAF, and may predict poor response to std. anti-EGFR therapy.  Mol Cancer Res; 14(3); 296-301. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4-icN-TENRLVg90H21EOLACvtfcHk0lg92pOwGICLiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlajtLw%253D&md5=3ce2af1a5f3f9b6f4f000cc9c69cee7a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-15-0392-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-15-0392-T%26sid%3Dliteratum%253Aachs%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DZehir%26aufirst%3DA.%26aulast%3DYaeger%26aufirst%3DR.%2BD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMiddha%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DHyman%26aufirst%3DD.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DShia%26aufirst%3DJ.%26aulast%3DVakiani%26aufirst%3DE.%26aulast%3DSaltz%26aufirst%3DL.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520Targetable%2520Kinase%2520Alterations%2520in%2520Patients%2520with%2520Colorectal%2520Carcinoma%2520that%2520are%2520Preferentially%2520Associated%2520with%2520Wild%2520Type%2520RAS%252FRAF%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2016%26volume%3D14%26spage%3D296%26epage%3D301%26doi%3D10.1158%2F1541-7786.MCR-15-0392-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paratala, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmazel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrosky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolfi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiClemente, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Rodriguez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyland-Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirshfield, K. M.</span></span> <span> </span><span class="NLM_article-title">RET Rearrangements are Actionable Alterations in Breast Cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4821</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07341-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fs41467-018-07341-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=30446652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BB3crhvVejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4821&author=B.+S.+Paratalaauthor=J.+H.+Chungauthor=C.+B.+Williamsauthor=B.+Yilmazelauthor=W.+Petroskyauthor=K.+Williamsauthor=A.+B.+Schrockauthor=L.+M.+Gayauthor=E.+Leeauthor=S.+C.+Dolfiauthor=K.+Phamauthor=S.+Linauthor=M.+Yaoauthor=A.+Kulkarniauthor=F.+DiClementeauthor=C.+Liuauthor=L.+Rodriguez-Rodriguezauthor=S.+Ganesanauthor=J.+S.+Rossauthor=S.+M.+Aliauthor=B.+Leyland-Jonesauthor=K.+M.+Hirshfield&title=RET+Rearrangements+are+Actionable+Alterations+in+Breast+Cancer&doi=10.1038%2Fs41467-018-07341-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">RET rearrangements are actionable alterations in breast cancer</span></div><div class="casAuthors">Paratala Bhavna S; Petrosky Whitney; Dolfi Sonia C; Lin Stephanie; Yao Ming; Kulkarni Atul; DiClemente Frances; Ganesan Shridar; Hirshfield Kim M; Paratala Bhavna S; Petrosky Whitney; Dolfi Sonia C; Lin Stephanie; Yao Ming; Kulkarni Atul; DiClemente Frances; Rodriguez-Rodriguez Lorna; Ganesan Shridar; Hirshfield Kim M; Chung Jon H; Yilmazel Bahar; Schrock Alexa B; Gay Laurie M; Ross Jeffrey S; Ali Siraj M; Williams Casey B; Williams Kirstin; Leyland-Jones Brian; Lee Ellen; Pham Kien; Liu Chen; Rodriguez-Rodriguez Lorna</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4821</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fusions involving the oncogenic gene RET have been observed in thyroid and lung cancers.  Here we report RET gene alterations, including amplification, missense mutations, known fusions, novel fusions, and rearrangements in breast cancer.  Their frequency, oncogenic potential, and actionability in breast cancer are described.  Two out of eight RET fusions (NCOA4-RET and a novel RASGEF1A-RET fusion) and RET amplification were functionally characterized and shown to activate RET kinase and drive signaling through MAPK and PI3K pathways.  These fusions and RET amplification can induce transformation of non-tumorigenic cells, support xenograft tumor formation, and render sensitivity to RET inhibition.  An index case of metastatic breast cancer progressing on HER2-targeted therapy was found to have the NCOA4-RET fusion.  Subsequent treatment with the RET inhibitor cabozantinib led to a rapid clinical and radiographic response.  RET alterations, identified by genomic profiling, are promising therapeutic targets and are present in a subset of breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBi3BP-gFLomK_SFaaT9INfW6udTcc2eYEmbzb6_Magrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crhvVejsQ%253D%253D&md5=63a94be3ca98d30c8a024da441d75963</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07341-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07341-4%26sid%3Dliteratum%253Aachs%26aulast%3DParatala%26aufirst%3DB.%2BS.%26aulast%3DChung%26aufirst%3DJ.%2BH.%26aulast%3DWilliams%26aufirst%3DC.%2BB.%26aulast%3DYilmazel%26aufirst%3DB.%26aulast%3DPetrosky%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DGay%26aufirst%3DL.%2BM.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DDolfi%26aufirst%3DS.%2BC.%26aulast%3DPham%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DKulkarni%26aufirst%3DA.%26aulast%3DDiClemente%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DRodriguez-Rodriguez%26aufirst%3DL.%26aulast%3DGanesan%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DHirshfield%26aufirst%3DK.%2BM.%26atitle%3DRET%2520Rearrangements%2520are%2520Actionable%2520Alterations%2520in%2520Breast%2520Cancer%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4821%26doi%3D10.1038%2Fs41467-018-07341-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elvin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldham, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washburn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serracino, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, D. W.</span></span> <span> </span><span class="NLM_article-title">Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6061</span>– <span class="NLM_lpage">6068</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F1078-0432.CCR-15-2568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=27334835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSmtr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=6061-6068&author=K.+Wangauthor=J.+S.+Russellauthor=J.+D.+McDermottauthor=J.+A.+Elvinauthor=D.+Khairaauthor=A.+Johnsonauthor=T.+A.+Jenningsauthor=S.+M.+Aliauthor=M.+Murrayauthor=C.+Marshallauthor=D.+S.+Oldhamauthor=D.+Washburnauthor=S.+J.+Wongauthor=J.+Chmieleckiauthor=R.+Yelenskyauthor=D.+Lipsonauthor=V.+A.+Millerauthor=P.+J.+Stephensauthor=H.+S.+Serracinoauthor=J.+S.+Rossauthor=D.+W.+Bowles&title=Profiling+of+149+Salivary+Duct+Carcinomas%2C+Carcinoma+Ex+Pleomorphic+Adenomas%2C+and+Adenocarcinomas%2C+Not+Otherwise+Specified+Reveals+Actionable+Genomic+Alterations&doi=10.1158%2F1078-0432.CCR-15-2568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations</span></div><div class="casAuthors">Wang, Kai; Russell, Jeffery S.; McDermott, Jessica D.; Elvin, Julia A.; Khaira, Depinder; Johnson, Adrienne; Jennings, Timothy A.; Ali, Siraj M.; Murray, Molly; Marshall, Carrie; Oldham, Dwight S.; Washburn, Donna; Wong, Stuart J.; Chmielecki, Juliann; Yelensky, Roman; Lipson, Doron; Miller, Vincent A.; Stephens, Philip J.; Serracino, Hilary S.; Ross, Jeffrey S.; Bowles, Daniel W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6061-6068</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We sought to identify genomic alterations (GA) in salivary gland adenocarcinomas, not otherwise specified (NOS), salivary duct carcinomas (SDC), carcinoma ex pleomorphic adenoma (ca ex PA), and salivary carcinoma, NOS.  Exptl. Design: DNA was extd. from 149 tumors.  Comprehensive genomic profiling (CGP) was performed on hybridization-captured adaptor ligation-based libraries of 182 or 315 cancer-related genes plus introns from 14 or 28 genes frequently rearranged for cancer and evaluated for all classes of GAs.  Results: A total of 590 GAs were found in 157 unique genes (mean 3.9/tumor).  GAs in the PI3K/AKT/mTOR pathway were more common in SDC (53.6%) than other histologies (P = 0.019) Cyclin-dependent kinase GAs varied among all histotypes: adenocarcinoma, NOS (34.6%); SDC (12.2%); ca ex PA (16.7%); carcinoma, NOS (31.2%; P = 0.043).  RAS GAs were obsd.: adenocarcinoma, NOS (17.3%); SDC (26.8%); ca ex PA (4.2%); and carcinoma, NOS (9.4%; P = 0.054).  ERBB2 GAs, including amplifications and mutations, were common: adenocarcinoma, NOS (13.5%); SDC (26.8%); ca ex PA (29.2%); carcinoma, NOS (18.8; P = 0.249).  Other notable GAs include TP53 in >45% of each histotype; NOTCH1: adenocarcinoma, NOS (7.7%), ca ex PA (8.3%), carcinoma, NOS (21.6%); NF1: adenocarcinoma, NOS (9.6%), SDC (17.1%), carcinoma, NOS (18.8%).  RET fusions were identified in one adenocarcinoma, NOS (CCDC6-RET) and two SDCs (NCOA4-RET).  Clin. responses were obsd. in patients treated with anti-HER2 and anti-RET-targeted therapies.  Conclusions: CGP of salivary adenocarcinoma, NOS, SDCs, ca ex PA, and carcinoma, NOS revealed diverse GAs that may lead to novel treatment options.  Clin Cancer Res; 22(24); 6061-8. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEd0PSGc63IbVg90H21EOLACvtfcHk0ljaQvqiVWX05w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSmtr%252FP&md5=a21a65ed4f89bbbb123df4e3671ec7e7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2568%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%26aulast%3DRussell%26aufirst%3DJ.%2BS.%26aulast%3DMcDermott%26aufirst%3DJ.%2BD.%26aulast%3DElvin%26aufirst%3DJ.%2BA.%26aulast%3DKhaira%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJennings%26aufirst%3DT.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DMurray%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DC.%26aulast%3DOldham%26aufirst%3DD.%2BS.%26aulast%3DWashburn%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DS.%2BJ.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DSerracino%26aufirst%3DH.%2BS.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DBowles%26aufirst%3DD.%2BW.%26atitle%3DProfiling%2520of%2520149%2520Salivary%2520Duct%2520Carcinomas%252C%2520Carcinoma%2520Ex%2520Pleomorphic%2520Adenomas%252C%2520and%2520Adenocarcinomas%252C%2520Not%2520Otherwise%2520Specified%2520Reveals%2520Actionable%2520Genomic%2520Alterations%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D6061%26epage%3D6068%26doi%3D10.1158%2F1078-0432.CCR-15-2568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braiteh, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolinakos, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenbowe, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span> <span> </span><span class="NLM_article-title">Emergence of RET Rearrangement Co-Existing with Activated EGFR Mutation in EGFR-Mutated NSCLC Patients who had Progressed on First- or Second-Generation EGFR TKI</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2015.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.lungcan.2015.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=26187428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FktFantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=357-359&author=S.+J.+Klempnerauthor=L.+A.+Bazhenovaauthor=F.+S.+Braitehauthor=P.+G.+Nikolinakosauthor=K.+Gowenauthor=C.+M.+Cervantesauthor=J.+Chmieleckiauthor=J.+R.+Greenboweauthor=J.+S.+Rossauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Aliauthor=S.+H.+Ou&title=Emergence+of+RET+Rearrangement+Co-Existing+with+Activated+EGFR+Mutation+in+EGFR-Mutated+NSCLC+Patients+who+had+Progressed+on+First-+or+Second-Generation+EGFR+TKI&doi=10.1016%2Fj.lungcan.2015.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI</span></div><div class="casAuthors">Klempner Samuel J; Cervantes Claudia M; Bazhenova Lyudmila A; Braiteh Fadi S; Nikolinakos Petros G; Gowen Kyle; Chmielecki Juliann; Greenbowe Joel R; Stephens Philip J; Miller Vincent A; Ali Siraj M; Ross Jeffrey S; Ou Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The gatekeeper mutation T790M mutation is the responsible for the majority of the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC).  Other previously described resistance mechanisms include HER2 amplification, MET amplification, PIK3CA mutation, epithelial-mesenchymal transition (EMT), small cell transformation have also been identified.  However other resistance mechanisms remains to be discovered.  MATERIALS AND METHODS:  Hybrid-capture based comprehensive genomic profiling (CGP) was performed on pre- and post-EGFR TKI progression EGFR-mutated NSCLC tumor samples during routine clinical care.  We identify two paired pre- and post-EGFR TKI progression EGFR-mutated NSCLC patient tumor samples where both post EGFR TKI samples harbored in-frame CCDC6-RET rearrangements but not in the pre-EGFR TKI tumor samples.  Furthermore analysis of the clinical database revealed one additional NCOA4-RET rearrangement co-existing with activated EGFR mutation in an EGFR-mutated NSCLC patient who had progressed on afatinib.  None of the known resistance mechanisms to EGFR TKI including EGFR T790M, EGFR amplification, HER2 amplification, MET amplification, PIK3CA mutation, BRAF mutation, EMT or small cell transformation was identified in the three post progression samples that now harbored RET rearrangements.  RESULTS AND CONCLUSIONS:  This is the first report of RET rearrangement co-existing with activated EGFR mutations in EGFR-mutated patients who had progressed on either first- or second generation EGFR TKI.  As such, RET rearrangement may serve as a potential resistance mechanism to EGFR TKI in EGFR-mutated NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC4yXiTTSim3WEEzDrymxmfW6udTcc2eYo7VWiRmgax7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FktFantw%253D%253D&md5=a3caf3ad2da9dbcf5be5e4ecb2c61130</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2015.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2015.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DBazhenova%26aufirst%3DL.%2BA.%26aulast%3DBraiteh%26aufirst%3DF.%2BS.%26aulast%3DNikolinakos%26aufirst%3DP.%2BG.%26aulast%3DGowen%26aufirst%3DK.%26aulast%3DCervantes%26aufirst%3DC.%2BM.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DGreenbowe%26aufirst%3DJ.%2BR.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BH.%26atitle%3DEmergence%2520of%2520RET%2520Rearrangement%2520Co-Existing%2520with%2520Activated%2520EGFR%2520Mutation%2520in%2520EGFR-Mutated%2520NSCLC%2520Patients%2520who%2520had%2520Progressed%2520on%2520First-%2520or%2520Second-Generation%2520EGFR%2520TKI%26jtitle%3DLung%2520Cancer%26date%3D2015%26volume%3D89%26spage%3D357%26epage%3D359%26doi%3D10.1016%2Fj.lungcan.2015.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span> <span> </span><span class="NLM_article-title">Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: an Update</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">3149</span>– <span class="NLM_lpage">3164</span>, <span class="refDoi"> DOI: 10.1210/jc.2013-1204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1210%2Fjc.2013-1204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=23744408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12gsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=3149-3164&author=S.+A.+Wellsauthor=F.+Paciniauthor=B.+G.+Robinsonauthor=M.+Santoro&title=Multiple+Endocrine+Neoplasia+Type+2+and+Familial+Medullary+Thyroid+Carcinoma%3A+an+Update&doi=10.1210%2Fjc.2013-1204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update</span></div><div class="casAuthors">Wells, Samuel A., Jr.; Pacini, Furio; Robinson, Bruce G.; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3149-3164</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndromes MEN2A and MEN2B and familial medullary thyroid carcinoma (FMTC) has expanded greatly.  In this manuscript, we summarize how recent discoveries have enhanced our understanding of the mol. basis of these diseases and led to improvements in the diagnosis and management of affected patients.  Evidence Acquisition: We reviewed the English literature through PubMed from 2000 to the present, using the search terms medullary thyroid carcinoma, multiple endocrine neoplasia type 2, familial medullary thyroid carcinoma, RET proto-oncogene, and calcitonin.  Evidence Synthesis: Over 70 RET mutations are known to cause MEN2A, MEN2B, or FMTC, and recent findings from studies of large kindreds with these syndromes have clouded the relationship between genotype and phenotype, primarily because of the varied clin. presentation of different families with the same RET mutation.  This clin. variability has also confounded decisions about the timing of prophylactic thyroidectomy for MTC, the dominant endocrinopathy assocd. with these syndromes.  A distinct advance has been the demonstration through phase II and phase III clin. trials that mol. targeted therapeutics are effective in the treatment of patients with locally advanced or metastatic MTC.  Conclusions: The effective management of patients with MEN2A, MEN2A, and FMTC depends on an understanding of the variable behavior of disease expression in patients with a specific RET mutation.  Information gained from mol. testing, biochem. anal., and clin. evaluation is important in providing effective management of patients with either early or advanced-stage MTC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyGQGQfacRvrVg90H21EOLACvtfcHk0ljrpY5oHzZqng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12gsL%252FM&md5=8732221749fa72c99546c0659db2e2e1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1210%2Fjc.2013-1204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2013-1204%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DPacini%26aufirst%3DF.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DMultiple%2520Endocrine%2520Neoplasia%2520Type%25202%2520and%2520Familial%2520Medullary%2520Thyroid%2520Carcinoma%253A%2520an%2520Update%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3D3149%26epage%3D3164%26doi%3D10.1210%2Fjc.2013-1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza-Menacho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacke, C. M.</span></span> <span> </span><span class="NLM_article-title">RET in Breast Cancer: Functional and Therapeutic Implications</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2010.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.molmed.2010.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=21251878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtV2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=149-157&author=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+M.+Isacke&title=RET+in+Breast+Cancer%3A+Functional+and+Therapeutic+Implications&doi=10.1016%2Fj.molmed.2010.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">RET in breast cancer: functional and therapeutic implications</span></div><div class="casAuthors">Morandi, Andrea; Plaza-Menacho, Ivan; Isacke, Clare M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent studies demonstrate that the receptor tyrosine kinase RET is overexpressed in a subset of ER-pos. breast cancers and that crosstalk between RET and ER is important in responses to endocrine therapy.  The development of small mol. inhibitors that target RET allows the opportunity to consider combination therapies as a strategy to improve response to treatment and to prevent and combat endocrine resistance.  This review discusses: (i) the current knowledge about RET, its co-receptors and ligands in breast cancer; (ii) the breast cancer clin. trials involving agents that target RET; and (iii) the challenges that remain in terms of specificity of available inhibitors and in understanding the complex mol. mechanisms that underlie the resistance to endocrine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjitcp-LZe6rVg90H21EOLACvtfcHk0ljrpY5oHzZqng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtV2qsro%253D&md5=5d50cc75916affcaa56ee983757abf68</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2010.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2010.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DIsacke%26aufirst%3DC.%2BM.%26atitle%3DRET%2520in%2520Breast%2520Cancer%253A%2520Functional%2520and%2520Therapeutic%2520Implications%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D149%26epage%3D157%26doi%3D10.1016%2Fj.molmed.2010.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armanini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerushalmi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haak-Frendscho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span> <span> </span><span class="NLM_article-title">Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5552</span>– <span class="NLM_lpage">5562</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F1078-0432.CCR-15-0468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=26240273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKjs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=5552-5562&author=M.+Nguyenauthor=S.+Miyakawaauthor=J.+Katoauthor=T.+Moriauthor=T.+Araiauthor=M.+Armaniniauthor=K.+Gelmonauthor=R.+Yerushalmiauthor=S.+Leungauthor=D.+Gaoauthor=G.+Landesauthor=M.+Haak-Frendschoauthor=K.+Eliasauthor=A.+D.+Simmons&title=Preclinical+Efficacy+and+Safety+Assessment+of+an+Antibody-Drug+Conjugate+Targeting+the+c-RET+Proto-Oncogene+for+Breast+Carcinoma&doi=10.1158%2F1078-0432.CCR-15-0468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma</span></div><div class="casAuthors">Nguyen, Minh; Miyakawa, Shuichi; Kato, Junichi; Mori, Toshiyuki; Arai, Toshimitsu; Armanini, Mark; Gelmon, Karen; Yerushalmi, Rinat; Leung, Samuel; Gao, Dongxia; Landes, Gregory; Haak-Frendscho, Mary; Elias, Kathleen; Simmons, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5552-5562</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The RET proto-oncogene has been implicated in breast cancer, and the studies herein describe the preclin. and safety assessment of an anti-RET antibody-drug conjugate (ADC) being developed for the treatment of breast cancer.  Exptl. Design: RET protein expression was analyzed in breast tumor samples using tissue microarrays.  The fully human anti-RET antibody (Y078) was conjugated to the DM1 and DM4 derivs. of the potent cytotoxic agent maytansine using thioether and disulfide linkers, resp.  The resulting compds., designated Y078-DM1 and Y078-DM4, were evaluated for antitumor activity using human breast cancer cell lines and established tumor xenograft models.  A single-dose, 28-day, safety study of Y078-DM1 was performed in cynomolgus monkeys.  Results: By immunohistochem., RET expression was detected in 57% of tumors (1,596 of 2,800 tumor sections) and was most common in HER2-pos. and basal breast cancer subtypes.  Potent in vitro cytotoxicity was achieved in human breast cancer cell lines that have expression levels comparable with those obsd. in breast cancer tissue samples.  Dose-response studies in xenograft models demonstrated antitumor activity with both weekly and every-3-wk dosing regimens.  In cynomolgus monkeys, a single injection of Y078-DM1 demonstrated dose-dependent, reversible drug-mediated alterations in blood chem. with evidence of on-target neuropathy.  Conclusions: RET is broadly expressed in breast cancer specimens and thus represents a potential therapeutic target; Y078-DM1 and Y078-DM4 demonstrated antitumor activity in preclin. models.  Optimization of the dosing schedule or an alternate cytotoxic agent with a different mechanism of action may reduce the potential risk of neuropathy.  Clin Cancer Res; 21(24); 5552-62.  ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxmnx_m4hKcrVg90H21EOLACvtfcHk0lj8GrOR2C1PJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKjs7jL&md5=4d98da9cdb9254aad762e9499f73a86f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0468%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DM.%26aulast%3DMiyakawa%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DJ.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DT.%26aulast%3DArmanini%26aufirst%3DM.%26aulast%3DGelmon%26aufirst%3DK.%26aulast%3DYerushalmi%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLandes%26aufirst%3DG.%26aulast%3DHaak-Frendscho%26aufirst%3DM.%26aulast%3DElias%26aufirst%3DK.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26atitle%3DPreclinical%2520Efficacy%2520and%2520Safety%2520Assessment%2520of%2520an%2520Antibody-Drug%2520Conjugate%2520Targeting%2520the%2520c-RET%2520Proto-Oncogene%2520for%2520Breast%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D5552%26epage%3D5562%26doi%3D10.1158%2F1078-0432.CCR-15-0468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brader, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. J.</span></span> <span> </span><span class="NLM_article-title">Paracrine Regulation of Pancreatic Cancer cell Invasion by Peripheral Nerves</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1093/jnci/djp456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1093%2Fjnci%2Fdjp456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=20068194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFakt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=107-118&author=Z.+Gilauthor=O.+Cavelauthor=K.+Kellyauthor=P.+Braderauthor=A.+Reinauthor=S.+P.+Gaoauthor=D.+L.+Carlsonauthor=J.+P.+Shahauthor=Y.+Fongauthor=R.+J.+Wong&title=Paracrine+Regulation+of+Pancreatic+Cancer+cell+Invasion+by+Peripheral+Nerves&doi=10.1093%2Fjnci%2Fdjp456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Paracrine Regulation of Pancreatic Cancer Cell Invasion by Peripheral Nerves</span></div><div class="casAuthors">Gil, Ziv; Cavel, Oren; Kelly, Kaitlyn; Brader, Peter; Rein, Avigail; Gao, Sizhi P.; Carlson, Diane L.; Shah, Jatin P.; Fong, Yuman; Wong, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-118</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background The ability of cancer to infiltrate along nerves is a common clin. observation in pancreas, head and neck, prostate, breast, and gastrointestinal carcinomas.  For these tumors, nerves may provide a conduit for local cancer progression into the central nervous system.  Although neural invasion is assocd. with poor outcome, the mechanism that triggers it is unknown.  Methods We used an in vitro Matrigel dorsal root ganglion and pancreatic cancer cell coculture model to assess the dynamic interactions between nerves and cancer cell migration and the role of glial cell-derived neurotrophic factor (GDNF).  An in vivo murine sciatic nerve model was used to study how nerve invasion affects sciatic nerve function.  Results Nerves induced a polarized neurotrophic migration of cancer cells (PNMCs) along their axons, which was more efficient than in the absence of nerves (migration distance: mean = 187.1 μm, 95% confidence interval [CI] = 148 to 226 μm vs 14.4 μm, 95% CI = 9.58 to 19.22 μm, difference = 143 μm; P < .001; n = 20).  PNMC was induced by secretion of GDNF, via phosphorylation of the RET-Ras-mitogen-activated protein kinase pathway.  Nerves from mice deficient in GDNF had reduced ability to attract cancer cells (nerve invasion index: wild type vs gdnf+/-, mean = 0.76, 95% CI = 0.75 to 0.77 vs 0.43, 95% CI = 0.42 to 0.44; P < .001; n = 60-66).  Tumor specimens excised from patients with neuroinvasive pancreatic carcinoma had higher expression of the GDNF receptors RET and GRFα1 as compared with normal tissue.  Finally, systemic therapy with pyrazolopyrimidine-1, a tyrosine kinase inhibitor targeting the RET pathway, suppressed nerve invasion toward the spinal cord and prevented paralysis in mice.  Conclusion These data provide evidence for paracrine regulation of pancreatic cancer invasion by nerves, which may have important implications for potential therapy directed against nerve invasion by cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD-nFBZgv00bVg90H21EOLACvtfcHk0lj8GrOR2C1PJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFakt7Y%253D&md5=892219b53b819677b670c71b101985bf</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjp456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjp456%26sid%3Dliteratum%253Aachs%26aulast%3DGil%26aufirst%3DZ.%26aulast%3DCavel%26aufirst%3DO.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DBrader%26aufirst%3DP.%26aulast%3DRein%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DS.%2BP.%26aulast%3DCarlson%26aufirst%3DD.%2BL.%26aulast%3DShah%26aufirst%3DJ.%2BP.%26aulast%3DFong%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DR.%2BJ.%26atitle%3DParacrine%2520Regulation%2520of%2520Pancreatic%2520Cancer%2520cell%2520Invasion%2520by%2520Peripheral%2520Nerves%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2010%26volume%3D102%26spage%3D107%26epage%3D118%26doi%3D10.1093%2Fjnci%2Fdjp456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernichenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakst, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barajas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deborde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. J.</span></span> <span> </span><span class="NLM_article-title">GFRα1 Released by Nerves Enhances Cancer Cell Perineural Invasion through GDNF-RET Signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E2008</span>– <span class="NLM_lpage">E2017</span>, <span class="refDoi"> DOI: 10.1073/pnas.1402944111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1073%2Fpnas.1402944111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24778213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFGisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E2008-E2017&author=S.+Heauthor=C.+H.+Chenauthor=N.+Chernichenkoauthor=S.+Heauthor=R.+L.+Bakstauthor=F.+Barajasauthor=S.+Debordeauthor=P.+J.+Allenauthor=E.+Vakianiauthor=Z.+Yuauthor=R.+J.+Wong&title=GFR%CE%B11+Released+by+Nerves+Enhances+Cancer+Cell+Perineural+Invasion+through+GDNF-RET+Signaling&doi=10.1073%2Fpnas.1402944111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling</span></div><div class="casAuthors">He, Shuangba; Chen, Chun-Hao; Chernichenko, Natalya; He, Shizhi; Bakst, Richard L.; Barajas, Fernando; Deborde, Sylvie; Allen, Peter J.; Vakiani, Efsevia; Yu, Zhenkun; Wong, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">E2008-E2017</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The ability of cancer cells to invade along nerves is assocd. with aggressive disease and diminished patient survival rates.  Perineural invasion (PNI) may be mediated by nerve secretion of glial cell line-derived neurotrophic factor (GDNF) attracting cancer cell migration through activation of cell surface Ret proto-oncogene (RET) receptors.  GDNF family receptor (GFR)α1 acts as coreceptor with RET, with both required for response to GDNF.  We demonstrate that GFRα1 released by nerves enhances PNI, even in the absence of cancer cell GFRα1 expression.  Cancer cell migration toward GDNF, RET phosphorylation, and MAPK pathway activity are increased with exposure to sol. GFRα1 in a dose-dependent fashion.  Dorsal root ganglia (DRG) release sol. GFRα1, which potentiates RET activation and cancer cell migration.  In vitro DRG coculture assays of PNI show diminished PNI with DRG from GFRα1+/- mice compared with GFRα1+/+ mice.  An in vivo murine model of PNI demonstrates that cancer cells lacking GFRα1 maintain an ability to invade nerves and impair nerve function, whereas those lacking RET lose this ability.  A tissue microarray of human pancreatic ductal adenocarcinomas demonstrates wide variance of cancer cell GFRα1 expression, suggesting an alternate source of GFRα1 in PNI.  These findings collectively demonstrate that GFRα1 released by nerves enhances PNI through GDNF-RET signaling and that GFRα1 expression by cancer cells enhances but is not required for PNI.  These results advance a mechanistic understanding of PNI and implicate the nerve itself as a key facilitator of this adverse cancer cell behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe3-IhA_AvmbVg90H21EOLACvtfcHk0lj8GrOR2C1PJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFGisL4%253D&md5=689468e21a62ba99f2d5c091e2019155</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1402944111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1402944111%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChernichenko%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DBakst%26aufirst%3DR.%2BL.%26aulast%3DBarajas%26aufirst%3DF.%26aulast%3DDeborde%26aufirst%3DS.%26aulast%3DAllen%26aufirst%3DP.%2BJ.%26aulast%3DVakiani%26aufirst%3DE.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DR.%2BJ.%26atitle%3DGFR%25CE%25B11%2520Released%2520by%2520Nerves%2520Enhances%2520Cancer%2520Cell%2520Perineural%2520Invasion%2520through%2520GDNF-RET%2520Signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE2008%26epage%3DE2017%26doi%3D10.1073%2Fpnas.1402944111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Falco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span> <span> </span><span class="NLM_article-title">The Molecular Basis for RET Tyrosine-kinase Inhibitors in Thyroid Cancer</span>. <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1016/j.beem.2017.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.beem.2017.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=28911727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVyitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=307-318&author=V.+De%0AFalcoauthor=F.+Carlomagnoauthor=H.+Y.+Liauthor=M.+Santoro&title=The+Molecular+Basis+for+RET+Tyrosine-kinase+Inhibitors+in+Thyroid+Cancer&doi=10.1016%2Fj.beem.2017.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer</span></div><div class="casAuthors">De Falco, Valentina; Carlomagno, Francesca; Li, Hong-yu; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">307-318</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">RET receptor tyrosine kinase acts as a mutated oncogenic driver in several human malignancies and it is over-expressed in other cancers.  Small mol. compds. with RET tyrosine kinase inhibitory activity are being investigated for the targeted treatment of these malignancies.  Multi-targeted compds. with RET inhibitory concn. in the nanomolar range have entered clin. practice.  This review summarizes mechanisms of RET oncogenic activity and properties of new compds. that, at the preclin. stage, have demonstrated promising anti-RET activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjmyfZyprDw7Vg90H21EOLACvtfcHk0li0fzyXTB_qVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVyitbo%253D&md5=5ee8bc030e96c39c3482848c450cf69b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.beem.2017.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beem.2017.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DThe%2520Molecular%2520Basis%2520for%2520RET%2520Tyrosine-kinase%2520Inhibitors%2520in%2520Thyroid%2520Cancer%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2017%26volume%3D31%26spage%3D307%26epage%3D318%26doi%3D10.1016%2Fj.beem.2017.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, G. G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S. W.</span></span> <span> </span><span class="NLM_article-title">Targeting RET-Driven Cancers: Lessons from Evolving Preclinical and Clinical Landscapes</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnrclinonc.2017.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=29134959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSitLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=151-167&author=A.+Drilonauthor=Z.+I.+Huauthor=G.+G.+Y.+Laiauthor=D.+S.+W.+Tan&title=Targeting+RET-Driven+Cancers%3A+Lessons+from+Evolving+Preclinical+and+Clinical+Landscapes&doi=10.1038%2Fnrclinonc.2017.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes</span></div><div class="casAuthors">Drilon, Alexander; Hu, Zishuo I.; Lai, Gillianne G. Y.; Tan, Daniel S. W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-167</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The gene encoding the receptor-tyrosine kinase RET was first discovered more than three decades ago, and activating RET rearrangements and mutations have since been identified as actionable drivers of oncogenesis.  Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been obsd. in patients with RET-rearranged lung cancers or RET-mutant thyroid cancers.  Nevertheless, response rates to RET-directed therapy are modest compared with those achieved using targeted therapies matched to other oncogenic drivers of solid tumors, such as sensitizing EGFR or BRAFV600E mutations, or ALK or ROS1 rearrangements.  To date, no RET-directed targeted therapeutic has received regulatory approval for the treatment of molecularly defined populations of patients with RET-mutant or RET-rearranged solid tumors.  In this Review, we discuss how emerging data have informed the debate over whether the limited success of multikinase inhibitors with activity against RET can be attributed to the tractability of RET as a drug target or to the lack, until 2017, of highly specific inhibitors of this oncoprotein in the clinic.  We emphasize that novel approaches to targeting RET-dependent tumors are necessary to improve the clin. efficacy of single-agent multikinase inhibition and, thus, hasten approvals of RET-directed targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHGH619E1uKrVg90H21EOLACvtfcHk0li0fzyXTB_qVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSitLbO&md5=44da2e242b7b5ad12eb628ed87b8fa74</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.175%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DZ.%2BI.%26aulast%3DLai%26aufirst%3DG.%2BG.%2BY.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26atitle%3DTargeting%2520RET-Driven%2520Cancers%253A%2520Lessons%2520from%2520Evolving%2520Preclinical%2520and%2520Clinical%2520Landscapes%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26spage%3D151%26epage%3D167%26doi%3D10.1038%2Fnrclinonc.2017.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Commander, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteside, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C.</span></span> <span> </span><span class="NLM_article-title">Vandetanib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1365</span>, <span class="refDoi"> DOI: 10.2165/11595310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.2165%2F11595310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=21770481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlakurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1355-1365&author=H.+Commanderauthor=G.+Whitesideauthor=C.+Perry&title=Vandetanib%3A+First+Global+Approval&doi=10.2165%2F11595310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib: first global approval</span></div><div class="casAuthors">Commander, Helen; Whiteside, Glenn; Perry, Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1355-1365</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC).  Regulatory submissions for this indication have been filed in the EU and Canada, with clin. development in malignant MTC ongoing in several other countries.  Vandetanib is being developed by AstraZeneca, and is also in phase II development for biliary, breast and prostate cancer.  Earlier, AstraZeneca withdrew regulatory filings for non-small cell lung cancer (NSCLC) in the US and EU, and later discontinued development.  This article summarizes the milestones in the development of vandetanib leading to this first approval in malignant MTC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsc9DGAyJOZ7Vg90H21EOLACvtfcHk0li0fzyXTB_qVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlakurzJ&md5=ffb345f58f8c488b3752dc43554054af</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2165%2F11595310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11595310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DCommander%26aufirst%3DH.%26aulast%3DWhiteside%26aufirst%3DG.%26aulast%3DPerry%26aufirst%3DC.%26atitle%3DVandetanib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D1355%26epage%3D1365%26doi%3D10.2165%2F11595310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grüllich, C.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib: a MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor</span>. <i>Recent Results Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-54490-3_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1007%2F978-3-642-54490-3_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24756794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVOqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2014&pages=207-214&author=C.+Gr%C3%BCllich&title=Cabozantinib%3A+a+MET%2C+RET%2C+and+VEGFR2+Tyrosine+Kinase+Inhibitor&doi=10.1007%2F978-3-642-54490-3_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Gruellich, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">207-214</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">2197-6767</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Cabozantinib is a receptor tyrosine kinase inhibitor with activity against MET, VEGFR2, FLT3, c-KIT, and RET.  Activity of cabozantinib toward a broad range of tumor models could be detected in several preclin. studies.  Of note, cabozantinib decreases metastasis potential and tumor invasiveness when compared with placebo or agents that target VEGFR and have no activity against MET.  Clin. phase I and II studies with cabozantinib have been conducted in various malignancies including medullary thyroid cancer (MTC), NSCLC, breast, ovarian, pancreatic, and prostate cancer.  In MTC, gain of function mutations of RET are central for tumorigenesis.  Hereditary forms of MTC (MEN II) are caused by germline mutations of RET, in sporadic MTC in up to 50 % of cases RET mutations occur.  Addnl., activating mol. changes in VEGFR and MET pathways have also been implicated in MTC progression.  Clin. responses with cabozantinib in MTC could be obsd. in early clin. trials, and following confirmation of clin. benefit in a randomized phase III trial, cabozantinib gained FDA approval for first-line treatment of advanced MTC in 2012.  In prostate cancer models, MET expression increases with androgen ablation and clin. progression of bone and lymph node metastasis.  A phase II trial with cabozantinib also showed very promising response rates in patients with metastatic prostate cancer.  Therefore, randomized phase III studies are currently ongoing to validate the efficacy of cabozantinib in heavily pretreated prostate cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofpYohX76awrVg90H21EOLACvtfcHk0li0fzyXTB_qVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVOqt7Y%253D&md5=e0adbd14c1da32af3e5ded5823f6ad32</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-54490-3_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-54490-3_12%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25BCllich%26aufirst%3DC.%26atitle%3DCabozantinib%253A%2520a%2520MET%252C%2520RET%252C%2520and%2520VEGFR2%2520Tyrosine%2520Kinase%2520Inhibitor%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2014%26volume%3D201%26spage%3D207%26epage%3D214%26doi%3D10.1007%2F978-3-642-54490-3_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagel, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dralle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baudin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarzab, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasselli, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmuir, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, M. J.</span></span> <span> </span><span class="NLM_article-title">Vandetanib in Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer: a Randomized, Double-Blind Phase III trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1200/JCO.2011.35.5040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1200%2FJCO.2011.35.5040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22025146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFGrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=134-141&author=S.+A.+Wellsauthor=B.+G.+Robinsonauthor=R.+F.+Gagelauthor=H.+Dralleauthor=J.+A.+Faginauthor=M.+Santoroauthor=E.+Baudinauthor=R.+Eliseiauthor=B.+Jarzabauthor=J.+R.+Vasselliauthor=J.+Readauthor=P.+Langmuirauthor=A.+J.+Ryanauthor=M.+J.+Schlumberger&title=Vandetanib+in+Patients+with+Locally+Advanced+or+Metastatic+Medullary+Thyroid+Cancer%3A+a+Randomized%2C+Double-Blind+Phase+III+trial&doi=10.1200%2FJCO.2011.35.5040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial</span></div><div class="casAuthors">Wells, Samuel A., Jr.; Robinson, Bruce G.; Gagel, Robert F.; Dralle, Henning; Fagin, James A.; Santoro, Massimo; Baudin, Eric; Elisei, Rossella; Jarzab, Barbara; Vasselli, James R.; Read, Jessica; Langmuir, Peter; Ryan, Anderson J.; Schlumberger, Martin I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-141</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC).  Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.  Patients and Methods Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo.  On objective disease progression, patients could elect to receive open-label vandetanib.  The primary end point was progression-free survival (PFS), detd. by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.  Results Between Dec. 2006 and Nov. 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100).  At data cutoff (July 2009; median follow-up, 24 mo), 37% of patients had progressed and 15% had died.  The study met its primary objective of PFS prolongation with vandetanib vs. placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001).  Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P = .001), and biochem. response (P < .001).  Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65).  A final survival anal. will take place when 50% of the patients have died.  Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%).  Conclusion Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnzd5Ld1n-AbVg90H21EOLACvtfcHk0lihwa6FW9HOVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFGrsb0%253D&md5=99ea5fa9e2cd53b14f85b8a37e1e3c2b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.5040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.5040%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DDralle%26aufirst%3DH.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DBaudin%26aufirst%3DE.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DVasselli%26aufirst%3DJ.%2BR.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DLangmuir%26aufirst%3DP.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26atitle%3DVandetanib%2520in%2520Patients%2520with%2520Locally%2520Advanced%2520or%2520Metastatic%2520Medullary%2520Thyroid%2520Cancer%253A%2520a%2520Randomized%252C%2520Double-Blind%2520Phase%2520III%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D134%26epage%3D141%26doi%3D10.1200%2FJCO.2011.35.5040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elisei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licitra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarzab, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medvedev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreissl, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaron, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelkin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, S. I.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib in Progressive Medullary Thyroid Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">3639</span>– <span class="NLM_lpage">3646</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.48.4659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3646&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+M%C3%BCllerauthor=P.+Sch%C3%B6ffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+Progressive+Medullary+Thyroid+Cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0lihwa6FW9HOVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%2BP.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520Progressive%2520Medullary%2520Thyroid%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3646%26doi%3D10.1200%2FJCO.2012.48.4659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habra, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newbold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianoukakis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzyzanowska, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutcus, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de las
Heras, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, S. I.</span></span> <span> </span><span class="NLM_article-title">Lenvatinib Versus Placebo in Radioiodine-Refractory Thyroid Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1406470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1056%2FNEJMoa1406470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=25671254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFWis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=621-630&author=M.+Schlumbergerauthor=M.+Taharaauthor=L.+J.+Wirthauthor=B.+Robinsonauthor=M.+S.+Broseauthor=R.+Eliseiauthor=M.+A.+Habraauthor=K.+Newboldauthor=M.+H.+Shahauthor=A.+O.+Hoffauthor=A.+G.+Gianoukakisauthor=N.+Kiyotaauthor=M.+H.+Taylorauthor=S.+B.+Kimauthor=M.+K.+Krzyzanowskaauthor=C.+E.+Dutcusauthor=B.+de+las%0AHerasauthor=J.+Zhuauthor=S.+I.+Sherman&title=Lenvatinib+Versus+Placebo+in+Radioiodine-Refractory+Thyroid+Cancer&doi=10.1056%2FNEJMoa1406470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lenvatinib versus placebo in radioiodine-refractory thyroid cancer</span></div><div class="casAuthors">Schlumberger, Martin; Tahara, Makoto; Wirth, Lori J.; Robinson, Bruce; Brose, Marcia S.; Elisei, Rossella; Habra, Mouhammed Amir; Newbold, Kate; Shah, Manisha H.; Hoff, Ana O.; Gianoukakis, Andrew G.; Kiyota, Naomi; Taylor, Matthew H.; Kim, Sung-Bae; Krzyzanowska, Monika K.; Dutcus, Corina E.; de las Heras, Begona; Zhu, Junming; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">621-630/1-621-630/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clin. activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).  In our phase 3, randomized, double-blind, multicenter study involving patients with progressive thyroid cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive lenvatinib (at a daily dose of 24 mg per day in 28-day cycles) and 131 patients to receive placebo.  At the time of disease progression, patients in the placebo group could receive open-label lenvatinib.  The primary end point was progression-free survival.  Secondary end points included the response rate, overall survival, and safety.  The median progression-free survival was 18.3 mo in the lenvatinib group and 3.6 mo in the placebo group (hazard ratio for progression or death, 0.21; 99% confidence interval, 0.14 to 0.31; P<0.001).  A progression-free survival benefit assocd. with lenvatinib was obsd. in all prespecified subgroups.  The response rate was 64.8% in the lenvatinib group (4 complete responses and 165 partial responses) and 1.5% in the placebo group (P<0.001).  The median overall survival was not reached in either group.  Treatment-related adverse effects of any grade, which occurred in more than 40% of patients in the lenvatinib group, were hypertension (in 67.8% of the patients), diarrhea (in 59.4%), fatigue or asthenia (in 59.0%), decreased appetite (in 50.2%), decreased wt. (in 46.4%), and nausea (in 41.0%).  Discontinuations of the study drug because of adverse effects occurred in 37 patients who received lenvatinib (14.2%) and 3 patients who received placebo (2.3%).  In the lenvatinib group, 6 of 20 deaths that occurred during the treatment period were considered to be drug-related.  Lenvatinib, as compared with placebo, was assocd. with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer.  Patients who received lenvatinib had more adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP3YOcsp5Eh7Vg90H21EOLACvtfcHk0lihwa6FW9HOVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFWis70%253D&md5=4670427f7c296a58bd24f90e042b743d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1406470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1406470%26sid%3Dliteratum%253Aachs%26aulast%3DSchlumberger%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DM.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DRobinson%26aufirst%3DB.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DHabra%26aufirst%3DM.%2BA.%26aulast%3DNewbold%26aufirst%3DK.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DHoff%26aufirst%3DA.%2BO.%26aulast%3DGianoukakis%26aufirst%3DA.%2BG.%26aulast%3DKiyota%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DM.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DKrzyzanowska%26aufirst%3DM.%2BK.%26aulast%3DDutcus%26aufirst%3DC.%2BE.%26aulast%3Dde%2Blas%2BHeras%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DLenvatinib%2520Versus%2520Placebo%2520in%2520Radioiodine-Refractory%2520Thyroid%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D621%26epage%3D630%26doi%3D10.1056%2FNEJMoa1406470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Development of Sorafenib for the Treatment of Thyroid Cancer</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1517/17460441.2015.1006194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1517%2F17460441.2015.1006194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=25662396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFehtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=427-439&author=P.+T.+Whiteauthor=M.+S.+Cohen&title=The+Discovery+and+Development+of+Sorafenib+for+the+Treatment+of+Thyroid+Cancer&doi=10.1517%2F17460441.2015.1006194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of sorafenib for the treatment of thyroid cancer</span></div><div class="casAuthors">White, Peter T.; Cohen, Mark S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">427-439</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Although the prognosis for most differentiated thyroid cancers (DTCs) remains excellent, recurrence and insensitivity to radioactive iodine (RAI) lead to therapeutic challenges and poorer outcomes.  In defining the pathogenesis of DTC, multiple genetic alterations have been identified in key pathways focused around receptor tyrosine kinases (RTKs) and the MAPK cascade.  Sorafenib was specifically developed to target rapidly accelerated fibrosarcoma (RAF) kinase in the MAPK pathway.  It has been shown, however, to have potent inhibition of several key RTKs, RAF kinase and the V600E BRAF mutation, gaining FDA approval in Nov. 2013 for advanced RAI-refractory DTC.  Areas covered: The authors provide a review of the targeted RAF kinase discovery strategy as well as the preclin. and clin. development of sorafenib, leading to FDA approval of DTC.  The authors also provide some insight into the clin. use of sorafenib and look at important considerations for treatment.  Expert opinion: Sorafenib significantly improves progression-free survival in metastatic DTC patients who are RAI-refractory.  However, the overall survival benefit is still unproven and requires addnl. follow up.  Despite its cost and significant side-effect profile, which results in dose redns. in the majority of DTC patients, sorafenib should be considered for the treatment of RAI-refractory advanced DTC patients following evaluation of their individual risk-benefit stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ZRrHxZhzUrVg90H21EOLACvtfcHk0liwbLWmOdUHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFehtr8%253D&md5=ec64129cfdfbf441102dba2f98878c73</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1006194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1006194%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DP.%2BT.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26atitle%3DThe%2520Discovery%2520and%2520Development%2520of%2520Sorafenib%2520for%2520the%2520Treatment%2520of%2520Thyroid%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D427%26epage%3D439%26doi%3D10.1517%2F17460441.2015.1006194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brubaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPietro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garralda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span> <span> </span><span class="NLM_article-title">Precision Targeted Therapy with BLU-667 for RET-Driven Cancers</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F2159-8290.CD-18-0338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=29657135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1altLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=836-849&author=V.+Subbiahauthor=J.+F.+Gainorauthor=R.+Rahalauthor=J.+D.+Brubakerauthor=J.+L.+Kimauthor=M.+Maynardauthor=W.+Huauthor=Q.+Caoauthor=M.+P.+Sheetsauthor=D.+Wilsonauthor=K.+J.+Wilsonauthor=L.+DiPietroauthor=P.+Flemingauthor=M.+Palmerauthor=M.+I.+Huauthor=L.+Wirthauthor=M.+S.+Broseauthor=S.+I.+Ouauthor=M.+Taylorauthor=E.+Garraldaauthor=S.+Millerauthor=B.+Wolfauthor=C.+Lengauerauthor=T.+Guziauthor=E.+K.+Evans&title=Precision+Targeted+Therapy+with+BLU-667+for+RET-Driven+Cancers&doi=10.1158%2F2159-8290.CD-18-0338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Precision Targeted Therapy with BLU-667 for RET-Driven Cancers</span></div><div class="casAuthors">Subbiah, Vivek; Gainor, Justin F.; Rahal, Rami; Brubaker, Jason D.; Kim, Joseph L.; Maynard, Michelle; Hu, Wei; Cao, Qiongfang; Sheets, Michael P.; Wilson, Douglas; Wilson, Kevin J.; Di Pietro, Lucian; Fleming, Paul; Palmer, Michael; Hu, Mimi I.; Wirth, Lori; Brose, Marcia S.; Ou, Sai-Hong Ignatius; Taylor, Matthew; Garralda, Elena; Miller, Stephen; Wolf, Beni; Lengauer, Christoph; Guzi, Timothy; Evans, Erica K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">836-849</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer.  No approved therapies have been designed to target RET; treatment has been limited to multikinase inhibitors (MKI), which can have significant off-target toxicities and limited efficacy.  BLU-667 is a highly potent and selective RET inhibitor designed to overcome these limitations.  In vitro, BLU-667 demonstrated ≥10-fold increased potency over approved MKIs against oncogenic RET variants and resistance mutants.  In vivo, BLU-667 potently inhibited growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2.  In first-in-human testing, BLU-667 significantly inhibited RET signaling and induced durable clin. responses in patients with RET-altered NSCLC and MTC without notable off-target toxicity, providing clin. validation for selective RET targeting.  Significance: Patients with RET-driven cancers derive limited benefit from available MKIs.  BLU-667 is a potent and selective RET inhibitor that induces tumor regression in cancer models with RET mutations and fusions.  BLU-667 attenuated RET signaling and produced durable clin. responses in patients with RET-altered tumors, clin. validating selective RET targeting.  Cancer Discov; 8(7); 836-49. .copyright.2018 AACR.  See related commentary by Iams and Lovly, p. 797.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9whHmxdlp0rVg90H21EOLACvtfcHk0lh1XD7kSggotw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1altLnE&md5=f910f4d236619a357cf42163583f5e7d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0338%26sid%3Dliteratum%253Aachs%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DRahal%26aufirst%3DR.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DMaynard%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DSheets%26aufirst%3DM.%2BP.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DDiPietro%26aufirst%3DL.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DM.%2BI.%26aulast%3DWirth%26aufirst%3DL.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DGarralda%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWolf%26aufirst%3DB.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DEvans%26aufirst%3DE.%2BK.%26atitle%3DPrecision%2520Targeted%2520Therapy%2520with%2520BLU-667%2520for%2520RET-Driven%2520Cancers%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D836%26epage%3D849%26doi%3D10.1158%2F2159-8290.CD-18-0338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velcheti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busaidy, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabanillas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsi-Travali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">Selective RET Kinase Inhibition for Patients with RET-Altered Cancers</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1869</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1093%2Fannonc%2Fmdy137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=29912274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbot12lsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=1869-1876&author=V.+Subbiahauthor=V.+Velchetiauthor=B.+B.+Tuchauthor=K.+Ebataauthor=N.+L.+Busaidyauthor=M.+E.+Cabanillasauthor=L.+J.+Wirthauthor=S.+Stockauthor=S.+Smithauthor=V.+Lauriaultauthor=S.+Corsi-Travaliauthor=D.+Henryauthor=M.+Burkardauthor=R.+Hamorauthor=K.+Bouhanaauthor=S.+Winskiauthor=R.+D.+Wallaceauthor=D.+Hartleyauthor=S.+Rhodesauthor=M.+Reddyauthor=B.+J.+Brandhuberauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=A.+Drilon&title=Selective+RET+Kinase+Inhibition+for+Patients+with+RET-Altered+Cancers&doi=10.1093%2Fannonc%2Fmdy137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selective RET kinase inhibition for patients with RET-altered cancers</span></div><div class="casAuthors">Subbiah V; Busaidy N L; Cabanillas M E; Velcheti V; Stock S; Tuch B B; Ebata K; Smith S; Lauriault V; Corsi-Travali S; Henry D; Brandhuber B J; Andrews S; Wirth L J; Burkard M; Hamor R; Bouhana K; Winski S; Wallace R D; Hartley D; Rhodes S; Reddy M; Rothenberg S M; Drilon A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1869-1876</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Alterations involving the RET kinase are implicated in the pathogenesis of lung, thyroid and other cancers.  However, the clinical activity of multikinase inhibitors (MKIs) with anti-RET activity in RET-altered patients appears limited, calling into question the therapeutic potential of targeting RET.  LOXO-292 is a selective RET inhibitor designed to inhibit diverse RET fusions, activating mutations and acquired resistance mutations.  Patients and methods:  Potent anti-RET activity, high selectivity, and central nervous system coverage were confirmed preclinically using a variety of in vitro and in vivo RET-dependent tumor models.  Due to clinical urgency, two patients with RET-altered, MKI-resistant cancers were treated with LOXO-292, utilizing rapid dose-titration guided by real-time pharmacokinetic assessments to achieve meaningful clinical exposures safely and rapidly.  Results:  LOXO-292 demonstrated potent and selective anti-RET activity preclinically against human cancer cell lines harboring endogenous RET gene alterations; cells engineered to express a KIF5B-RET fusion protein -/+ the RET V804M gatekeeper resistance mutation or the common RET activating mutation M918T; and RET-altered human cancer cell line and patient-derived xenografts, including a patient-derived RET fusion-positive xenograft injected orthotopically into the brain.  A patient with RET M918T-mutant medullary thyroid cancer metastatic to the liver and an acquired RET V804M gatekeeper resistance mutation, previously treated with six MKI regimens, experienced rapid reductions in tumor calcitonin, CEA and cell-free DNA, resolution of painful hepatomegaly and tumor-related diarrhea and a confirmed tumor response.  A second patient with KIF5B-RET fusion-positive lung cancer, acquired resistance to alectinib and symptomatic brain metastases experienced a dramatic response in the brain, and her symptoms resolved.  Conclusions:  These results provide proof-of-concept of the clinical actionability of RET alterations, and identify selective RET inhibition by LOXO-292 as a promising treatment in heavily pretreated, multikinase inhibitor-experienced patients with diverse RET-altered tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQnDC8BTRt7OdfST00W0BcfW6udTcc2eZNOwAHuzkDabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbot12lsA%253D%253D&md5=1acdc0949007df1a17f9ccbf227b8633</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy137%26sid%3Dliteratum%253Aachs%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DVelcheti%26aufirst%3DV.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DBusaidy%26aufirst%3DN.%2BL.%26aulast%3DCabanillas%26aufirst%3DM.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DStock%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DCorsi-Travali%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DD.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DBouhana%26aufirst%3DK.%26aulast%3DWinski%26aufirst%3DS.%26aulast%3DWallace%26aufirst%3DR.%2BD.%26aulast%3DHartley%26aufirst%3DD.%26aulast%3DRhodes%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DM.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DSelective%2520RET%2520Kinase%2520Inhibition%2520for%2520Patients%2520with%2520RET-Altered%2520Cancers%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3D1869%26epage%3D1876%26doi%3D10.1093%2Fannonc%2Fmdy137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszanski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgensztern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seery, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolinakos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F2159-8290.CD-18-0839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=30487236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOmsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=384-395&author=A.+Drilonauthor=S.+Fuauthor=M.+R.+Patelauthor=M.+Fakihauthor=D.+Wangauthor=A.+J.+Olszanskiauthor=D.+Morgenszternauthor=S.+V.+Liuauthor=B.+C.+Choauthor=L.+Bazhenovaauthor=C.+P.+Rodriguezauthor=R.+C.+Doebeleauthor=A.+Wozniakauthor=K.+L.+Reckampauthor=T.+Seeryauthor=P.+Nikolinakosauthor=Z.+Huauthor=J.+W.+Oliverauthor=D.+Troneauthor=K.+McArthurauthor=R.+Patelauthor=P.+S.+Multaniauthor=M.+J.+Ahn&title=A+Phase+I%2FIb+Trial+of+the+VEGFR-Sparing+Multikinase+RET+Inhibitor+RXDX-105&doi=10.1158%2F2159-8290.CD-18-0839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105</span></div><div class="casAuthors">Drilon, Alexander; Fu, Siqing; Patel, Manish R.; Fakih, Marwan; Wang, Ding; Olszanski, Anthony J.; Morgensztern, Daniel; Liu, Stephen V.; Cho, Byoung Chul; Bazhenova, Lyudmila; Rodriguez, Cristina P.; Doebele, Robert C.; Wozniak, Antoinette; Reckamp, Karen L.; Seery, Tara; Nikolinakos, Petros; Hu, Zheyi; Oliver, Jennifer W.; Trone, Denise; McArthur, Katherine; Patel, Rupal; Multani, Pratik S.; Ahn, Myung-Ju</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-395</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">RET fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLC).  The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial.  A recommended phase II dose of 275 mg fed daily was identified.  The most common treatment-related adverse events were fatigue (25%), diarrhea (24%), hypophosphatemia (18%), maculopapular rash (18%), and nonmaculopapular rash (17%).  In the phase Ib cohort of RET inhibitor-na.ovrddot.ive patients with RET fusion-pos. NSCLCs, the objective response rate (ORR) was 19% (95% CI, 8%-38%, n = 6/31).  Interestingly, the ORR varied significantly by the gene fusion partner (P < 0.001, Fisher exact test): 0% (95% CI, 0%-17%, n = 0/20) with KIF5B (the most common upstream partner for RET fusion-pos. NSCLC), and 67% (95% CI, 30%-93%, n = 6/9) with non-KIF5B partners.  The median duration of response in all RET fusion-pos. NSCLCs was not reached (range, 5 to 18+ months).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLZba-OIyH67Vg90H21EOLACvtfcHk0lh1XD7kSggotw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOmsLrN&md5=920590dca8e2475da2443d0721412b49</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0839%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFakih%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DOlszanski%26aufirst%3DA.%2BJ.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DRodriguez%26aufirst%3DC.%2BP.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DSeery%26aufirst%3DT.%26aulast%3DNikolinakos%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DOliver%26aufirst%3DJ.%2BW.%26aulast%3DTrone%26aufirst%3DD.%26aulast%3DMcArthur%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DA%2520Phase%2520I%252FIb%2520Trial%2520of%2520the%2520VEGFR-Sparing%2520Multikinase%2520RET%2520Inhibitor%2520RXDX-105%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D384%26epage%3D395%26doi%3D10.1158%2F2159-8290.CD-18-0839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moccia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brescia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Falco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Admire, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8717</span>– <span class="NLM_lpage">8721</span>, <span class="refDoi"> DOI: 10.1002/anie.201501104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1002%2Fanie.201501104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8717-8721&author=B.+Frettauthor=F.+Carlomagnoauthor=M.+L.+Mocciaauthor=A.+Bresciaauthor=G.+Federicoauthor=V.+De+Falcoauthor=B.+Admireauthor=Z.+Chenauthor=W.+Qiauthor=M.+Santoroauthor=H.+Y.+Li&title=Fragment-Based+Discovery+of+a+Dual+pan-RET%2FVEGFR2+Kinase+Inhibitor+Optimized+for+Single-Agent+Polypharmacology&doi=10.1002%2Fanie.201501104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span></div><div class="casAuthors">Frett, Brendan; Carlomagno, Francesca; Moccia, Maria Luisa; Brescia, Annalisa; Federico, Giorgia; De Falco, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hong-yu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8717-8721</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is assocd. with several cancers.  A fragment-based chem. screen led to the identification of a novel RET inhibitor, Pz-1.  Modeling and kinetic anal. identified Pz-1 as a type II tyrosine kinase inhibitor that is able to bind the "DFG-out" conformation of the kinase.  Importantly, from a single-agent polypharmacol. standpoint, Pz-1 was shown to be active on VEGFR2, which can block the blood supply required for RET-stimulated growth.  In cell-based assays, 1.0 nM of Pz-1 strongly inhibited phosphorylation of all tested RET oncoproteins.  At 1.0 mg kg-1 day-1 per os, Pz-1 abrogated the formation of tumors induced by RET-mutant fibroblasts and blocked the phosphorylation of both RET and VEGFR2 in tumor tissue.  Pz-1 featured no detectable toxicity at concns. of up to 100.0 mg kg-1, which indicates a large therapeutic window.  This study validates the effectiveness and usefulness of a medicinal chem./polypharmacol. approach to obtain an inhibitor capable of targeting multiple oncogenic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcoWkpO70i7rVg90H21EOLACvtfcHk0lhq2hl8WBo7dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtLnL&md5=05039c7074e7375de3884e0550d8c7ff</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.201501104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201501104%26sid%3Dliteratum%253Aachs%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DMoccia%26aufirst%3DM.%2BL.%26aulast%3DBrescia%26aufirst%3DA.%26aulast%3DFederico%26aufirst%3DG.%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DAdmire%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%2BY.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Dual%2520pan-RET%252FVEGFR2%2520Kinase%2520Inhibitor%2520Optimized%2520for%2520Single-Agent%2520Polypharmacology%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D8717%26epage%3D8721%26doi%3D10.1002%2Fanie.201501104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, H.</span></span> <span> </span><span class="NLM_article-title">Drug-Metabolizing Enzyme Systems I</span>. In  <i>Comprehensive Medicinal Chemistry III</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span>, <span class="NLM_string-name">Rotella, D.</span>, <span class="NLM_string-name">Ward, S.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">50</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2FB978-0-12-409547-2.12314-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=45-50&author=H.+Yamazakiauthor=S.+Chackalamannil&author=D.+Rotella&author=S.+Ward&title=Comprehensive+Medicinal+Chemistry+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-409547-2.12314-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-409547-2.12314-5%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DH.%26atitle%3DDrug-Metabolizing%2520Enzyme%2520Systems%2520I%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520III%26aulast%3DChackalamannil%26aufirst%3DS.%26pub%3DElsevier%26date%3D2017%26spage%3D45%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lhq2hl8WBo7dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anaganti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecchio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billaud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span> <span> </span><span class="NLM_article-title">Disease Associated Mutations at Valine 804 in the RET Receptor Tyrosine Kinase Confer Resistance to Selective Kinase Inhibitors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6063</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1207810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fsj.onc.1207810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=15184865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVKlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6056-6063&author=F.+Carlomagnoauthor=T.+Guidaauthor=S.+Anagantiauthor=G.+Vecchioauthor=A.+Fuscoauthor=A.+J.+Ryanauthor=M.+Billaudauthor=M.+Santoro&title=Disease+Associated+Mutations+at+Valine+804+in+the+RET+Receptor+Tyrosine+Kinase+Confer+Resistance+to+Selective+Kinase+Inhibitors&doi=10.1038%2Fsj.onc.1207810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors</span></div><div class="casAuthors">Carlomagno, Francesca; Guida, Teresa; Anaganti, Suresh; Vecchio, Giancarlo; Fusco, Alfredo; Ryan, Anderson J.; Billaud, Marc; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6056-6063</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC50≤100 nM) towards constitutively active oncogenic RET kinases.  Here, we show that most oncogenic MEN2-assocd. RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition.  In contrast, MEN2-assocd. swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compds.  Substitution of valine 804 with the small amino- acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC50: 20 nM) than the wild-type kinase.  Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJql666y5D-bVg90H21EOLACvtfcHk0liQMK0r7JrYCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVKlt7c%253D&md5=39ec0aa2550048d7cd9a5536a6180fc0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207810%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DGuida%26aufirst%3DT.%26aulast%3DAnaganti%26aufirst%3DS.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DBillaud%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DDisease%2520Associated%2520Mutations%2520at%2520Valine%2520804%2520in%2520the%2520RET%2520Receptor%2520Tyrosine%2520Kinase%2520Confer%2520Resistance%2520to%2520Selective%2520Kinase%2520Inhibitors%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6056%26epage%3D6063%26doi%3D10.1038%2Fsj.onc.1207810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redaelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza-Menacho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorti-Passerini, C.</span></span> <span> </span><span class="NLM_article-title">Ponatinib is a Potent Inhibitor of Wild-Type and Drug-Resistant Gatekeeper Mutant RET Kinase</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2013.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.mce.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=23811235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2013&pages=1-6&author=L.+Mologniauthor=S.+Redaelliauthor=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+Gambacorti-Passerini&title=Ponatinib+is+a+Potent+Inhibitor+of+Wild-Type+and+Drug-Resistant+Gatekeeper+Mutant+RET+Kinase&doi=10.1016%2Fj.mce.2013.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span></div><div class="casAuthors">Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a mol. target in these tumors.  Vandetanib was recently approved for the treatment of medullary thyroid cancer.  However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants in chronic myeloid leukemia.  Ponatinib is a multi-target kinase inhibitor that was recently approved for treatment-refractory Philadelphia-pos. leukemia.  We show here potent inhibition of oncogenic RET by ponatinib, including the drug-insensitive V804M/L mutants.  Ponatinib inhibited the growth of RET+ and BCR-ABL+ cells with similar potency, while not affecting RET-neg. cells.  Both in biochem. and in cellular assays ponatinib compared favorably with known RET inhibitors, such as vandetanib, cabozantinib, sorafenib, sunitinib and motesanib, used as ref. compds.  We suggest that ponatinib should be considered for the treatment of RET+ tumors, in particular those expressing vandetanib-resistant V804M/L mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1KRyhCS6ULVg90H21EOLACvtfcHk0liQMK0r7JrYCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP&md5=f08de33f80af574f3ec843d26269ed98</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DPonatinib%2520is%2520a%2520Potent%2520Inhibitor%2520of%2520Wild-Type%2520and%2520Drug-Resistant%2520Gatekeeper%2520Mutant%2520RET%2520Kinase%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D377%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.mce.2013.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brägelmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tischler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrugalla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richters, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leenders, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diebold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautschi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Drugging the Catalytically Inactive State of RET kinase in RET-Rearranged Tumors</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">eaah6144</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aah6144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1126%2Fscitranslmed.aah6144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=28615362" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaah6144&author=D.+Plenkerauthor=M.+Riedelauthor=J.+Br%C3%A4gelmannauthor=M.+A.+Dammertauthor=R.+Chauhanauthor=P.+P.+Knowlesauthor=C.+Lorenzauthor=M.+Keulauthor=M.+B%C3%BChrmannauthor=O.+Pagelauthor=V.+Tischlerauthor=A.+H.+Scheelauthor=D.+Sch%C3%BCtteauthor=Y.+Songauthor=J.+Starkauthor=F.+Mrugallaauthor=Y.+Alberauthor=A.+Richtersauthor=J.+Engelauthor=F.+Leendersauthor=J.+M.+Heuckmannauthor=J.+Wolfauthor=J.+Dieboldauthor=G.+Pallauthor=M.+Peiferauthor=M.+Aertsauthor=K.+Gevaertauthor=R.+P.+Zahediauthor=R.+Buettnerauthor=K.+M.+Shokatauthor=N.+Q.+McDonaldauthor=S.+M.+Kastauthor=O.+Gautschiauthor=R.+K.+Thomasauthor=M.+L.+Sos&title=Drugging+the+Catalytically+Inactive+State+of+RET+kinase+in+RET-Rearranged+Tumors&doi=10.1126%2Fscitranslmed.aah6144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aah6144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aah6144%26sid%3Dliteratum%253Aachs%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DRiedel%26aufirst%3DM.%26aulast%3DBr%25C3%25A4gelmann%26aufirst%3DJ.%26aulast%3DDammert%26aufirst%3DM.%2BA.%26aulast%3DChauhan%26aufirst%3DR.%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DLorenz%26aufirst%3DC.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DPagel%26aufirst%3DO.%26aulast%3DTischler%26aufirst%3DV.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DSch%25C3%25BCtte%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DStark%26aufirst%3DJ.%26aulast%3DMrugalla%26aufirst%3DF.%26aulast%3DAlber%26aufirst%3DY.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLeenders%26aufirst%3DF.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DDiebold%26aufirst%3DJ.%26aulast%3DPall%26aufirst%3DG.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DAerts%26aufirst%3DM.%26aulast%3DGevaert%26aufirst%3DK.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DGautschi%26aufirst%3DO.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DDrugging%2520the%2520Catalytically%2520Inactive%2520State%2520of%2520RET%2520kinase%2520in%2520RET-Rearranged%2520Tumors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26spage%3Deaah6144%26doi%3D10.1126%2Fscitranslmed.aah6144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesen, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allali-Hassani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finerty, P. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasney, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span> <span> </span><span class="NLM_article-title">Chemical Screening Methods to Identify Ligands that Promote Protein Stability, Protein Crystallization, and Structure Determination</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">15835</span>– <span class="NLM_lpage">15840</span>, <span class="refDoi"> DOI: 10.1073/pnas.0605224103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1073%2Fpnas.0605224103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=17035505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFymur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=15835-15840&author=M.+Vedadiauthor=F.+H.+Niesenauthor=A.+Allali-Hassaniauthor=O.+Y.+Fedorovauthor=P.+J.+Finertyauthor=G.+A.+Wasneyauthor=R.+Yeungauthor=C.+Arrowsmithauthor=L.+J.+Ballauthor=H.+Berglundauthor=R.+Huiauthor=B.+D.+Marsdenauthor=P.+Nordlundauthor=M.+Sundstromauthor=J.+Weigeltauthor=A.+M.+Edwards&title=Chemical+Screening+Methods+to+Identify+Ligands+that+Promote+Protein+Stability%2C+Protein+Crystallization%2C+and+Structure+Determination&doi=10.1073%2Fpnas.0605224103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination</span></div><div class="casAuthors">Vedadi, Masoud; Niesen, Frank H.; Allali-Hassani, Abdellah; Fedorov, Oleg Y.; Finerty, Patrick J., Jr.; Wasney, Gregory A.; Yeung, Ron; Arrowsmith, Cheryl; Ball, Linda J.; Berglund, Helena; Hui, Raymond; Marsden, Brian D.; Nordlund, Paer; Sundstrom, Michael; Weigelt, Johan; Edwards, Aled M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">15835-15840</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The 3D structures of human therapeutic targets are enabling for drug discovery.  However, their purifn. and crystn. remain rate detg.  In individual cases, ligands have been used to increase the success rate of protein purifn. and crystn., but the broad applicability of this approach is unknown.  The authors implemented two screening platforms, based on either fluorometry or static light scattering, to measure the increase in protein thermal stability upon binding of a ligand without the need to monitor enzyme activity.  In total, 221 different proteins from humans and human parasites were screened against one or both of two sorts of small-mol. libraries.  The first library comprised different salts, pH conditions, and commonly found small mols. and was applicable to all proteins.  The second comprised compds. specific for protein families of particular interest (e.g., protein kinases).  In 20 cases, including nine unique human protein kinases, a small mol. was identified that stabilized the proteins and promoted structure detn.  The methods are cost-effective, can be implemented in any lab., promise to increase the success rates of purifying and crystg. human proteins significantly, and identify new ligands for these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4duhcFpFn-bVg90H21EOLACvtfcHk0lho0KM3q3W-Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFymur%252FN&md5=6515225c1613291deb7bb774d900f605</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0605224103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0605224103%26sid%3Dliteratum%253Aachs%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DNiesen%26aufirst%3DF.%2BH.%26aulast%3DAllali-Hassani%26aufirst%3DA.%26aulast%3DFedorov%26aufirst%3DO.%2BY.%26aulast%3DFinerty%26aufirst%3DP.%2BJ.%26aulast%3DWasney%26aufirst%3DG.%2BA.%26aulast%3DYeung%26aufirst%3DR.%26aulast%3DArrowsmith%26aufirst%3DC.%26aulast%3DBall%26aufirst%3DL.%2BJ.%26aulast%3DBerglund%26aufirst%3DH.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DMarsden%26aufirst%3DB.%2BD.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DSundstrom%26aufirst%3DM.%26aulast%3DWeigelt%26aufirst%3DJ.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26atitle%3DChemical%2520Screening%2520Methods%2520to%2520Identify%2520Ligands%2520that%2520Promote%2520Protein%2520Stability%252C%2520Protein%2520Crystallization%252C%2520and%2520Structure%2520Determination%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D15835%26epage%3D15840%26doi%3D10.1073%2Fpnas.0605224103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakaoku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagatoishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span> <span> </span><span class="NLM_article-title">A Secondary RET Mutation in the Activation Loop Conferring Resistance to Vandetanib</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">625</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-02994-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fs41467-018-02994-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=29434222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MrgslSgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=625&author=T.+Nakaokuauthor=T.+Kohnoauthor=M.+Arakiauthor=S.+Nihoauthor=R.+Chauhanauthor=P.+P.+Knowlesauthor=K.+Tsuchiharaauthor=S.+Matsumotoauthor=Y.+Shimadaauthor=S.+Mimakiauthor=G.+Ishiiauthor=H.+Ichikawaauthor=S.+Nagatoishiauthor=K.+Tsumotoauthor=Y.+Okunoauthor=K.+Yohauthor=N.+Q.+McDonaldauthor=K.+Goto&title=A+Secondary+RET+Mutation+in+the+Activation+Loop+Conferring+Resistance+to+Vandetanib&doi=10.1038%2Fs41467-018-02994-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A secondary RET mutation in the activation loop conferring resistance to vandetanib</span></div><div class="casAuthors">Nakaoku Takashi; Kohno Takashi; Shimada Yoko; Kohno Takashi; Tsuchihara Katsuya; Matsumoto Shingo; Mimaki Sachiyo; Ichikawa Hitoshi; Araki Mitsugu; Araki Mitsugu; Okuno Yasushi; Niho Seiji; Matsumoto Shingo; Yoh Kiyotaka; Goto Koichi; Chauhan Rakhee; Knowles Phillip P; McDonald Neil Q; Ishii Genichiro; Nagatoishi Satoru; Tsumoto Kouhei; McDonald Neil Q</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">625</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment.  The resistant tumor acquired a secondary mutation resulting in a serine-to-phenylalanine substitution at codon 904 in the activation loop of the RET kinase domain.  The S904F mutation confers resistance to vandetanib by increasing the ATP affinity and autophosphorylation activity of RET kinase.  A reduced interaction with the drug is also observed in vitro for the S904F mutant by thermal shift assay.  A crystal structure of the S904F mutant reveals a small hydrophobic core around F904 likely to enhance basal kinase activity by stabilizing an active conformer.  Our findings indicate that missense mutations in the activation loop of the kinase domain are able to increase kinase activity and confer drug resistance through allosteric effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9xn_VdnX4Cf69nzq6467DfW6udTcc2eaXYmB--CzjdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrgslSgtg%253D%253D&md5=0c9d8b569d55d00076026f20a7679a52</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-02994-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-02994-7%26sid%3Dliteratum%253Aachs%26aulast%3DNakaoku%26aufirst%3DT.%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DChauhan%26aufirst%3DR.%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DTsuchihara%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DMimaki%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DIchikawa%26aufirst%3DH.%26aulast%3DNagatoishi%26aufirst%3DS.%26aulast%3DTsumoto%26aufirst%3DK.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DYoh%26aufirst%3DK.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DGoto%26aufirst%3DK.%26atitle%3DA%2520Secondary%2520RET%2520Mutation%2520in%2520the%2520Activation%2520Loop%2520Conferring%2520Resistance%2520to%2520Vandetanib%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D625%26doi%3D10.1038%2Fs41467-018-02994-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">7604</span>– <span class="NLM_lpage">7614</span>, <span class="refDoi"> DOI: 10.1021/jm0504858</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0504858" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCltbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7604-7614&author=A.+N.+Bullockauthor=J.+E.+Debreczeniauthor=O.+Y.+Fedorovauthor=A.+Nelsonauthor=B.+D.+Marsdenauthor=S.+Knapp&title=Structural+Basis+of+Inhibitor+Specificity+of+the+Human+Protooncogene+Proviral+Insertion+Site+in+Moloney+Murine+Leukemia+Virus+%28PIM-1%29+Kinase&doi=10.1021%2Fjm0504858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase</span></div><div class="casAuthors">Bullock, Alex N.; Debreczeni, Judit E.; Fedorov, Oleg Y.; Nelson, Adam; Marsden, Brian D.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7604-7614</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kinase PIM-1 plays a pivotal role in cytokine signaling and is implicated in the development of a no. of tumors.  The three-dimensional structure of PIM-1 is characterized by an unique hinge region which lacks a second hydrogen bond donor and makes it particularly important to det. how inhibitors bind to this kinase.  We detd. the structures of PIM-1 in complex with bisindolylmaleimide (BIM-1) and established the structure-activity relationship (SAR) for this inhibitor class.  In addn., we screened a kinase targeted library and identified a no. of high affinity inhibitors of PIM-1 such as imidazo[1,2-b]pyridazines, pyrazolo[1,5-a]pyrimidines, and members of the flavonoid family.  In this paper we present an initial SAR of the identified scaffolds detd. on the basis of a thermostability shift assay, calorimetric binding data, and biochem. assays which may find applications for the treatment of PIM-1 dependent cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp28lXmrIarT7Vg90H21EOLACvtfcHk0lho0KM3q3W-Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCltbjL&md5=762eab52382fe72eed93e00ce37b390e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm0504858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0504858%26sid%3Dliteratum%253Aachs%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DFedorov%26aufirst%3DO.%2BY.%26aulast%3DNelson%26aufirst%3DA.%26aulast%3DMarsden%26aufirst%3DB.%2BD.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DStructural%2520Basis%2520of%2520Inhibitor%2520Specificity%2520of%2520the%2520Human%2520Protooncogene%2520Proviral%2520Insertion%2520Site%2520in%2520Moloney%2520Murine%2520Leukemia%2520Virus%2520%2528PIM-1%2529%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7604%26epage%3D7614%26doi%3D10.1021%2Fjm0504858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span> <span> </span><span class="NLM_article-title">Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7921</span>– <span class="NLM_lpage">7932</span>, <span class="refDoi"> DOI: 10.1021/jm8010299</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010299" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7921-7932&author=I.+Kufarevaauthor=R.+Abagyan&title=Type-II+Kinase+Inhibitor+Docking%2C+Screening%2C+and+Profiling+Using+Modified+Structures+of+Active+Kinase+States&doi=10.1021%2Fjm8010299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States</span></div><div class="casAuthors">Kufareva, Irina; Abagyan, Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7921-7932</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Type-II kinase inhibitors represent a class of chems. that trap their target kinases in an inactive, so-called DFG-out state, occupying a hydrophobic pocket adjacent to the ATP binding site.  These compds. are often more specific than those that target active DFG-in kinase conformations.  Unfortunately, the discovery of novel type-II scaffolds presents a considerable challenge, partially because the lack of compatible kinase structures makes structure-based methods inapplicable.  We present a computational protocol for converting multiple available DFG-in structures of various kinases (∼70% of mammalian structural kinome) into accurate and specific models of their type-II bound state.  The models, described as deletion-of-loop Asp-Phe-Gly-in (DOLPHIN) kinase models, demonstrate exceptional performance in various inhibitor discovery applications, including compd. pose prediction, screening, and in silico activity profiling.  Given the abundance of the DFG-in structures, the presented approach opens possibilities for kinome-wide discovery of specific mols. targeting inactive kinase states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp699dzZf5YRLVg90H21EOLACvtfcHk0lhJQQLPp8ztRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK&md5=64fb7b9f789940dd61c68015341af4a6</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm8010299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010299%26sid%3Dliteratum%253Aachs%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DAbagyan%26aufirst%3DR.%26atitle%3DType-II%2520Kinase%2520Inhibitor%2520Docking%252C%2520Screening%252C%2520and%2520Profiling%2520Using%2520Modified%2520Structures%2520of%2520Active%2520Kinase%2520States%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7921%26epage%3D7932%26doi%3D10.1021%2Fjm8010299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plaza-Menacho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnouin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Torres, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Rust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouilleron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span> <span> </span><span class="NLM_article-title">Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation in Trans</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2014.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.molcel.2014.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24560924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFCku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=738-751&author=I.+Plaza-Menachoauthor=K.+Barnouinauthor=K.+Goodmanauthor=R.+J.+Mart%C3%ADnez-Torresauthor=A.+Borgauthor=J.+Murray-Rustauthor=S.+Mouilleronauthor=P.+Knowlesauthor=N.+Q.+McDonald&title=Oncogenic+RET+Kinase+Domain+Mutations+Perturb+the+Autophosphorylation+Trajectory+by+Enhancing+Substrate+Presentation+in+Trans&doi=10.1016%2Fj.molcel.2014.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans</span></div><div class="casAuthors">Plaza-Menacho, Ivan; Barnouin, Karin; Goodman, Kerry; Martinez-Torres, Ruben J.; Borg, Annabel; Murray-Rust, Judith; Mouilleron, Stephane; Knowles, Phillip; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">738-751</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To decipher the mol. basis for RET kinase activation and oncogenic deregulation, we defined the temporal sequence of RET autophosphorylation by label-free quant. mass spectrometry.  Early autophosphorylation sites map to regions flanking the kinase domain core, while sites within the activation loop only form at later time points.  Comparison with oncogenic RET kinase revealed that late autophosphorylation sites become phosphorylated much earlier than wild-type RET, which is due to a combination of an enhanced enzymic activity, increased ATP affinity, and surprisingly, by providing a better intermol. substrate.  Structural anal. of oncogenic M918T and wild-type RET kinase domains reveal a cis-inhibitory mechanism involving tethering contacts between the glycine-rich loop, activation loop, and αC-helix.  Tether mutations only affected substrate presentation but perturbed the autophosphorylation trajectory similar to oncogenic mutations.  This study reveals an unappreciated role for oncogenic RET kinase mutations in promoting intermol. autophosphorylation by enhancing substrate presentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNqTC9t3FwObVg90H21EOLACvtfcHk0lhJQQLPp8ztRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFCku7c%253D&md5=ebac0e5fec3e9f67cfa18730b0a5e84e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DBarnouin%26aufirst%3DK.%26aulast%3DGoodman%26aufirst%3DK.%26aulast%3DMart%25C3%25ADnez-Torres%26aufirst%3DR.%2BJ.%26aulast%3DBorg%26aufirst%3DA.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DMouilleron%26aufirst%3DS.%26aulast%3DKnowles%26aufirst%3DP.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DOncogenic%2520RET%2520Kinase%2520Domain%2520Mutations%2520Perturb%2520the%2520Autophosphorylation%2520Trajectory%2520by%2520Enhancing%2520Substrate%2520Presentation%2520in%2520Trans%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D53%26spage%3D738%26epage%3D751%26doi%3D10.1016%2Fj.molcel.2014.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furitsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oritani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, Y.</span></span> <span> </span><span class="NLM_article-title">Constitutively Activating Mutations of C-Kit Receptor Tyrosine Kinase Confer Factor-Independent Growth and Tumorigenicity of Factor-Dependent Hematopoietic Cell Lines</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1182/blood.V85.3.790.bloodjournal853790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1182%2Fblood.V85.3.790.bloodjournal853790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=7530509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADyaK2MXjtlCqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1995&pages=790-798&author=H.+Kitayamaauthor=Y.+Kanakuraauthor=T.+Furitsuauthor=T.+Tsujimuraauthor=K.+Oritaniauthor=H.+Ikedaauthor=H.+Sugaharaauthor=H.+Mitsuiauthor=Y.+Kanayamaauthor=Y.+Kitamura&title=Constitutively+Activating+Mutations+of+C-Kit+Receptor+Tyrosine+Kinase+Confer+Factor-Independent+Growth+and+Tumorigenicity+of+Factor-Dependent+Hematopoietic+Cell+Lines&doi=10.1182%2Fblood.V85.3.790.bloodjournal853790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines</span></div><div class="casAuthors">Kitayama, Hitoshi; Kanakura, Yuzuru; Furitsu, Takuma; Tsujimura, Tohru; Oritani, Kenji; Ikeda, Hirokazu; Sugahara, Hiroyuki; Mitsui, Hideki; Kanayama, Yoshio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">790-8</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">The c-kit receptor tyrosine kinase (KIT) is activated upon ligand binding, thereby leading to a variety of signaling events that play a fundamental role in hematopoiesis.  In addn. to ligand-dependent activation, we have previously shown that KIT is constitutively activated in a ligand-independent manner by two-point mutations, Val-559 → Gly (G559) mutation in the juxtamembrane domain and Asp-814 → Val (V814) mutation in the phosphotransferase domain.  To investigate the biochem. consequence and biol. significance of these mutations, retroviral vectors encoding KITG559 or KITV814 were introduced into murine pro-B-type Ba/F3 cells and myeloid FDC-P1 cells, both of which require interleukin-3 (IL-3) for their growth and survival.  In the cells, KITG559 or KITV814 were found to be constitutively phosphorylated on tyrosine in the absence of stem cell factor (SCF) that is a ligand for KIT.  Chem. crosslinking anal. showed that a substantial fraction of the phosphorylated KITG559 underwent dimerization even in the absence of SCF, whereas the phosphorylated KITV814 did not, suggesting the distinct mechanisms underlying constitutive activation of KIT by G559 and V814 mutations.  Furthermore, the cells expressing either KITG559 or KITV814 were found to show a factor-independent growth, whereas the cells expressing wild-type KIT (KITWT) proliferated in response to SCF as well as IL-3.  Moreover, s.c. injection of Ba/F3 cells expressing KITG559 or KITV814 into nude mice resulted in prodn. of large tumors at all sites of the injection within 2 wk, and all nude mice quickly succumbed to leukemia and died.  These results suggest that, although the mechanisms underlying constitutive activation of KITG559 or KITV814 may be different, both of the activating mutations have a function to induce a factor-independent and tumorigenic phenotype.  Also, the data of this study raise the possibility that the constitutively activating mutations of c-kit may play a causal role in development of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraa_gnNjI0kbVg90H21EOLACvtfcHk0ljTbu6mAZGszg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtlCqur4%253D&md5=f932500323514ebe817c62f64b98bb90</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood.V85.3.790.bloodjournal853790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V85.3.790.bloodjournal853790%26sid%3Dliteratum%253Aachs%26aulast%3DKitayama%26aufirst%3DH.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DFuritsu%26aufirst%3DT.%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DOritani%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DSugahara%26aufirst%3DH.%26aulast%3DMitsui%26aufirst%3DH.%26aulast%3DKanayama%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DConstitutively%2520Activating%2520Mutations%2520of%2520C-Kit%2520Receptor%2520Tyrosine%2520Kinase%2520Confer%2520Factor-Independent%2520Growth%2520and%2520Tumorigenicity%2520of%2520Factor-Dependent%2520Hematopoietic%2520Cell%2520Lines%26jtitle%3DBlood%26date%3D1995%26volume%3D85%26spage%3D790%26epage%3D798%26doi%3D10.1182%2Fblood.V85.3.790.bloodjournal853790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkaniga, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaganti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span> <span> </span><span class="NLM_article-title">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1731</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01092</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01092" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Khur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1731-1760&author=W.+Yanauthor=N.+R.+Lakkanigaauthor=F.+Carlomagnoauthor=M.+Santoroauthor=N.+Q.+McDonaldauthor=F.+Lvauthor=N.+Gunagantiauthor=B.+Frettauthor=H.+Y.+Li&title=Insights+into+Current+Tropomyosin+Receptor+Kinase+%28TRK%29+Inhibitors%3A+Development+and+Clinical+Application&doi=10.1021%2Facs.jmedchem.8b01092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span></div><div class="casAuthors">Yan, Wei; Lakkaniga, Naga Rajiv; Carlomagno, Francesca; Santoro, Massimo; McDonald, Neil Q.; Lv, Fengping; Gunaganti, Naresh; Frett, Brendan; Li, Hong-yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1731-1760</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib.  Annually, it is estd. that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement.  In this Perspective, we discuss current development and clin. applications for TRK precision medicine by providing the following: (1) the biol. background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and anal. of their cocrystal structures, (3) an overview of TRK clin. trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwUthQyJEzFrVg90H21EOLACvtfcHk0ljTbu6mAZGszg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Khur%252FO&md5=5ce2f8d295cf46f84b46f5890dad0160</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01092%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DLakkaniga%26aufirst%3DN.%2BR.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DGunaganti%26aufirst%3DN.%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.%2BY.%26atitle%3DInsights%2520into%2520Current%2520Tropomyosin%2520Receptor%2520Kinase%2520%2528TRK%2529%2520Inhibitors%253A%2520Development%2520and%2520Clinical%2520Application%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1731%26epage%3D1760%26doi%3D10.1021%2Facs.jmedchem.8b01092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+Kinase+by+Utilizing+a+Novel+Allosteric+Binding+Site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0ljTbu6mAZGszg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520Kinase%2520by%2520Utilizing%2520a%2520Novel%2520Allosteric%2520Binding%2520Site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Rust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibáñez, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span> <span> </span><span class="NLM_article-title">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">33577</span>– <span class="NLM_lpage">33587</span>, <span class="refDoi"> DOI: 10.1074/jbc.M605604200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kjaerauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ib%C3%A1%C3%B1ezauthor=N.+Q.+McDonald&title=Structure+and+Chemical+Inhibition+of+the+RET+Tyrosine+Kinase+Domain&doi=10.1074%2Fjbc.M605604200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0lh4k1IoJKfc8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520Chemical%2520Inhibition%2520of%2520the%2520RET%2520Tyrosine%2520Kinase%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587%26doi%3D10.1074%2Fjbc.M605604200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geneste, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudkin, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuffenecker, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billaud, M.</span></span> <span> </span><span class="NLM_article-title">Oncogenic Activation of RET by Two Distinct FMTC Mutations Affecting the Tyrosine Kinase Domain</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fsj.onc.1201199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=9242375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADyaK2sXlt1Sqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1997&pages=393-402&author=A.+Pasiniauthor=O.+Genesteauthor=P.+Legrandauthor=M.+Schlumbergerauthor=M.+Rosselauthor=L.+Fournierauthor=B.+B.+Rudkinauthor=I.+Schuffeneckerauthor=G.+M.+Lenoirauthor=M.+Billaud&title=Oncogenic+Activation+of+RET+by+Two+Distinct+FMTC+Mutations+Affecting+the+Tyrosine+Kinase+Domain&doi=10.1038%2Fsj.onc.1201199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain</span></div><div class="casAuthors">Pasini, Andrea; Geneste, Olivier; Legrand, Pierre; Schlumberger, Martin; Rossel, Mireille; Fournier, Laurence; Rudkin, Brian B.; Schuffenecker, Isabelle; Lenoir, Gilbert M.; Billaud, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-402</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are two dominantly inherited disorders caused by germline mutations of the RET proto-oncogene.  The RET gene codes for a receptor tyrosine kinase.  The majority of MEN2A and FMTC mutations are clustered in the extra-cellular cysteine-rich domain and result in constitutive activation of the tyrosine kinase through the formation of disulfide-bonded RET homodimers.  Recently, two novel point mutations have been identified in the germline of five distinct FMTC families.  Both mutations occur within the catalytic domain of the RET kinase and lead to the substitution of either glutamic acid 768 or valine 804 by an aspartic acid and a leucine resp.  The authors have introduced each FMTC mutation in two RET isoforms: RET51 the long isoform (1114 aa) and RET9 the short isoform (1072 aa) which differ in the C-terminal region of the protein.  The RET51 isoform carrying either E768D or V804L mutation was autophosphorylated, displayed a transforming activity upon expression in Rat1 fibroblasts and induced neuronal differentiation of PC12 cells.  However, the transforming capacity of these RET51-FMTC mutants was severalfold less potent compared to the same isoform carrying either the MEN2A mutation (C634R) or the MEN2B mutation (M918T).  In contrast, RET9 contg. mutations E768D or V804L was not autophosphorylated, exhibited a poor oncogenic potential in fibroblasts and did not promote neuritic outgrowth upon expression in PC12 cells.  Overall, these findings demonstrate that mutations E768D and V804L are gain-of-function mutations that confer to the long RET isoform the capacity to exert a biol. effect, although these mutations are more weakly activating than the MEN2A and MEN2B mutations.  These results may provide a biochem. basis as to why the phenotypic consequences of these mutations are restricted to thyroid C-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqela5Vlh60QrVg90H21EOLACvtfcHk0lh4k1IoJKfc8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlt1Sqtbg%253D&md5=96747637bd386fed52375064de2af4f8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201199%26sid%3Dliteratum%253Aachs%26aulast%3DPasini%26aufirst%3DA.%26aulast%3DGeneste%26aufirst%3DO.%26aulast%3DLegrand%26aufirst%3DP.%26aulast%3DSchlumberger%26aufirst%3DM.%26aulast%3DRossel%26aufirst%3DM.%26aulast%3DFournier%26aufirst%3DL.%26aulast%3DRudkin%26aufirst%3DB.%2BB.%26aulast%3DSchuffenecker%26aufirst%3DI.%26aulast%3DLenoir%26aufirst%3DG.%2BM.%26aulast%3DBillaud%26aufirst%3DM.%26atitle%3DOncogenic%2520Activation%2520of%2520RET%2520by%2520Two%2520Distinct%2520FMTC%2520Mutations%2520Affecting%2520the%2520Tyrosine%2520Kinase%2520Domain%26jtitle%3DOncogene%26date%3D1997%26volume%3D15%26spage%3D393%26epage%3D402%26doi%3D10.1038%2Fsj.onc.1201199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushijima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagao, M.</span></span> <span> </span><span class="NLM_article-title">cDNA Cloning and Characterization of Ret Activated in a Human Papillary Thyroid Carcinoma Cell Line</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(90)92335-W</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2F0006-291X%2890%2992335-W" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=2334411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADyaK3cXktFyrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=1990&pages=402-408&author=Y.+Ishizakaauthor=T.+Ushijimaauthor=T.+Sugimuraauthor=M.+Nagao&title=cDNA+Cloning+and+Characterization+of+Ret+Activated+in+a+Human+Papillary+Thyroid+Carcinoma+Cell+Line&doi=10.1016%2F0006-291X%2890%2992335-W"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line</span></div><div class="casAuthors">Ishizaka, Yukihito; Ushijima, Toshikazu; Sugimura, Takashi; Nagao, Minako</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">402-8</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Activated ret cDNAs (retTPC) were obtained from human papillary thyroid carcinoma cell line, TPC-1, and their structures were characterized.  The nucleotide sequence indicated that recombination had occurred just upstream of the kinase domain of the ret proto-oncogene and that the position, where the conserved sequence of the ret proto-oncogene starts in retTPC transcripts, was exactly the same as that of ret-II which was previously analyzed.  Furthermore, a unique 13-glycine stretch, which is also present in a small subunit of the calcium-dependent protease, calpain, was detected in the replaced sequence of retTPC.  The aberrant tyrosine kinase activity induced by the rearrangement of ret protooncogene could be involved in the development of papillary thyroid carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZAA0q8KYZNrVg90H21EOLACvtfcHk0lh4k1IoJKfc8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktFyrtbc%253D&md5=81e59bfc46e5a8e6036c0d7da7683fcb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2890%2992335-W&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252890%252992335-W%26sid%3Dliteratum%253Aachs%26aulast%3DIshizaka%26aufirst%3DY.%26aulast%3DUshijima%26aufirst%3DT.%26aulast%3DSugimura%26aufirst%3DT.%26aulast%3DNagao%26aufirst%3DM.%26atitle%3DcDNA%2520Cloning%2520and%2520Characterization%2520of%2520Ret%2520Activated%2520in%2520a%2520Human%2520Papillary%2520Thyroid%2520Carcinoma%2520Cell%2520Line%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1990%26volume%3D168%26spage%3D402%26epage%3D408%26doi%3D10.1016%2F0006-291X%2890%2992335-W" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Franciscis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panariello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colantuoni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusco, A.</span></span> <span> </span><span class="NLM_article-title">Point Mutation of the RET Proto-Oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1995.1287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1006%2Fbbrc.1995.1287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=7864888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADyaK2MXjvVyqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=1995&pages=1022-1028&author=F.+Carlomagnoauthor=D.+Salvatoreauthor=M.+Santoroauthor=V.+de+Franciscisauthor=L.+Quadroauthor=L.+Panarielloauthor=V.+Colantuoniauthor=A.+Fusco&title=Point+Mutation+of+the+RET+Proto-Oncogene+in+the+TT+Human+Medullary+Thyroid+Carcinoma+Cell+Line&doi=10.1006%2Fbbrc.1995.1287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line</span></div><div class="casAuthors">Carlomagno, Francesca; Salvatore, Domenico; Santoro, Massimo; de Franciscis, Vittorio; Quadro, Loredana; Panariello, Luigi; Colantuoni, Vittorio; Fusco, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1022-8</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a tyrosine-kinase receptor specifically expressed in tissues of neuroectodermal origin.  Recently specific point mutations of RET have been demonstrated to be responsible for the Multiple Endocrine Neoplasia type 2A and 2B and Familial Medullary Thyroid Carcinoma syndromes, characterized by the occurrence of medullary thyroid carcinomas.  Here we report that a human medullary thyroid carcinoma cell line, the TT cell line, harbours a MEN2A-type mutation, specifically a cysteine to triptophan substitution at the level of the RET codon 634.  This mutation is heterozygous and both normal and mutated alleles are expressed.  We suggest that the TT cell line could be a useful cell system to investigate the role played by the RET oncogene in the transformation and differentiation of human thyroid C-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Ot8w4LkPbbVg90H21EOLACvtfcHk0lgPOoif9QsV2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjvVyqs74%253D&md5=580b07bb815deef0181f8d378e6d9ca0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1995.1287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1995.1287%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSalvatore%26aufirst%3DD.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3Dde%2BFranciscis%26aufirst%3DV.%26aulast%3DQuadro%26aufirst%3DL.%26aulast%3DPanariello%26aufirst%3DL.%26aulast%3DColantuoni%26aufirst%3DV.%26aulast%3DFusco%26aufirst%3DA.%26atitle%3DPoint%2520Mutation%2520of%2520the%2520RET%2520Proto-Oncogene%2520in%2520the%2520TT%2520Human%2520Medullary%2520Thyroid%2520Carcinoma%2520Cell%2520Line%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D207%26spage%3D1022%26epage%3D1028%26doi%3D10.1006%2Fbbrc.1995.1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makinoshima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchihara, K.</span></span> <span> </span><span class="NLM_article-title">Identification of a Lung Adenocarcinoma Cell Line with CCDC6-RET Fusion Gene and the Effect of RET Inhibitors in Vitro and in Vivo</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1111/cas.12175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1111%2Fcas.12175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=23578175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFGmsbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=896-903&author=M.+Suzukiauthor=H.+Makinoshimaauthor=S.+Matsumotoauthor=A.+Suzukiauthor=S.+Mimakiauthor=K.+Matsushimaauthor=K.+Yohauthor=K.+Gotoauthor=Y.+Suzukiauthor=G.+Ishiiauthor=A.+Ochiaiauthor=K.+Tsutaauthor=T.+Shibataauthor=T.+Kohnoauthor=H.+Esumiauthor=K.+Tsuchihara&title=Identification+of+a+Lung+Adenocarcinoma+Cell+Line+with+CCDC6-RET+Fusion+Gene+and+the+Effect+of+RET+Inhibitors+in+Vitro+and+in+Vivo&doi=10.1111%2Fcas.12175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo</span></div><div class="casAuthors">Suzuki, Makito; Makinoshima, Hideki; Matsumoto, Shingo; Suzuki, Ayako; Mimaki, Sachiyo; Matsushima, Koutatsu; Yoh, Kiyotaka; Goto, Koichi; Suzuki, Yutaka; Ishii, Genichiro; Ochiai, Atsushi; Tsuta, Koji; Shibata, Tatsuhiro; Kohno, Takashi; Esumi, Hiroyasu; Tsuchihara, Katsuya</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">896-903</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Rearrangements of the proto-oncogene RET are newly identified potential driver mutations in lung adenocarcinoma (LAD).  However, the absence of cell lines harboring RET fusion genes has hampered the investigation of the biol. relevance of RET and the development of RET-targeted therapy.  Thus, we aimed to identify a RET fusion pos. LAD cell line.  Eleven LAD cell lines were screened for RET fusion transcripts by reverse transcription-polymerase chain reaction.  The biol. relevance of the CCDC6-RET gene products was assessed by cell growth, survival and phosphorylation of ERK1/2 and AKT with or without the suppression of RET expression using RNA interference.  The efficacy of RET inhibitors was evaluated in vitro using a culture system and in an in vivo xenograft model.  Expression of the CCDC6-RET fusion gene in LC-2/ad cells was demonstrated by the mRNA and protein levels, and the genomic break-point was confirmed by genomic DNA sequencing.  Mutations in KRAS and EGFR were not obsd. in the LC-2/ad cells.  CCDC6-RET was constitutively active, and the introduction of a siRNA targeting the RET 3' region decreased cell proliferation by downregulating RET and ERK1/2 phosphorylation.  Moreover, treatment with RET-inhibitors, including vandetanib, reduced cell viability, which was accompanied by the downregulation of the AKT and ERK1/2 signaling pathways.  Vandetanib exhibited anti-tumor effects in the xenograft model.  Endogenously expressing CCDC6-RET contributed to cell growth.  The inhibition of kinase activity could be an effective treatment strategy for LAD.  LC-2/ad is a useful model for developing fusion RET-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozFPtfC_fKsLVg90H21EOLACvtfcHk0lgPOoif9QsV2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFGmsbfN&md5=f226982ebc36869700c45b23ee6bfac7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fcas.12175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12175%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DMakinoshima%26aufirst%3DH.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DMimaki%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DK.%26aulast%3DYoh%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DOchiai%26aufirst%3DA.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DEsumi%26aufirst%3DH.%26aulast%3DTsuchihara%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520a%2520Lung%2520Adenocarcinoma%2520Cell%2520Line%2520with%2520CCDC6-RET%2520Fusion%2520Gene%2520and%2520the%2520Effect%2520of%2520RET%2520Inhibitors%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DCancer%2520Sci.%26date%3D2013%26volume%3D104%26spage%3D896%26epage%3D903%26doi%3D10.1111%2Fcas.12175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitagliano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellone, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span> <span> </span><span class="NLM_article-title">Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1897</span>– <span class="NLM_lpage">1902</span>, <span class="refDoi"> DOI: 10.1210/jc.2002-021278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1210%2Fjc.2002-021278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=12679489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFCltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=1897-1902&author=F.+Carlomagnoauthor=D.+Vitaglianoauthor=T.+Guidaauthor=F.+Basoloauthor=M.+D.+Castelloneauthor=R.+M.+Melilloauthor=A.+Fuscoauthor=M.+Santoro&title=Efficient+Inhibition+of+RET%2FPapillary+Thyroid+Carcinoma+Oncogenic+Kinases+by+4-amino-5-%284-chloro-phenyl%29-7-%28t-butyl%29pyrazolo%5B3%2C4-d%5Dpyrimidine+%28PP2%29&doi=10.1210%2Fjc.2002-021278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Comment: Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)</span></div><div class="casAuthors">Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Basolo, Fulvio; Castellone, Maria Domenica; Melillo, Rosa Marina; Fusco, Alfredo; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1897-1902</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Inappropriate activation of the RET receptor tyrosine kinase causes development of papillary and medullary thyroid cancer.  We have previously shown that pyrazolopyrimidine is a potent inhibitor of the RET kinase.  Here, we show that 4-amino-5-(4-chloro-phenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2), another pyrazolopyrimidine, blocks the enzymic activity of the isolated RET kinase and RET/PTC1 oncoprotein at IC50 in the nanomolar range.  PP2 blocked in vivo phosphorylation and signaling of the RET/PTC1 oncoprotein.  PP2 prevented serum-independent growth of RET/PTC1-transformed NIH3T3 fibroblasts and of TPC1 and FB2, two human papillary thyroid carcinoma cell lines that carry spontaneous RET/PTC1 rearrangements.  Finally, PP2 blocked invasion of type 1 collagen matrix by TPC1 cells.  Thus, pyrazolopirimidines hold promise for the treatment of human cancers sustaining oncogenic activation of RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaaPru7feflrVg90H21EOLACvtfcHk0lgPOoif9QsV2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFCltLc%253D&md5=4e207efc7c20be1fa2bc3439ff2ef257</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1210%2Fjc.2002-021278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2002-021278%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DVitagliano%26aufirst%3DD.%26aulast%3DGuida%26aufirst%3DT.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DCastellone%26aufirst%3DM.%2BD.%26aulast%3DMelillo%26aufirst%3DR.%2BM.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DEfficient%2520Inhibition%2520of%2520RET%252FPapillary%2520Thyroid%2520Carcinoma%2520Oncogenic%2520Kinases%2520by%25204-amino-5-%25284-chloro-phenyl%2529-7-%2528t-butyl%2529pyrazolo%255B3%252C4-d%255Dpyrimidine%2520%2528PP2%2529%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2003%26volume%3D88%26spage%3D1897%26epage%3D1902%26doi%3D10.1210%2Fjc.2002-021278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Lingtian  Zhang</span>, <span class="hlFld-ContribAuthor ">Fengping  Lv</span>, <span class="hlFld-ContribAuthor ">Marialuisa  Moccia</span>, <span class="hlFld-ContribAuthor ">Francesca  Carlomagno</span>, <span class="hlFld-ContribAuthor ">Christophe  Landry</span>, <span class="hlFld-ContribAuthor ">Massimo  Santoro</span>, <span class="hlFld-ContribAuthor ">Fabien  Gosselet</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113265. <a href="https://doi.org/10.1016/j.ejmech.2021.113265" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113265%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrazolo-thieno%25255B3%25252C2-d%25255Dpyrimidinylamino-phenyl%252Bacetamides%252Bas%252Btype-II%252Bpan-tropomyosin%252Breceptor%252Bkinase%252B%252528TRK%252529%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%26aulast%3DYan%26aufirst%3DWei%26date%3D2021%26volume%3D216%26spage%3D113265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ru  Wang</span>, <span class="hlFld-ContribAuthor ">Hu  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  You</span>, <span class="hlFld-ContribAuthor ">Xin-Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Bing-Bing  Lv</span>, <span class="hlFld-ContribAuthor ">Li-Qin  Cao</span>, <span class="hlFld-ContribAuthor ">Jia-Yu  Xue</span>, <span class="hlFld-ContribAuthor ">Yun-Gen  Xu</span>, <span class="hlFld-ContribAuthor ">Lei  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>36 </em>, 127788. <a href="https://doi.org/10.1016/j.bmcl.2021.127788" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127788</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127788%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252BVEGFR-2%252Binhibitors%252Bembedding%252B6%25252C7-dimethoxyquinazoline%252Band%252Bdiarylamide%252Bfragments%26aulast%3DWang%26aufirst%3DRu%26date%3D2021%26volume%3D36%26spage%3D127788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara  Fancelli</span>, <span class="hlFld-ContribAuthor ">Enrico  Caliman</span>, <span class="hlFld-ContribAuthor ">Francesca  Mazzoni</span>, <span class="hlFld-ContribAuthor ">Marco  Brugia</span>, <span class="hlFld-ContribAuthor ">Francesca  Castiglione</span>, <span class="hlFld-ContribAuthor ">Luca  Voltolini</span>, <span class="hlFld-ContribAuthor ">Serena  Pillozzi</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Antonuzzo</span>. </span><span class="cited-content_cbyCitation_article-title">Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 1091. <a href="https://doi.org/10.3390/cancers13051091" title="DOI URL">https://doi.org/10.3390/cancers13051091</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13051091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13051091%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DChasing%252Bthe%252BTarget%25253A%252BNew%252BPhenomena%252Bof%252BResistance%252Bto%252BNovel%252BSelective%252BRET%252BInhibitors%252Bin%252BLung%252BCancer.%252BUpdated%252BEvidence%252Band%252BFuture%252BPerspectives%26aulast%3DFancelli%26aufirst%3DSara%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D1091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Somaraju  Yugandar</span>, <span class="hlFld-ContribAuthor ">Taiki  Morita</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Nakamura</span>. </span><span class="cited-content_cbyCitation_article-title">Rhodium(
              iii
              )-catalysed decarboxylative C–H functionalization of isoxazoles with alkenes and sulfoxonium ylides. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (42)
                                     , 8625-8628. <a href="https://doi.org/10.1039/D0OB02027C" title="DOI URL">https://doi.org/10.1039/D0OB02027C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB02027C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB02027C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRhodium%252528%252Biii%252B%252529-catalysed%252Bdecarboxylative%252BC%2525E2%252580%252593H%252Bfunctionalization%252Bof%252Bisoxazoles%252Bwith%252Balkenes%252Band%252Bsulfoxonium%252Bylides%26aulast%3DYugandar%26aufirst%3DSomaraju%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D42%26spage%3D8625%26epage%3D8628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naga Rajiv  Lakkaniga</span>, <span class="hlFld-ContribAuthor ">Naresh  Gunaganti</span>, <span class="hlFld-ContribAuthor ">Lingtian  Zhang</span>, <span class="hlFld-ContribAuthor ">Binyam  Belachew</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Yuet-Kin  Leung</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112691. <a href="https://doi.org/10.1016/j.ejmech.2020.112691" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112691%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Binhibitors%252Bof%252BRET%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DLakkaniga%26aufirst%3DNaga%2BRajiv%26date%3D2020%26volume%3D206%26spage%3D112691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naga Rajiv  Lakkaniga</span>, <span class="hlFld-ContribAuthor ">Lingtian  Zhang</span>, <span class="hlFld-ContribAuthor ">Binyam  Belachew</span>, <span class="hlFld-ContribAuthor ">Naresh  Gunaganti</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112589. <a href="https://doi.org/10.1016/j.ejmech.2020.112589" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112589%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSP-96%25252C%252Bthe%252Bfirst%252Bnon-ATP-competitive%252BAurora%252BKinase%252BB%252Binhibitor%25252C%252Bfor%252Breduced%252Bmyelosuppression%26aulast%3DLakkaniga%26aufirst%3DNaga%2BRajiv%26date%3D2020%26volume%3D203%26spage%3D112589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Metabolism of Pz-1 and bioisosteric replacement methods. Pz-1 is hydrolyzed, oxidized, or demethylated via phase 1 metabolic systems. Hydrolysis and oxidation occur in the selectivity region for binding to RET and VEGFR2, while demethylation occurs at the solvent front for both kinases. Bioisosteric replacement at the solvent front was performed by replacing methylpyrazole with (methylsulfonyl)benzene, generating NPA101.3. VEGFR2 DFG-out crystal structure (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OH4">2OH4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Computational modeling of NPA101.3. (A) NPA101.3 computationally modeled in a RET DFG-out homology model. The model shows the hydrogen bond at the ATP binding site with A807, a hydrogen bond network at the DFG motif, and interaction with Y806 via π–π stacking. The model also shows that <i>p</i>-sulfone of NPA101.3 is solvent-exposed. Hydrogen bonds are shown with blue dotted lines. (B) NPA101.3 computationally modeled in a RET/V804M DFG-out homology model. NPA101.3 can accommodate bulky mutations at the gatekeeper residue. (C) NPA101.3 computationally modeled in the VEGFR2 kinase. The binding mode is nearly identical to the binding mode in RET, with the exception of the isoxazole orientation in the allosteric pocket. Flexibility at the methylene linker is predicted to permit the balanced affinity of NPA101.3 for RET and VEGFR2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Thermal shift assay determination of the type 2 binding mode of NPA101.3. (A) Representative experiment of binding of NPA101.3 to the wild type RET core kinase domain monitored by the change in thermal stability. The melting temperature (<i>T</i><sub>m</sub>) is obtained from the first derivative of the change in fluorescence (−d<i>F</i>/d<i>t</i>) taken from the top of the peak in the derivative plot. (B) Plot of the derivative of the change in fluorescence (−d<i>F</i>/d<i>t</i>) for the wild type protein or V804M mutant in the presence of NPA101.3 (red) or buffer (blue) for a representative experiment. The compound binds equally well to either RET protein. (C) Tabulated average melting temperature differences (Δ<i>T</i><sub>m</sub>) from four independent experiments after the addition of NPA101.3, PP1 (a known type 1 inhibitor), or Sorafenib (a known type 2 inhibitor). The respective SD errors are shown for each drug.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. NPA101.3-mediated inhibition of phosphorylation and signaling of oncogenic RET mutants and VEGFR2 in intact cells. Serum-starved RAT1 cells exogenously expressing the (A and B) indicated RET point mutants or (C) NIH3T3 cells exogenously expressing the indicated RET rearranged mutants were treated for 2 h with the indicated concentrations of the compound. Total cell lysates (50 μg) were subjected to immunoblotting with anti-phospho-Y1062 (αp1062) and anti-phospho-Y905 (αp905) RET antibodies. The blots were normalized using the anti-RET (αRET) antibody. (D) HEK293 cells were transiently transfected with human VEGFR2; 36 h after transfection, cells were serum starved for 12 h. The indicated doses of the compound or vehicle (NT) were added for 2 h, and then VEGFA (100 ng/mL) stimulation was applied for 15 min. Cell lysates were immunoblotted with the anti-phospho-VEGFR2 (αpVEGFR2) antibody. The blot was normalized using the anti-VEGFR2 (αVEGFR2) antibody.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. NPA101.3-mediated inhibition of proliferation of RET-transformed Ba/F3 cells. Parental and RET/C634R-, RET M918T-, and NCOA4-RET-transfected Ba/F3 cells were incubated with vehicle (NT, not treated) or the indicated concentrations of NPA101.3 and counted at the indicated time points. Parental cells were supplemented with IL-3 (10 ng/mL). Data are the mean ± SD of a single experiment performed in triplicate. Growth inhibition IC<sub>50</sub> doses of the compound for the different cell lines are reported; 95% confidence intervals are indicated in brackets.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/medium/jm9b01336_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of NPA101.3 on <i>in vivo</i> tumor growth. NIH3T3 cells transformed by RET/C634Y or HRAS/G12V were inoculated subcutaneously into nu/nu mice. After 4 days, animals were randomly assigned to receive for the indicated time periods the compound (1.0, 3.0, or 10 mg/kg/day) (24 mice; 8 mice/group for 1, 3, and 10 mg/kg doses) or vehicle (8 mice) by oral gavage. The average size of tumors is reported ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01336/20210220/images/large/jm9b01336_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01336&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53084" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53084" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, L. M.</span></span> <span> </span><span class="NLM_article-title">RET Revisited: Expanding the Oncogenic Portfolio</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1038/nrc3680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnrc3680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24561444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=173-186&author=L.+M.+Mulligan&title=RET+Revisited%3A+Expanding+the+Oncogenic+Portfolio&doi=10.1038%2Fnrc3680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">RET revisited: expanding the oncogenic portfolio</span></div><div class="casAuthors">Mulligan, Lois M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-186</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RET receptor tyrosine kinase is crucial for normal development but also contributes to pathologies that reflect both the loss and the gain of RET function.  Activation of RET occurs via oncogenic mutations in familial and sporadic cancers - most notably, those of the thyroid and the lung.  RET has also recently been implicated in the progression of breast and pancreatic tumors, among others, which makes it an attractive target for small-mol. kinase inhibitors as therapeutics.  However, the complex roles of RET in homeostasis and survival of neural lineages and in tumor-assocd. inflammation might also suggest potential long-term pitfalls of broadly targeting RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohwDQSALnEwbVg90H21EOLACvtfcHk0lgNaHskMktLsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D&md5=665dae74c8f7a1df0e413ca15ca86440</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc3680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3680%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26atitle%3DRET%2520Revisited%253A%2520Expanding%2520the%2520Oncogenic%2520Portfolio%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D173%26epage%3D186%26doi%3D10.1038%2Fnrc3680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, N.</span></span>; <span class="NLM_contrib-group">Cancer Genome Atlas Research Network</span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Integrated Genomic Characterization of Papillary Thyroid Carcinoma</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">676</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.09.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.cell.2014.09.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=25417114" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2014&pages=676-690&author=N.+Agrawalauthor=Cancer+Genome+Atlas+Research+Network&title=Integrated+Genomic+Characterization+of+Papillary+Thyroid+Carcinoma&doi=10.1016%2Fj.cell.2014.09.050"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.09.050%26sid%3Dliteratum%253Aachs%26aulast%3DAgrawal%26aufirst%3DN.%26aulast%3D%26atitle%3DIntegrated%2520Genomic%2520Characterization%2520of%2520Papillary%2520Thyroid%2520Carcinoma%26jtitle%3DCell%26date%3D2014%26volume%3D159%26spage%3D676%26epage%3D690%26doi%3D10.1016%2Fj.cell.2014.09.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grubbs, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busaidy, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrier, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waguespack, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, G. J.</span></span> <span> </span><span class="NLM_article-title">RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1210/jc.2014-4153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1210%2Fjc.2014-4153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=25546157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVGisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=788-793&author=E.+G.+Grubbsauthor=P.+K.+Ngauthor=J.+Buiauthor=N.+L.+Busaidyauthor=K.+Chenauthor=J.+E.+Leeauthor=X.+Luauthor=H.+Luauthor=F.+Meric-Bernstamauthor=G.+B.+Millsauthor=G.+Palmerauthor=N.+D.+Perrierauthor=K.+L.+Scottauthor=K.+R.+Shawauthor=S.+G.+Waguespackauthor=M.+D.+Williamsauthor=R.+Yelenskyauthor=G.+J.+Cote&title=RET+Fusion+as+a+Novel+Driver+of+Medullary+Thyroid+Carcinoma&doi=10.1210%2Fjc.2014-4153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">RET fusion as a novel driver of medullary thyroid carcinoma</span></div><div class="casAuthors">Grubbs, Elizabeth G.; Ng, Patrick Kwok-Shing; Bui, Jacquelin; Busaidy, Naifa L.; Chen, Ken; Lee, Jeffrey E.; Lu, Xinyan; Lu, Hengyu; Meric-Bernstam, Funda; Mills, Gordon B.; Palmer, Gary; Perrier, Nancy D.; Scott, Kenneth L.; Shaw, Kenna R.; Waguespack, Steven G.; Williams, Michelle D.; Yelensky, Roman; Cote, Gilbert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">788-793</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Introduction: Oncogenic RET tyrosine kinase gene fusions and activating mutations have recently been identified in lung cancers, prompting initiation of targeted therapy trials in this disease.  Although RET point mutation has been identified as a driver of tumorigenesis in medullary thyroid carcinoma (MTC), no fusions have been described to date.  Objective: We evaluated the role of RET fusion as an oncogenic driver in MTC.  Methods: We describe a patient who died from aggressive sporadic MTC < 10 mo after diagnosis.  Her tumor was evaluated by means of next-generation sequencing, including an intronic capture strategy.  Results: A reciprocal translocation involving RET intron 12 was identified.  The fusion was validated using a targeted break apart fluorescence in situ hybridization probe, and RNA sequencing confirmed the existence of an in-frame fusion transcript joining MYH13 exon 35 with RET exon 12.  Ectopic expression of fusion product in a murine Ba/F3 cell reporter model established strong oncogenicity.  Three tyrosine kinase inhibitors currently used to treat MTC in clin. practice blocked tumorigenic cell growth.  Conclusion: This finding represents the report of a novel RET fusion, the first of its kind described in MTC.  The finding of this potential novel oncogenic mechanism has clear implications for sporadic MTC, which in the majority of cases has no driver mutation identified.  The presence of a RET fusion also provides a plausible target for RET tyrosine kinase inhibitor therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI15Lf8n2UYrVg90H21EOLACvtfcHk0lj7tRwwVCwbMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVGisb8%253D&md5=13a711308a94082ca23d5a190ad999ac</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1210%2Fjc.2014-4153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2014-4153%26sid%3Dliteratum%253Aachs%26aulast%3DGrubbs%26aufirst%3DE.%2BG.%26aulast%3DNg%26aufirst%3DP.%2BK.%26aulast%3DBui%26aufirst%3DJ.%26aulast%3DBusaidy%26aufirst%3DN.%2BL.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DPalmer%26aufirst%3DG.%26aulast%3DPerrier%26aufirst%3DN.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BL.%26aulast%3DShaw%26aufirst%3DK.%2BR.%26aulast%3DWaguespack%26aufirst%3DS.%2BG.%26aulast%3DWilliams%26aufirst%3DM.%2BD.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DCote%26aufirst%3DG.%2BJ.%26atitle%3DRET%2520Fusion%2520as%2520a%2520Novel%2520Driver%2520of%2520Medullary%2520Thyroid%2520Carcinoma%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2015%26volume%3D100%26spage%3D788%26epage%3D793%26doi%3D10.1210%2Fjc.2014-4153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totoki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nammo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogiwara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oike, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schetter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaug, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiku, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokota, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span> <span> </span><span class="NLM_article-title">KIF5B-RET Fusions in Lung Adenocarcinoma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1038/nm.2644</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnm.2644" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22327624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=375-377&author=T.+Kohnoauthor=H.+Ichikawaauthor=Y.+Totokiauthor=K.+Yasudaauthor=M.+Hiramotoauthor=T.+Nammoauthor=H.+Sakamotoauthor=K.+Tsutaauthor=K.+Furutaauthor=Y.+Shimadaauthor=R.+Iwakawaauthor=H.+Ogiwaraauthor=T.+Oikeauthor=M.+Enariauthor=A.+J.+Schetterauthor=H.+Okayamaauthor=A.+Haugenauthor=V.+Skaugauthor=S.+Chikuauthor=I.+Yamanakaauthor=Y.+Araiauthor=S.+Watanabeauthor=I.+Sekineauthor=S.+Ogawaauthor=C.+C.+Harrisauthor=H.+Tsudaauthor=T.+Yoshidaauthor=J.+Yokotaauthor=T.+Shibata&title=KIF5B-RET+Fusions+in+Lung+Adenocarcinoma&doi=10.1038%2Fnm.2644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">KIF5B-RET fusions in lung adenocarcinoma</span></div><div class="casAuthors">Kohno, Takashi; Ichikawa, Hitoshi; Totoki, Yasushi; Yasuda, Kazuki; Hiramoto, Masaki; Nammo, Takao; Sakamoto, Hiromi; Tsuta, Koji; Furuta, Koh; Shimada, Yoko; Iwakawa, Reika; Ogiwara, Hideaki; Oike, Takahiro; Enari, Masato; Schetter, Aaron J.; Okayama, Hirokazu; Haugen, Aage; Skaug, Vidar; Chiku, Suenori; Yamanaka, Itaru; Arai, Yasuhito; Watanabe, Shun-ichi; Sekine, Ikuo; Ogawa, Seishi; Harris, Curtis C.; Tsuda, Hitoshi; Yoshida, Teruhiko; Yokota, Jun; Shibata, Tatsuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">375-377</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing.  The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHQqNYV3xGfbVg90H21EOLACvtfcHk0lj7tRwwVCwbMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaltb8%253D&md5=301f964ad413e020aba11122dff13054</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm.2644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2644%26sid%3Dliteratum%253Aachs%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DIchikawa%26aufirst%3DH.%26aulast%3DTotoki%26aufirst%3DY.%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DHiramoto%26aufirst%3DM.%26aulast%3DNammo%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DFuruta%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DIwakawa%26aufirst%3DR.%26aulast%3DOgiwara%26aufirst%3DH.%26aulast%3DOike%26aufirst%3DT.%26aulast%3DEnari%26aufirst%3DM.%26aulast%3DSchetter%26aufirst%3DA.%2BJ.%26aulast%3DOkayama%26aufirst%3DH.%26aulast%3DHaugen%26aufirst%3DA.%26aulast%3DSkaug%26aufirst%3DV.%26aulast%3DChiku%26aufirst%3DS.%26aulast%3DYamanaka%26aufirst%3DI.%26aulast%3DArai%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DSekine%26aufirst%3DI.%26aulast%3DOgawa%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DC.%2BC.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DYokota%26aufirst%3DJ.%26aulast%3DShibata%26aufirst%3DT.%26atitle%3DKIF5B-RET%2520Fusions%2520in%2520Lung%2520Adenocarcinoma%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D375%26epage%3D377%26doi%3D10.1038%2Fnm.2644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamanaka, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninomiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span> <span> </span><span class="NLM_article-title">RET, ROS1 and ALK Fusions in Lung Cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">378</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1038/nm.2658</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnm.2658" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22327623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=378-381&author=K.+Takeuchiauthor=M.+Sodaauthor=Y.+Togashiauthor=R.+Suzukiauthor=S.+Sakataauthor=S.+Hatanoauthor=R.+Asakaauthor=W.+Hamanakaauthor=H.+Ninomiyaauthor=H.+Ueharaauthor=Y.+Lim+Choiauthor=Y.+Satohauthor=S.+Okumuraauthor=K.+Nakagawaauthor=H.+Manoauthor=Y.+Ishikawa&title=RET%2C+ROS1+and+ALK+Fusions+in+Lung+Cancer&doi=10.1038%2Fnm.2658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">RET, ROS1 and ALK fusions in lung cancer</span></div><div class="casAuthors">Takeuchi, Kengo; Soda, Manabu; Togashi, Yuki; Suzuki, Ritsuro; Sakata, Seiji; Hatano, Satoko; Asaka, Reimi; Hamanaka, Wakako; Ninomiya, Hironori; Uehara, Hirofumi; Lim Choi, Young; Satoh, Yukitoshi; Okumura, Sakae; Nakagawa, Ken; Mano, Hiroyuki; Ishikawa, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">378-381</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Through an integrated mol.- and histopathol.-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-pos. and 13 ROS1-fusion-pos. adenocarcinomas, including for unidentified fusion partners for ROS1.  In addn., we discovered previously unidentified kinase fusions that may be promising for mol.-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain contg. 6 (CCDC6)-RET, in 14 adenocarcinomas.  A multivariate anal. of 1,116 adenocarcinomas contg. these 71 kinase-fusion-pos. adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathol. stage and neg. kinase-fusion status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhJr0BIAnHWLVg90H21EOLACvtfcHk0lj7tRwwVCwbMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFaks7s%253D&md5=986c7eba0992b29950756e129a395d60</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnm.2658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2658%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DTogashi%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DSakata%26aufirst%3DS.%26aulast%3DHatano%26aufirst%3DS.%26aulast%3DAsaka%26aufirst%3DR.%26aulast%3DHamanaka%26aufirst%3DW.%26aulast%3DNinomiya%26aufirst%3DH.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DLim%2BChoi%26aufirst%3DY.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DOkumura%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26atitle%3DRET%252C%2520ROS1%2520and%2520ALK%2520Fusions%2520in%2520Lung%2520Cancer%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D378%26epage%3D381%26doi%3D10.1038%2Fnm.2658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donahue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downing, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frampton, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juhn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwirko, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peretz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nechushtan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soussan-Gutman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span> <span> </span><span class="NLM_article-title">Identification of New ALK and RET Gene Fusions from Colorectal and Lung Cancer Biopsies</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">384</span>, <span class="refDoi"> DOI: 10.1038/nm.2673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnm.2673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22327622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFalsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=382-384&author=D.+Lipsonauthor=M.+Capellettiauthor=R.+Yelenskyauthor=G.+Ottoauthor=A.+Parkerauthor=M.+Jaroszauthor=J.+A.+Curranauthor=S.+Balasubramanianauthor=T.+Bloomauthor=K.+W.+Brennanauthor=A.+Donahueauthor=S.+R.+Downingauthor=G.+M.+Framptonauthor=L.+Garciaauthor=F.+Juhnauthor=K.+C.+Mitchellauthor=E.+Whiteauthor=J.+Whiteauthor=Z.+Zwirkoauthor=T.+Peretzauthor=H.+Nechushtanauthor=L.+Soussan-Gutmanauthor=J.+Kimauthor=H.+Sasakiauthor=H.+R.+Kimauthor=S.+I.+Parkauthor=D.+Ercanauthor=C.+E.+Sheehanauthor=J.+S.+Rossauthor=M.+T.+Croninauthor=P.+A.+J%C3%A4nneauthor=P.+J.+Stephens&title=Identification+of+New+ALK+and+RET+Gene+Fusions+from+Colorectal+and+Lung+Cancer+Biopsies&doi=10.1038%2Fnm.2673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies</span></div><div class="casAuthors">Lipson, Doron; Capelletti, Marzia; Yelensky, Roman; Otto, Geoff; Parker, Alex; Jarosz, Mirna; Curran, John A.; Balasubramanian, Sohail; Bloom, Troy; Brennan, Kristina W.; Donahue, Amy; Downing, Sean R.; Frampton, Garrett M.; Garcia, Lazaro; Juhn, Frank; Mitchell, Kathy C.; White, Emily; White, Jared; Zwirko, Zac; Peretz, Tamar; Nechushtan, Hovav; Soussan-Gutman, Lior; Kim, Jhingook; Sasaki, Hidefumi; Kim, Hyeong Ryul; Park, Seung-il; Ercan, Dalia; Sheehan, Christine E.; Ross, Jeffrey S.; Cronin, Maureen T.; Jaenne, Pasi A.; Stephens, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-384</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non-small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clin. relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorectal cancer sample and KIF5B-RET in a lung adenocarcinoma.  Further screening of 561 lung adenocarcinomas identified 11 addnl. tumors with KIF5B-RET gene fusions (2.0%; 95% CI 0.8-3.1%).  Cells expressing oncogenic KIF5B-RET are sensitive to multi-kinase inhibitors that inhibit RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9dSer699HbVg90H21EOLACvtfcHk0ljkBam_JwSZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFalsbk%253D&md5=9ab47602d1e1ed547cb852a34d29e5bb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnm.2673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2673%26sid%3Dliteratum%253Aachs%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DJarosz%26aufirst%3DM.%26aulast%3DCurran%26aufirst%3DJ.%2BA.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DBloom%26aufirst%3DT.%26aulast%3DBrennan%26aufirst%3DK.%2BW.%26aulast%3DDonahue%26aufirst%3DA.%26aulast%3DDowning%26aufirst%3DS.%2BR.%26aulast%3DFrampton%26aufirst%3DG.%2BM.%26aulast%3DGarcia%26aufirst%3DL.%26aulast%3DJuhn%26aufirst%3DF.%26aulast%3DMitchell%26aufirst%3DK.%2BC.%26aulast%3DWhite%26aufirst%3DE.%26aulast%3DWhite%26aufirst%3DJ.%26aulast%3DZwirko%26aufirst%3DZ.%26aulast%3DPeretz%26aufirst%3DT.%26aulast%3DNechushtan%26aufirst%3DH.%26aulast%3DSoussan-Gutman%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DPark%26aufirst%3DS.%2BI.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DSheehan%26aufirst%3DC.%2BE.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26atitle%3DIdentification%2520of%2520New%2520ALK%2520and%2520RET%2520Gene%2520Fusions%2520from%2520Colorectal%2520and%2520Lung%2520Cancer%2520Biopsies%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D382%26epage%3D384%26doi%3D10.1038%2Fnm.2673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballerini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prade, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toujani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deswarte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbelstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapillonne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautier, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pages, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansat-De Mas, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadieu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huguet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastugue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broccardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabesse, E.</span></span> <span> </span><span class="NLM_article-title">RET Fusion Genes are Associated with Chronic Myelomonocytic Leukemia and Enhance Monocytic Differentiation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2384</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1038/leu.2012.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fleu.2012.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22513837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GiurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2384-2389&author=P.+Balleriniauthor=S.+Struskiauthor=C.+Cressonauthor=N.+Pradeauthor=S.+Toujaniauthor=C.+Deswarteauthor=S.+Dobbelsteinauthor=A.+Petitauthor=H.+Lapillonneauthor=E.+F.+Gautierauthor=C.+Demurauthor=E.+Lippertauthor=P.+Pagesauthor=V.+Mansat-De+Masauthor=J.+Donadieuauthor=F.+Huguetauthor=N.+Dastugueauthor=C.+Broccardoauthor=C.+Perotauthor=E.+Delabesse&title=RET+Fusion+Genes+are+Associated+with+Chronic+Myelomonocytic+Leukemia+and+Enhance+Monocytic+Differentiation&doi=10.1038%2Fleu.2012.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation</span></div><div class="casAuthors">Ballerini, P.; Struski, S.; Cresson, C.; Prade, N.; Toujani, S.; Deswarte, C.; Dobbelstein, S.; Petit, A.; Lapillonne, H.; Gautier, E.-F.; Demur, C.; Lippert, E.; Pages, P.; Mansat-De Mas, V.; Donadieu, J.; Huguet, F.; Dastugue, N.; Broccardo, C.; Perot, C.; Delabesse, E.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2384-2389</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Myeloproliferative neoplasms are frequently assocd. with aberrant constitutive tyrosine kinase (TK) activity resulting from chimeric fusion genes or point mutations such as BCR-ABL1 or JAK2 V617F.  We report here the cloning and functional characterization of two novel fusion genes BCR-RET and FGFR1OP-RET in chronic myelomonocytic leukemia (CMML) cases generated by two balanced translocations t(10;22)(q11;q11) and t(6;10)(q27;q11), resp.  The two RET fusion genes leading to the aberrant activation of RET, are able to transform hematopoietic cells and skew the hematopoietic differentiation program towards the monocytic/macrophage lineage.  The RET fusion genes seem to constitutively mimic the same signaling pathway as RAS mutations frequently involved in CMML.  One patient was treated with Sorafenib, a specific inhibitor of the RET TK function, and demonstrated cytol. and clin. remissions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpya3dQPOlhQLVg90H21EOLACvtfcHk0ljkBam_JwSZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GiurzE&md5=729bb3f8447df9949a9fc86623337150</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fleu.2012.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2012.109%26sid%3Dliteratum%253Aachs%26aulast%3DBallerini%26aufirst%3DP.%26aulast%3DStruski%26aufirst%3DS.%26aulast%3DCresson%26aufirst%3DC.%26aulast%3DPrade%26aufirst%3DN.%26aulast%3DToujani%26aufirst%3DS.%26aulast%3DDeswarte%26aufirst%3DC.%26aulast%3DDobbelstein%26aufirst%3DS.%26aulast%3DPetit%26aufirst%3DA.%26aulast%3DLapillonne%26aufirst%3DH.%26aulast%3DGautier%26aufirst%3DE.%2BF.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DLippert%26aufirst%3DE.%26aulast%3DPages%26aufirst%3DP.%26aulast%3DMansat-De%2BMas%26aufirst%3DV.%26aulast%3DDonadieu%26aufirst%3DJ.%26aulast%3DHuguet%26aufirst%3DF.%26aulast%3DDastugue%26aufirst%3DN.%26aulast%3DBroccardo%26aufirst%3DC.%26aulast%3DPerot%26aufirst%3DC.%26aulast%3DDelabesse%26aufirst%3DE.%26atitle%3DRET%2520Fusion%2520Genes%2520are%2520Associated%2520with%2520Chronic%2520Myelomonocytic%2520Leukemia%2520and%2520Enhance%2520Monocytic%2520Differentiation%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D2384%26epage%3D2389%26doi%3D10.1038%2Fleu.2012.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallavicini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruneri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trubia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviele, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anaganti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fiore, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minucci, S.</span></span> <span> </span><span class="NLM_article-title">Functional Characterization of a Novel FGFR1OP-RET Rearrangement in Hematopoietic Malignancies</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2013.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.molonc.2013.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24315414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvF2rsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=221-231&author=D.+Bossiauthor=F.+Carlomagnoauthor=I.+Pallaviciniauthor=G.+Pruneriauthor=M.+Trubiaauthor=P.+R.+Ravieleauthor=A.+Marinelliauthor=S.+Anagantiauthor=M.+C.+Coxauthor=G.+Vialeauthor=M.+Santoroauthor=P.+P.+Di+Fioreauthor=S.+Minucci&title=Functional+Characterization+of+a+Novel+FGFR1OP-RET+Rearrangement+in+Hematopoietic+Malignancies&doi=10.1016%2Fj.molonc.2013.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies</span></div><div class="casAuthors">Bossi, Daniela; Carlomagno, Francesca; Pallavicini, Isabella; Pruneri, Giancarlo; Trubia, Maurizio; Raviele, Paola Rafaniello; Marinelli, Alessandra; Anaganti, Suresh; Cox, Maria Christina; Viale, Giuseppe; Santoro, Massimo; Di Fiore, Pier Paolo; Minucci, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-231</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The RET (REarranged during Transfection) receptor tyrosine kinase is targeted by oncogenic rearrangements in thyroid and lung adenocarcinoma.  Recently, a RET (exon 12) rearrangement with FGFR1OP [fibroblast growth factor receptor 1 (FGFR1) oncogene partner] (exon 12) was identified in one chronic myelomonocytic leukemia (CMML) patient.  We report the mol. cloning and functional characterization of a novel FGFR1OP (exon 11)-RET (exon 11) gene fusion event (named FGFR1OP-RET), mediated by a reciprocal translocation t(6; 10)(q27; q11), in a patient affected by primary myelofibrosis (PMF) with secondary acute myeloid leukemia (AML).  The FGFR1OP-RET fusion protein displayed constitutive tyrosine kinase and transforming activity in NIH3T3 fibroblasts, and induced IL3-independent growth and activation of PI3K/STAT signaling in hematopoietic Ba/F3 cells.  FGFR1OP-RET supported cytokine-independent growth, protection from stress and enhanced self-renewal of primary murine hematopoietic progenitor and stem cells in vitro.  In vivo, FGFR1OP-RET caused a spectrum of disease phenotypes, with >50% of mice showing a fatal myeloproliferative disorder (MPD).  Other phenotypes were leukemia transplantable in secondary recipients, dramatic expansion of the mast cell lineage, and redn. of repopulating activity upon lethal irradn.  In conclusion, FGFR1OP-RET chimeric oncogenes are endowed with leukemogenic potential and assocd. to myeloid neoplasms (CMML and PMF/AML).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprMnoS-3RcaLVg90H21EOLACvtfcHk0lg6Z3OufDDY6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvF2rsLfJ&md5=e2af92bdeccf6d132f9ecaea05ba1c98</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2013.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2013.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DD.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DPallavicini%26aufirst%3DI.%26aulast%3DPruneri%26aufirst%3DG.%26aulast%3DTrubia%26aufirst%3DM.%26aulast%3DRaviele%26aufirst%3DP.%2BR.%26aulast%3DMarinelli%26aufirst%3DA.%26aulast%3DAnaganti%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DM.%2BC.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DDi%2BFiore%26aufirst%3DP.%2BP.%26aulast%3DMinucci%26aufirst%3DS.%26atitle%3DFunctional%2520Characterization%2520of%2520a%2520Novel%2520FGFR1OP-RET%2520Rearrangement%2520in%2520Hematopoietic%2520Malignancies%26jtitle%3DMol.%2520Oncol.%26date%3D2014%26volume%3D8%26spage%3D221%26epage%3D231%26doi%3D10.1016%2Fj.molonc.2013.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wiesner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteve-Puig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparatta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerroni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busam, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutzner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, B. C.</span></span> <span> </span><span class="NLM_article-title">Kinase Fusions are Frequent in Spitz Tumours and Spitzoid Melanomas</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3116</span>, <span class="refDoi"> DOI: 10.1038/ncomms4116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fncomms4116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24445538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3116&author=T.+Wiesnerauthor=J.+Heauthor=R.+Yelenskyauthor=R.+Esteve-Puigauthor=T.+Bottonauthor=I.+Yehauthor=D.+Lipsonauthor=G.+Ottoauthor=K.+Brennanauthor=R.+Muraliauthor=M.+Garridoauthor=V.+A.+Millerauthor=J.+S.+Rossauthor=M.+F.+Bergerauthor=A.+Sparattaauthor=G.+Palmedoauthor=L.+Cerroniauthor=K.+J.+Busamauthor=H.+Kutznerauthor=M.+T.+Croninauthor=P.+J.+Stephensauthor=B.+C.+Bastian&title=Kinase+Fusions+are+Frequent+in+Spitz+Tumours+and+Spitzoid+Melanomas&doi=10.1038%2Fncomms4116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase fusions are frequent in Spitz tumours and spitzoid melanomas</span></div><div class="casAuthors">Wiesner Thomas; Murali Rajmohan; Berger Michael F; Busam Klaus J; Bastian Boris C; Wiesner Thomas; Cerroni Lorenzo; He Jie; Yelensky Roman; Lipson Doron; Otto Geoff; Brennan Kristina; Miller Vincent A; Ross Jeffrey S; Cronin Maureen T; Stephens Philip J; Esteve-Puig Rosaura; Botton Thomas; Yeh Iwei; Garrido Maria; Sparatta Alyssa; Bastian Boris C; Murali Rajmohan; Bastian Boris C; Palmedo Gabriele; Kutzner Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3116</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spitzoid neoplasms are a group of melanocytic tumours with distinctive histopathological features.  They include benign tumours (Spitz naevi), malignant tumours (spitzoid melanomas) and tumours with borderline histopathological features and uncertain clinical outcome (atypical Spitz tumours).  Their genetic underpinnings are poorly understood, and alterations in common melanoma-associated oncogenes are typically absent.  Here we show that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern.  The chimeric proteins are constitutively active, stimulate oncogenic signalling pathways, are tumourigenic and are found in the entire biologic spectrum of spitzoid neoplasms, including 55% of Spitz naevi, 56% of atypical Spitz tumours and 39% of spitzoid melanomas.  Kinase inhibitors suppress the oncogenic signalling of the fusion proteins in vitro.  In summary, kinase fusions account for the majority of oncogenic aberrations in spitzoid neoplasms and may serve as therapeutic targets for metastatic spitzoid melanomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRd1A4UrEIWolQKX3ooHxWjfW6udTcc2eYtTvR_s1Zsybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cznt1Whsw%253D%253D&md5=c98dfce5cbc4b2c38e3898b9e0c4c4fa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fncomms4116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4116%26sid%3Dliteratum%253Aachs%26aulast%3DWiesner%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DEsteve-Puig%26aufirst%3DR.%26aulast%3DBotton%26aufirst%3DT.%26aulast%3DYeh%26aufirst%3DI.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DOtto%26aufirst%3DG.%26aulast%3DBrennan%26aufirst%3DK.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DBerger%26aufirst%3DM.%2BF.%26aulast%3DSparatta%26aufirst%3DA.%26aulast%3DPalmedo%26aufirst%3DG.%26aulast%3DCerroni%26aufirst%3DL.%26aulast%3DBusam%26aufirst%3DK.%2BJ.%26aulast%3DKutzner%26aufirst%3DH.%26aulast%3DCronin%26aufirst%3DM.%2BT.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DBastian%26aufirst%3DB.%2BC.%26atitle%3DKinase%2520Fusions%2520are%2520Frequent%2520in%2520Spitz%2520Tumours%2520and%2520Spitzoid%2520Melanomas%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3116%26doi%3D10.1038%2Fncomms4116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Rolle, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seery, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanford, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, V. K.</span></span> <span> </span><span class="NLM_article-title">Identification and Characterization of RET Fusions in Advanced Colorectal Cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">28929</span>– <span class="NLM_lpage">28937</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.18632%2Foncotarget.4325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=26078337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbjsl2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=28929-28937&author=A.+F.+Le%0ARolleauthor=S.+J.+Klempnerauthor=C.+R.+Garrettauthor=T.+Seeryauthor=E.+M.+Sanfordauthor=S.+Balasubramanianauthor=J.+S.+Rossauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Aliauthor=V.+K.+Chiu&title=Identification+and+Characterization+of+RET+Fusions+in+Advanced+Colorectal+Cancer&doi=10.18632%2Foncotarget.4325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of RET fusions in advanced colorectal cancer</span></div><div class="casAuthors">Le Rolle Anne-France; Klempner Samuel J; Seery Tara; Chiu Vi K; Le Rolle Anne-France; Klempner Samuel J; Seery Tara; Chiu Vi K; Garrett Christopher R; Sanford Eric M; Balasubramanian Sohail; Ross Jeffrey S; Stephens Philip J; Miller Vincent A; Ali Siraj M; Ross Jeffrey S</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">28929-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is an unmet clinical need for molecularly directed therapies available for metastatic colorectal cancer.  Comprehensive genomic profiling has the potential to identify actionable genomic alterations in colorectal cancer.  Through comprehensive genomic profiling we prospectively identified 6 RET fusion kinases, including two novel fusions of CCDC6-RET and NCOA4-RET, in metastatic colorectal cancer (CRC) patients.  RET fusion kinases represent a novel class of oncogenic driver in CRC and occurred at a 0.2% frequency without concurrent driver mutations, including KRAS, NRAS, BRAF, PIK3CA or other fusion tyrosine kinases.  Multiple RET kinase inhibitors were cytotoxic to RET fusion kinase positive cancer cells and not RET fusion kinase negative CRC cells.  The presence of a RET fusion kinase may identify a subset of metastatic CRC patients with a high response rate to RET kinase inhibition.  This is the first characterization of RET fusions in CRC patients and highlights the therapeutic significance of prospective comprehensive genomic profiling in advanced CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwwUHokNNKkEbxh97K6Vt6fW6udTcc2eYKx05Dui1CwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbjsl2ksw%253D%253D&md5=224fa8b7f303111457f6cfa9862394c0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4325%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BRolle%26aufirst%3DA.%2BF.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DSeery%26aufirst%3DT.%26aulast%3DSanford%26aufirst%3DE.%2BM.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DChiu%26aufirst%3DV.%2BK.%26atitle%3DIdentification%2520and%2520Characterization%2520of%2520RET%2520Fusions%2520in%2520Advanced%2520Colorectal%2520Cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D28929%26epage%3D28937%26doi%3D10.18632%2Foncotarget.4325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hechtman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaeger, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma that are Preferentially Associated with Wild Type RAS/RAF</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-15-0392-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F1541-7786.MCR-15-0392-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=26660078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlajtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=296-301&author=J.+F.+Hechtmanauthor=A.+Zehirauthor=R.+D.+Yaegerauthor=L.+Wangauthor=S.+Middhaauthor=T.+Zhengauthor=D.+Hymanauthor=D.+Solitauthor=M.+E.+Arcilaauthor=L.+Borsuauthor=J.+Shiaauthor=E.+Vakianiauthor=L.+Saltzauthor=M.+Ladanyi&title=Identification+of+Targetable+Kinase+Alterations+in+Patients+with+Colorectal+Carcinoma+that+are+Preferentially+Associated+with+Wild+Type+RAS%2FRAF&doi=10.1158%2F1541-7786.MCR-15-0392-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF</span></div><div class="casAuthors">Hechtman, Jaclyn F.; Zehir, Ahmet; Yaeger, Rona; Wang, Lu; Middha, Sumit; Zheng, Tao; Hyman, David M.; Solit, David; Arcila, Maria E.; Borsu, Laetitia; Shia, Jinru; Vakiani, Efsevia; Saltz, Leonard; Ladanyi, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">296-301</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted therapy for metastatic colorectal carcinoma consists of anti-EGFR therapy for patients with RAS/RAF wild-type tumors.  However, the response rate remains low, suggesting the presence of alternative drivers possibly also representing potential therapeutic targets.  We investigated receptor tyrosine kinase (RTK) alterations and MAP2K1 (MEK1) mutations in a large cohort of colorectal carcinoma patients studied by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets and The Cancer Genome Atlas, focusing on amplifications, fusions, and hotspot mutations in RTK genes and MAP2K1.  RTK gene amplifications were confirmed with FISH and immunohistochem. (IHC) staining.  Among 751 colorectal carcinoma cases with next-generation sequencing data, 7% and 1% of colorectal carcinoma harbored RTK alterations and MAP2K1 hotspot mutations (n = 7), resp.  RTK-altered cases had fewer concurrent RAS/RAF mutations (P = 0.003) than RTK/MAP2K1 wild-type colorectal carcinoma.  MAP2K1-mutated colorectal carcinoma showed no RAS/RAF mutations.  ERBB2 (n = 32) and EGFR (n = 13) were the most frequently altered RTKs, both activated by amplification and/or hotspot mutations.  Three RTK fusions were identified: NCOA4-RET, ERBB2-GRB7, and ETV6-NTRK3.  Only 1 of 6 patients with an RTK or MAP2K1 alteration who received anti-EGFR and/or anti-ERBB2 therapy demonstrated stable disease; the rest progressed immediately.  Overall, RTK alterations and MAP2K1 mutations occur in approx. 8% of colorectal carcinoma.  In spite of the usual absence of RAS/RAF mutations, response to anti-EGFR and/or anti-ERBB2 therapy was poor in this limited group.  Larger studies are warranted to further define these kinase alterations as novel therapeutic targets in colorectal carcinoma and as neg. predictors of response to anti-EGFR therapy.  Implications: Targetable kinase alterations were identified in a subset of advanced colorectal carcinoma patients, preferentially assocd. with wild-type RAS/RAF, and may predict poor response to std. anti-EGFR therapy.  Mol Cancer Res; 14(3); 296-301. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4-icN-TENRLVg90H21EOLACvtfcHk0lg5EnxoiwVBrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlajtLw%253D&md5=3ce2af1a5f3f9b6f4f000cc9c69cee7a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-15-0392-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-15-0392-T%26sid%3Dliteratum%253Aachs%26aulast%3DHechtman%26aufirst%3DJ.%2BF.%26aulast%3DZehir%26aufirst%3DA.%26aulast%3DYaeger%26aufirst%3DR.%2BD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMiddha%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DHyman%26aufirst%3DD.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DShia%26aufirst%3DJ.%26aulast%3DVakiani%26aufirst%3DE.%26aulast%3DSaltz%26aufirst%3DL.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520Targetable%2520Kinase%2520Alterations%2520in%2520Patients%2520with%2520Colorectal%2520Carcinoma%2520that%2520are%2520Preferentially%2520Associated%2520with%2520Wild%2520Type%2520RAS%252FRAF%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2016%26volume%3D14%26spage%3D296%26epage%3D301%26doi%3D10.1158%2F1541-7786.MCR-15-0392-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paratala, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yilmazel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrosky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolfi, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiClemente, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Rodriguez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyland-Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirshfield, K. M.</span></span> <span> </span><span class="NLM_article-title">RET Rearrangements are Actionable Alterations in Breast Cancer</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4821</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07341-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fs41467-018-07341-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=30446652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BB3crhvVejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4821&author=B.+S.+Paratalaauthor=J.+H.+Chungauthor=C.+B.+Williamsauthor=B.+Yilmazelauthor=W.+Petroskyauthor=K.+Williamsauthor=A.+B.+Schrockauthor=L.+M.+Gayauthor=E.+Leeauthor=S.+C.+Dolfiauthor=K.+Phamauthor=S.+Linauthor=M.+Yaoauthor=A.+Kulkarniauthor=F.+DiClementeauthor=C.+Liuauthor=L.+Rodriguez-Rodriguezauthor=S.+Ganesanauthor=J.+S.+Rossauthor=S.+M.+Aliauthor=B.+Leyland-Jonesauthor=K.+M.+Hirshfield&title=RET+Rearrangements+are+Actionable+Alterations+in+Breast+Cancer&doi=10.1038%2Fs41467-018-07341-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">RET rearrangements are actionable alterations in breast cancer</span></div><div class="casAuthors">Paratala Bhavna S; Petrosky Whitney; Dolfi Sonia C; Lin Stephanie; Yao Ming; Kulkarni Atul; DiClemente Frances; Ganesan Shridar; Hirshfield Kim M; Paratala Bhavna S; Petrosky Whitney; Dolfi Sonia C; Lin Stephanie; Yao Ming; Kulkarni Atul; DiClemente Frances; Rodriguez-Rodriguez Lorna; Ganesan Shridar; Hirshfield Kim M; Chung Jon H; Yilmazel Bahar; Schrock Alexa B; Gay Laurie M; Ross Jeffrey S; Ali Siraj M; Williams Casey B; Williams Kirstin; Leyland-Jones Brian; Lee Ellen; Pham Kien; Liu Chen; Rodriguez-Rodriguez Lorna</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4821</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Fusions involving the oncogenic gene RET have been observed in thyroid and lung cancers.  Here we report RET gene alterations, including amplification, missense mutations, known fusions, novel fusions, and rearrangements in breast cancer.  Their frequency, oncogenic potential, and actionability in breast cancer are described.  Two out of eight RET fusions (NCOA4-RET and a novel RASGEF1A-RET fusion) and RET amplification were functionally characterized and shown to activate RET kinase and drive signaling through MAPK and PI3K pathways.  These fusions and RET amplification can induce transformation of non-tumorigenic cells, support xenograft tumor formation, and render sensitivity to RET inhibition.  An index case of metastatic breast cancer progressing on HER2-targeted therapy was found to have the NCOA4-RET fusion.  Subsequent treatment with the RET inhibitor cabozantinib led to a rapid clinical and radiographic response.  RET alterations, identified by genomic profiling, are promising therapeutic targets and are present in a subset of breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQBi3BP-gFLomK_SFaaT9INfW6udTcc2eYP8VyT3OhqF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crhvVejsQ%253D%253D&md5=63a94be3ca98d30c8a024da441d75963</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07341-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07341-4%26sid%3Dliteratum%253Aachs%26aulast%3DParatala%26aufirst%3DB.%2BS.%26aulast%3DChung%26aufirst%3DJ.%2BH.%26aulast%3DWilliams%26aufirst%3DC.%2BB.%26aulast%3DYilmazel%26aufirst%3DB.%26aulast%3DPetrosky%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DGay%26aufirst%3DL.%2BM.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DDolfi%26aufirst%3DS.%2BC.%26aulast%3DPham%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DM.%26aulast%3DKulkarni%26aufirst%3DA.%26aulast%3DDiClemente%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DRodriguez-Rodriguez%26aufirst%3DL.%26aulast%3DGanesan%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DHirshfield%26aufirst%3DK.%2BM.%26atitle%3DRET%2520Rearrangements%2520are%2520Actionable%2520Alterations%2520in%2520Breast%2520Cancer%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4821%26doi%3D10.1038%2Fs41467-018-07341-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elvin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldham, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washburn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelensky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serracino, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, D. W.</span></span> <span> </span><span class="NLM_article-title">Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6061</span>– <span class="NLM_lpage">6068</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F1078-0432.CCR-15-2568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=27334835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSmtr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=6061-6068&author=K.+Wangauthor=J.+S.+Russellauthor=J.+D.+McDermottauthor=J.+A.+Elvinauthor=D.+Khairaauthor=A.+Johnsonauthor=T.+A.+Jenningsauthor=S.+M.+Aliauthor=M.+Murrayauthor=C.+Marshallauthor=D.+S.+Oldhamauthor=D.+Washburnauthor=S.+J.+Wongauthor=J.+Chmieleckiauthor=R.+Yelenskyauthor=D.+Lipsonauthor=V.+A.+Millerauthor=P.+J.+Stephensauthor=H.+S.+Serracinoauthor=J.+S.+Rossauthor=D.+W.+Bowles&title=Profiling+of+149+Salivary+Duct+Carcinomas%2C+Carcinoma+Ex+Pleomorphic+Adenomas%2C+and+Adenocarcinomas%2C+Not+Otherwise+Specified+Reveals+Actionable+Genomic+Alterations&doi=10.1158%2F1078-0432.CCR-15-2568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations</span></div><div class="casAuthors">Wang, Kai; Russell, Jeffery S.; McDermott, Jessica D.; Elvin, Julia A.; Khaira, Depinder; Johnson, Adrienne; Jennings, Timothy A.; Ali, Siraj M.; Murray, Molly; Marshall, Carrie; Oldham, Dwight S.; Washburn, Donna; Wong, Stuart J.; Chmielecki, Juliann; Yelensky, Roman; Lipson, Doron; Miller, Vincent A.; Stephens, Philip J.; Serracino, Hilary S.; Ross, Jeffrey S.; Bowles, Daniel W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6061-6068</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: We sought to identify genomic alterations (GA) in salivary gland adenocarcinomas, not otherwise specified (NOS), salivary duct carcinomas (SDC), carcinoma ex pleomorphic adenoma (ca ex PA), and salivary carcinoma, NOS.  Exptl. Design: DNA was extd. from 149 tumors.  Comprehensive genomic profiling (CGP) was performed on hybridization-captured adaptor ligation-based libraries of 182 or 315 cancer-related genes plus introns from 14 or 28 genes frequently rearranged for cancer and evaluated for all classes of GAs.  Results: A total of 590 GAs were found in 157 unique genes (mean 3.9/tumor).  GAs in the PI3K/AKT/mTOR pathway were more common in SDC (53.6%) than other histologies (P = 0.019) Cyclin-dependent kinase GAs varied among all histotypes: adenocarcinoma, NOS (34.6%); SDC (12.2%); ca ex PA (16.7%); carcinoma, NOS (31.2%; P = 0.043).  RAS GAs were obsd.: adenocarcinoma, NOS (17.3%); SDC (26.8%); ca ex PA (4.2%); and carcinoma, NOS (9.4%; P = 0.054).  ERBB2 GAs, including amplifications and mutations, were common: adenocarcinoma, NOS (13.5%); SDC (26.8%); ca ex PA (29.2%); carcinoma, NOS (18.8; P = 0.249).  Other notable GAs include TP53 in >45% of each histotype; NOTCH1: adenocarcinoma, NOS (7.7%), ca ex PA (8.3%), carcinoma, NOS (21.6%); NF1: adenocarcinoma, NOS (9.6%), SDC (17.1%), carcinoma, NOS (18.8%).  RET fusions were identified in one adenocarcinoma, NOS (CCDC6-RET) and two SDCs (NCOA4-RET).  Clin. responses were obsd. in patients treated with anti-HER2 and anti-RET-targeted therapies.  Conclusions: CGP of salivary adenocarcinoma, NOS, SDCs, ca ex PA, and carcinoma, NOS revealed diverse GAs that may lead to novel treatment options.  Clin Cancer Res; 22(24); 6061-8. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEd0PSGc63IbVg90H21EOLACvtfcHk0lhrkbqXokqVwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSmtr%252FP&md5=a21a65ed4f89bbbb123df4e3671ec7e7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2568%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%26aulast%3DRussell%26aufirst%3DJ.%2BS.%26aulast%3DMcDermott%26aufirst%3DJ.%2BD.%26aulast%3DElvin%26aufirst%3DJ.%2BA.%26aulast%3DKhaira%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJennings%26aufirst%3DT.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DMurray%26aufirst%3DM.%26aulast%3DMarshall%26aufirst%3DC.%26aulast%3DOldham%26aufirst%3DD.%2BS.%26aulast%3DWashburn%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DS.%2BJ.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DYelensky%26aufirst%3DR.%26aulast%3DLipson%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DSerracino%26aufirst%3DH.%2BS.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DBowles%26aufirst%3DD.%2BW.%26atitle%3DProfiling%2520of%2520149%2520Salivary%2520Duct%2520Carcinomas%252C%2520Carcinoma%2520Ex%2520Pleomorphic%2520Adenomas%252C%2520and%2520Adenocarcinomas%252C%2520Not%2520Otherwise%2520Specified%2520Reveals%2520Actionable%2520Genomic%2520Alterations%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D6061%26epage%3D6068%26doi%3D10.1158%2F1078-0432.CCR-15-2568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braiteh, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolinakos, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenbowe, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span> <span> </span><span class="NLM_article-title">Emergence of RET Rearrangement Co-Existing with Activated EGFR Mutation in EGFR-Mutated NSCLC Patients who had Progressed on First- or Second-Generation EGFR TKI</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2015.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.lungcan.2015.06.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=26187428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FktFantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=357-359&author=S.+J.+Klempnerauthor=L.+A.+Bazhenovaauthor=F.+S.+Braitehauthor=P.+G.+Nikolinakosauthor=K.+Gowenauthor=C.+M.+Cervantesauthor=J.+Chmieleckiauthor=J.+R.+Greenboweauthor=J.+S.+Rossauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Aliauthor=S.+H.+Ou&title=Emergence+of+RET+Rearrangement+Co-Existing+with+Activated+EGFR+Mutation+in+EGFR-Mutated+NSCLC+Patients+who+had+Progressed+on+First-+or+Second-Generation+EGFR+TKI&doi=10.1016%2Fj.lungcan.2015.06.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI</span></div><div class="casAuthors">Klempner Samuel J; Cervantes Claudia M; Bazhenova Lyudmila A; Braiteh Fadi S; Nikolinakos Petros G; Gowen Kyle; Chmielecki Juliann; Greenbowe Joel R; Stephens Philip J; Miller Vincent A; Ali Siraj M; Ross Jeffrey S; Ou Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The gatekeeper mutation T790M mutation is the responsible for the majority of the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated non-small cell lung cancer (NSCLC).  Other previously described resistance mechanisms include HER2 amplification, MET amplification, PIK3CA mutation, epithelial-mesenchymal transition (EMT), small cell transformation have also been identified.  However other resistance mechanisms remains to be discovered.  MATERIALS AND METHODS:  Hybrid-capture based comprehensive genomic profiling (CGP) was performed on pre- and post-EGFR TKI progression EGFR-mutated NSCLC tumor samples during routine clinical care.  We identify two paired pre- and post-EGFR TKI progression EGFR-mutated NSCLC patient tumor samples where both post EGFR TKI samples harbored in-frame CCDC6-RET rearrangements but not in the pre-EGFR TKI tumor samples.  Furthermore analysis of the clinical database revealed one additional NCOA4-RET rearrangement co-existing with activated EGFR mutation in an EGFR-mutated NSCLC patient who had progressed on afatinib.  None of the known resistance mechanisms to EGFR TKI including EGFR T790M, EGFR amplification, HER2 amplification, MET amplification, PIK3CA mutation, BRAF mutation, EMT or small cell transformation was identified in the three post progression samples that now harbored RET rearrangements.  RESULTS AND CONCLUSIONS:  This is the first report of RET rearrangement co-existing with activated EGFR mutations in EGFR-mutated patients who had progressed on either first- or second generation EGFR TKI.  As such, RET rearrangement may serve as a potential resistance mechanism to EGFR TKI in EGFR-mutated NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC4yXiTTSim3WEEzDrymxmfW6udTcc2eY2WEdBJ1nnY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FktFantw%253D%253D&md5=a3caf3ad2da9dbcf5be5e4ecb2c61130</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2015.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2015.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DBazhenova%26aufirst%3DL.%2BA.%26aulast%3DBraiteh%26aufirst%3DF.%2BS.%26aulast%3DNikolinakos%26aufirst%3DP.%2BG.%26aulast%3DGowen%26aufirst%3DK.%26aulast%3DCervantes%26aufirst%3DC.%2BM.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DGreenbowe%26aufirst%3DJ.%2BR.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BH.%26atitle%3DEmergence%2520of%2520RET%2520Rearrangement%2520Co-Existing%2520with%2520Activated%2520EGFR%2520Mutation%2520in%2520EGFR-Mutated%2520NSCLC%2520Patients%2520who%2520had%2520Progressed%2520on%2520First-%2520or%2520Second-Generation%2520EGFR%2520TKI%26jtitle%3DLung%2520Cancer%26date%3D2015%26volume%3D89%26spage%3D357%26epage%3D359%26doi%3D10.1016%2Fj.lungcan.2015.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span> <span> </span><span class="NLM_article-title">Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: an Update</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">3149</span>– <span class="NLM_lpage">3164</span>, <span class="refDoi"> DOI: 10.1210/jc.2013-1204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1210%2Fjc.2013-1204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=23744408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12gsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=3149-3164&author=S.+A.+Wellsauthor=F.+Paciniauthor=B.+G.+Robinsonauthor=M.+Santoro&title=Multiple+Endocrine+Neoplasia+Type+2+and+Familial+Medullary+Thyroid+Carcinoma%3A+an+Update&doi=10.1210%2Fjc.2013-1204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update</span></div><div class="casAuthors">Wells, Samuel A., Jr.; Pacini, Furio; Robinson, Bruce G.; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3149-3164</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndromes MEN2A and MEN2B and familial medullary thyroid carcinoma (FMTC) has expanded greatly.  In this manuscript, we summarize how recent discoveries have enhanced our understanding of the mol. basis of these diseases and led to improvements in the diagnosis and management of affected patients.  Evidence Acquisition: We reviewed the English literature through PubMed from 2000 to the present, using the search terms medullary thyroid carcinoma, multiple endocrine neoplasia type 2, familial medullary thyroid carcinoma, RET proto-oncogene, and calcitonin.  Evidence Synthesis: Over 70 RET mutations are known to cause MEN2A, MEN2B, or FMTC, and recent findings from studies of large kindreds with these syndromes have clouded the relationship between genotype and phenotype, primarily because of the varied clin. presentation of different families with the same RET mutation.  This clin. variability has also confounded decisions about the timing of prophylactic thyroidectomy for MTC, the dominant endocrinopathy assocd. with these syndromes.  A distinct advance has been the demonstration through phase II and phase III clin. trials that mol. targeted therapeutics are effective in the treatment of patients with locally advanced or metastatic MTC.  Conclusions: The effective management of patients with MEN2A, MEN2A, and FMTC depends on an understanding of the variable behavior of disease expression in patients with a specific RET mutation.  Information gained from mol. testing, biochem. anal., and clin. evaluation is important in providing effective management of patients with either early or advanced-stage MTC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyGQGQfacRvrVg90H21EOLACvtfcHk0lhTYEN5RQj-xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12gsL%252FM&md5=8732221749fa72c99546c0659db2e2e1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1210%2Fjc.2013-1204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2013-1204%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DPacini%26aufirst%3DF.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DMultiple%2520Endocrine%2520Neoplasia%2520Type%25202%2520and%2520Familial%2520Medullary%2520Thyroid%2520Carcinoma%253A%2520an%2520Update%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3D3149%26epage%3D3164%26doi%3D10.1210%2Fjc.2013-1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza-Menacho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacke, C. M.</span></span> <span> </span><span class="NLM_article-title">RET in Breast Cancer: Functional and Therapeutic Implications</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/j.molmed.2010.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.molmed.2010.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=21251878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtV2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=149-157&author=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+M.+Isacke&title=RET+in+Breast+Cancer%3A+Functional+and+Therapeutic+Implications&doi=10.1016%2Fj.molmed.2010.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">RET in breast cancer: functional and therapeutic implications</span></div><div class="casAuthors">Morandi, Andrea; Plaza-Menacho, Ivan; Isacke, Clare M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Recent studies demonstrate that the receptor tyrosine kinase RET is overexpressed in a subset of ER-pos. breast cancers and that crosstalk between RET and ER is important in responses to endocrine therapy.  The development of small mol. inhibitors that target RET allows the opportunity to consider combination therapies as a strategy to improve response to treatment and to prevent and combat endocrine resistance.  This review discusses: (i) the current knowledge about RET, its co-receptors and ligands in breast cancer; (ii) the breast cancer clin. trials involving agents that target RET; and (iii) the challenges that remain in terms of specificity of available inhibitors and in understanding the complex mol. mechanisms that underlie the resistance to endocrine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjitcp-LZe6rVg90H21EOLACvtfcHk0lgzK5b5s4pOxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtV2qsro%253D&md5=5d50cc75916affcaa56ee983757abf68</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2010.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2010.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DIsacke%26aufirst%3DC.%2BM.%26atitle%3DRET%2520in%2520Breast%2520Cancer%253A%2520Functional%2520and%2520Therapeutic%2520Implications%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D149%26epage%3D157%26doi%3D10.1016%2Fj.molmed.2010.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armanini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yerushalmi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haak-Frendscho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elias, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span> <span> </span><span class="NLM_article-title">Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5552</span>– <span class="NLM_lpage">5562</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-0468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F1078-0432.CCR-15-0468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=26240273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKjs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=5552-5562&author=M.+Nguyenauthor=S.+Miyakawaauthor=J.+Katoauthor=T.+Moriauthor=T.+Araiauthor=M.+Armaniniauthor=K.+Gelmonauthor=R.+Yerushalmiauthor=S.+Leungauthor=D.+Gaoauthor=G.+Landesauthor=M.+Haak-Frendschoauthor=K.+Eliasauthor=A.+D.+Simmons&title=Preclinical+Efficacy+and+Safety+Assessment+of+an+Antibody-Drug+Conjugate+Targeting+the+c-RET+Proto-Oncogene+for+Breast+Carcinoma&doi=10.1158%2F1078-0432.CCR-15-0468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma</span></div><div class="casAuthors">Nguyen, Minh; Miyakawa, Shuichi; Kato, Junichi; Mori, Toshiyuki; Arai, Toshimitsu; Armanini, Mark; Gelmon, Karen; Yerushalmi, Rinat; Leung, Samuel; Gao, Dongxia; Landes, Gregory; Haak-Frendscho, Mary; Elias, Kathleen; Simmons, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5552-5562</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The RET proto-oncogene has been implicated in breast cancer, and the studies herein describe the preclin. and safety assessment of an anti-RET antibody-drug conjugate (ADC) being developed for the treatment of breast cancer.  Exptl. Design: RET protein expression was analyzed in breast tumor samples using tissue microarrays.  The fully human anti-RET antibody (Y078) was conjugated to the DM1 and DM4 derivs. of the potent cytotoxic agent maytansine using thioether and disulfide linkers, resp.  The resulting compds., designated Y078-DM1 and Y078-DM4, were evaluated for antitumor activity using human breast cancer cell lines and established tumor xenograft models.  A single-dose, 28-day, safety study of Y078-DM1 was performed in cynomolgus monkeys.  Results: By immunohistochem., RET expression was detected in 57% of tumors (1,596 of 2,800 tumor sections) and was most common in HER2-pos. and basal breast cancer subtypes.  Potent in vitro cytotoxicity was achieved in human breast cancer cell lines that have expression levels comparable with those obsd. in breast cancer tissue samples.  Dose-response studies in xenograft models demonstrated antitumor activity with both weekly and every-3-wk dosing regimens.  In cynomolgus monkeys, a single injection of Y078-DM1 demonstrated dose-dependent, reversible drug-mediated alterations in blood chem. with evidence of on-target neuropathy.  Conclusions: RET is broadly expressed in breast cancer specimens and thus represents a potential therapeutic target; Y078-DM1 and Y078-DM4 demonstrated antitumor activity in preclin. models.  Optimization of the dosing schedule or an alternate cytotoxic agent with a different mechanism of action may reduce the potential risk of neuropathy.  Clin Cancer Res; 21(24); 5552-62.  ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxmnx_m4hKcrVg90H21EOLACvtfcHk0lgzK5b5s4pOxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKjs7jL&md5=4d98da9cdb9254aad762e9499f73a86f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-0468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-0468%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DM.%26aulast%3DMiyakawa%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DJ.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DArai%26aufirst%3DT.%26aulast%3DArmanini%26aufirst%3DM.%26aulast%3DGelmon%26aufirst%3DK.%26aulast%3DYerushalmi%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLandes%26aufirst%3DG.%26aulast%3DHaak-Frendscho%26aufirst%3DM.%26aulast%3DElias%26aufirst%3DK.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26atitle%3DPreclinical%2520Efficacy%2520and%2520Safety%2520Assessment%2520of%2520an%2520Antibody-Drug%2520Conjugate%2520Targeting%2520the%2520c-RET%2520Proto-Oncogene%2520for%2520Breast%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D5552%26epage%3D5562%26doi%3D10.1158%2F1078-0432.CCR-15-0468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brader, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. J.</span></span> <span> </span><span class="NLM_article-title">Paracrine Regulation of Pancreatic Cancer cell Invasion by Peripheral Nerves</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1093/jnci/djp456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1093%2Fjnci%2Fdjp456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=20068194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFakt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=107-118&author=Z.+Gilauthor=O.+Cavelauthor=K.+Kellyauthor=P.+Braderauthor=A.+Reinauthor=S.+P.+Gaoauthor=D.+L.+Carlsonauthor=J.+P.+Shahauthor=Y.+Fongauthor=R.+J.+Wong&title=Paracrine+Regulation+of+Pancreatic+Cancer+cell+Invasion+by+Peripheral+Nerves&doi=10.1093%2Fjnci%2Fdjp456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Paracrine Regulation of Pancreatic Cancer Cell Invasion by Peripheral Nerves</span></div><div class="casAuthors">Gil, Ziv; Cavel, Oren; Kelly, Kaitlyn; Brader, Peter; Rein, Avigail; Gao, Sizhi P.; Carlson, Diane L.; Shah, Jatin P.; Fong, Yuman; Wong, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-118</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background The ability of cancer to infiltrate along nerves is a common clin. observation in pancreas, head and neck, prostate, breast, and gastrointestinal carcinomas.  For these tumors, nerves may provide a conduit for local cancer progression into the central nervous system.  Although neural invasion is assocd. with poor outcome, the mechanism that triggers it is unknown.  Methods We used an in vitro Matrigel dorsal root ganglion and pancreatic cancer cell coculture model to assess the dynamic interactions between nerves and cancer cell migration and the role of glial cell-derived neurotrophic factor (GDNF).  An in vivo murine sciatic nerve model was used to study how nerve invasion affects sciatic nerve function.  Results Nerves induced a polarized neurotrophic migration of cancer cells (PNMCs) along their axons, which was more efficient than in the absence of nerves (migration distance: mean = 187.1 μm, 95% confidence interval [CI] = 148 to 226 μm vs 14.4 μm, 95% CI = 9.58 to 19.22 μm, difference = 143 μm; P < .001; n = 20).  PNMC was induced by secretion of GDNF, via phosphorylation of the RET-Ras-mitogen-activated protein kinase pathway.  Nerves from mice deficient in GDNF had reduced ability to attract cancer cells (nerve invasion index: wild type vs gdnf+/-, mean = 0.76, 95% CI = 0.75 to 0.77 vs 0.43, 95% CI = 0.42 to 0.44; P < .001; n = 60-66).  Tumor specimens excised from patients with neuroinvasive pancreatic carcinoma had higher expression of the GDNF receptors RET and GRFα1 as compared with normal tissue.  Finally, systemic therapy with pyrazolopyrimidine-1, a tyrosine kinase inhibitor targeting the RET pathway, suppressed nerve invasion toward the spinal cord and prevented paralysis in mice.  Conclusion These data provide evidence for paracrine regulation of pancreatic cancer invasion by nerves, which may have important implications for potential therapy directed against nerve invasion by cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD-nFBZgv00bVg90H21EOLACvtfcHk0lhtRyxCOd85Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFakt7Y%253D&md5=892219b53b819677b670c71b101985bf</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjp456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjp456%26sid%3Dliteratum%253Aachs%26aulast%3DGil%26aufirst%3DZ.%26aulast%3DCavel%26aufirst%3DO.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DBrader%26aufirst%3DP.%26aulast%3DRein%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DS.%2BP.%26aulast%3DCarlson%26aufirst%3DD.%2BL.%26aulast%3DShah%26aufirst%3DJ.%2BP.%26aulast%3DFong%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DR.%2BJ.%26atitle%3DParacrine%2520Regulation%2520of%2520Pancreatic%2520Cancer%2520cell%2520Invasion%2520by%2520Peripheral%2520Nerves%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2010%26volume%3D102%26spage%3D107%26epage%3D118%26doi%3D10.1093%2Fjnci%2Fdjp456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernichenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakst, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barajas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deborde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, R. J.</span></span> <span> </span><span class="NLM_article-title">GFRα1 Released by Nerves Enhances Cancer Cell Perineural Invasion through GDNF-RET Signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E2008</span>– <span class="NLM_lpage">E2017</span>, <span class="refDoi"> DOI: 10.1073/pnas.1402944111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1073%2Fpnas.1402944111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24778213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFGisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E2008-E2017&author=S.+Heauthor=C.+H.+Chenauthor=N.+Chernichenkoauthor=S.+Heauthor=R.+L.+Bakstauthor=F.+Barajasauthor=S.+Debordeauthor=P.+J.+Allenauthor=E.+Vakianiauthor=Z.+Yuauthor=R.+J.+Wong&title=GFR%CE%B11+Released+by+Nerves+Enhances+Cancer+Cell+Perineural+Invasion+through+GDNF-RET+Signaling&doi=10.1073%2Fpnas.1402944111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling</span></div><div class="casAuthors">He, Shuangba; Chen, Chun-Hao; Chernichenko, Natalya; He, Shizhi; Bakst, Richard L.; Barajas, Fernando; Deborde, Sylvie; Allen, Peter J.; Vakiani, Efsevia; Yu, Zhenkun; Wong, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">E2008-E2017</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The ability of cancer cells to invade along nerves is assocd. with aggressive disease and diminished patient survival rates.  Perineural invasion (PNI) may be mediated by nerve secretion of glial cell line-derived neurotrophic factor (GDNF) attracting cancer cell migration through activation of cell surface Ret proto-oncogene (RET) receptors.  GDNF family receptor (GFR)α1 acts as coreceptor with RET, with both required for response to GDNF.  We demonstrate that GFRα1 released by nerves enhances PNI, even in the absence of cancer cell GFRα1 expression.  Cancer cell migration toward GDNF, RET phosphorylation, and MAPK pathway activity are increased with exposure to sol. GFRα1 in a dose-dependent fashion.  Dorsal root ganglia (DRG) release sol. GFRα1, which potentiates RET activation and cancer cell migration.  In vitro DRG coculture assays of PNI show diminished PNI with DRG from GFRα1+/- mice compared with GFRα1+/+ mice.  An in vivo murine model of PNI demonstrates that cancer cells lacking GFRα1 maintain an ability to invade nerves and impair nerve function, whereas those lacking RET lose this ability.  A tissue microarray of human pancreatic ductal adenocarcinomas demonstrates wide variance of cancer cell GFRα1 expression, suggesting an alternate source of GFRα1 in PNI.  These findings collectively demonstrate that GFRα1 released by nerves enhances PNI through GDNF-RET signaling and that GFRα1 expression by cancer cells enhances but is not required for PNI.  These results advance a mechanistic understanding of PNI and implicate the nerve itself as a key facilitator of this adverse cancer cell behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe3-IhA_AvmbVg90H21EOLACvtfcHk0lhtRyxCOd85Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFGisL4%253D&md5=689468e21a62ba99f2d5c091e2019155</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1402944111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1402944111%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChernichenko%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DBakst%26aufirst%3DR.%2BL.%26aulast%3DBarajas%26aufirst%3DF.%26aulast%3DDeborde%26aufirst%3DS.%26aulast%3DAllen%26aufirst%3DP.%2BJ.%26aulast%3DVakiani%26aufirst%3DE.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DR.%2BJ.%26atitle%3DGFR%25CE%25B11%2520Released%2520by%2520Nerves%2520Enhances%2520Cancer%2520Cell%2520Perineural%2520Invasion%2520through%2520GDNF-RET%2520Signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE2008%26epage%3DE2017%26doi%3D10.1073%2Fpnas.1402944111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Falco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span> <span> </span><span class="NLM_article-title">The Molecular Basis for RET Tyrosine-kinase Inhibitors in Thyroid Cancer</span>. <i>Best Pract. Res. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.1016/j.beem.2017.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.beem.2017.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=28911727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVyitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=307-318&author=V.+De%0AFalcoauthor=F.+Carlomagnoauthor=H.+Y.+Liauthor=M.+Santoro&title=The+Molecular+Basis+for+RET+Tyrosine-kinase+Inhibitors+in+Thyroid+Cancer&doi=10.1016%2Fj.beem.2017.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer</span></div><div class="casAuthors">De Falco, Valentina; Carlomagno, Francesca; Li, Hong-yu; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Endocrinology & Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">307-318</span>CODEN:
                <span class="NLM_cas:coden">BPRCE9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">RET receptor tyrosine kinase acts as a mutated oncogenic driver in several human malignancies and it is over-expressed in other cancers.  Small mol. compds. with RET tyrosine kinase inhibitory activity are being investigated for the targeted treatment of these malignancies.  Multi-targeted compds. with RET inhibitory concn. in the nanomolar range have entered clin. practice.  This review summarizes mechanisms of RET oncogenic activity and properties of new compds. that, at the preclin. stage, have demonstrated promising anti-RET activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjmyfZyprDw7Vg90H21EOLACvtfcHk0lhtRyxCOd85Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVyitbo%253D&md5=5ee8bc030e96c39c3482848c450cf69b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.beem.2017.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beem.2017.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DThe%2520Molecular%2520Basis%2520for%2520RET%2520Tyrosine-kinase%2520Inhibitors%2520in%2520Thyroid%2520Cancer%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2017%26volume%3D31%26spage%3D307%26epage%3D318%26doi%3D10.1016%2Fj.beem.2017.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, G. G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S. W.</span></span> <span> </span><span class="NLM_article-title">Targeting RET-Driven Cancers: Lessons from Evolving Preclinical and Clinical Landscapes</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2017.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnrclinonc.2017.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=29134959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSitLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=151-167&author=A.+Drilonauthor=Z.+I.+Huauthor=G.+G.+Y.+Laiauthor=D.+S.+W.+Tan&title=Targeting+RET-Driven+Cancers%3A+Lessons+from+Evolving+Preclinical+and+Clinical+Landscapes&doi=10.1038%2Fnrclinonc.2017.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes</span></div><div class="casAuthors">Drilon, Alexander; Hu, Zishuo I.; Lai, Gillianne G. Y.; Tan, Daniel S. W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-167</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The gene encoding the receptor-tyrosine kinase RET was first discovered more than three decades ago, and activating RET rearrangements and mutations have since been identified as actionable drivers of oncogenesis.  Several multikinase inhibitors with activity against RET have been explored in the clinic, and confirmed responses to targeted therapy with these agents have been obsd. in patients with RET-rearranged lung cancers or RET-mutant thyroid cancers.  Nevertheless, response rates to RET-directed therapy are modest compared with those achieved using targeted therapies matched to other oncogenic drivers of solid tumors, such as sensitizing EGFR or BRAFV600E mutations, or ALK or ROS1 rearrangements.  To date, no RET-directed targeted therapeutic has received regulatory approval for the treatment of molecularly defined populations of patients with RET-mutant or RET-rearranged solid tumors.  In this Review, we discuss how emerging data have informed the debate over whether the limited success of multikinase inhibitors with activity against RET can be attributed to the tractability of RET as a drug target or to the lack, until 2017, of highly specific inhibitors of this oncoprotein in the clinic.  We emphasize that novel approaches to targeting RET-dependent tumors are necessary to improve the clin. efficacy of single-agent multikinase inhibition and, thus, hasten approvals of RET-directed targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHGH619E1uKrVg90H21EOLACvtfcHk0ljTKsdc0w0GqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSitLbO&md5=44da2e242b7b5ad12eb628ed87b8fa74</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2017.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2017.175%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DZ.%2BI.%26aulast%3DLai%26aufirst%3DG.%2BG.%2BY.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26atitle%3DTargeting%2520RET-Driven%2520Cancers%253A%2520Lessons%2520from%2520Evolving%2520Preclinical%2520and%2520Clinical%2520Landscapes%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D15%26spage%3D151%26epage%3D167%26doi%3D10.1038%2Fnrclinonc.2017.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Commander, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteside, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C.</span></span> <span> </span><span class="NLM_article-title">Vandetanib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1365</span>, <span class="refDoi"> DOI: 10.2165/11595310-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.2165%2F11595310-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=21770481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlakurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=1355-1365&author=H.+Commanderauthor=G.+Whitesideauthor=C.+Perry&title=Vandetanib%3A+First+Global+Approval&doi=10.2165%2F11595310-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib: first global approval</span></div><div class="casAuthors">Commander, Helen; Whiteside, Glenn; Perry, Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1355-1365</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC).  Regulatory submissions for this indication have been filed in the EU and Canada, with clin. development in malignant MTC ongoing in several other countries.  Vandetanib is being developed by AstraZeneca, and is also in phase II development for biliary, breast and prostate cancer.  Earlier, AstraZeneca withdrew regulatory filings for non-small cell lung cancer (NSCLC) in the US and EU, and later discontinued development.  This article summarizes the milestones in the development of vandetanib leading to this first approval in malignant MTC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsc9DGAyJOZ7Vg90H21EOLACvtfcHk0ljTKsdc0w0GqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlakurzJ&md5=ffb345f58f8c488b3752dc43554054af</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2165%2F11595310-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11595310-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DCommander%26aufirst%3DH.%26aulast%3DWhiteside%26aufirst%3DG.%26aulast%3DPerry%26aufirst%3DC.%26atitle%3DVandetanib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D1355%26epage%3D1365%26doi%3D10.2165%2F11595310-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grüllich, C.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib: a MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor</span>. <i>Recent Results Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1007/978-3-642-54490-3_12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1007%2F978-3-642-54490-3_12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24756794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVOqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2014&pages=207-214&author=C.+Gr%C3%BCllich&title=Cabozantinib%3A+a+MET%2C+RET%2C+and+VEGFR2+Tyrosine+Kinase+Inhibitor&doi=10.1007%2F978-3-642-54490-3_12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor</span></div><div class="casAuthors">Gruellich, Carsten</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">207-214</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">2197-6767</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Cabozantinib is a receptor tyrosine kinase inhibitor with activity against MET, VEGFR2, FLT3, c-KIT, and RET.  Activity of cabozantinib toward a broad range of tumor models could be detected in several preclin. studies.  Of note, cabozantinib decreases metastasis potential and tumor invasiveness when compared with placebo or agents that target VEGFR and have no activity against MET.  Clin. phase I and II studies with cabozantinib have been conducted in various malignancies including medullary thyroid cancer (MTC), NSCLC, breast, ovarian, pancreatic, and prostate cancer.  In MTC, gain of function mutations of RET are central for tumorigenesis.  Hereditary forms of MTC (MEN II) are caused by germline mutations of RET, in sporadic MTC in up to 50 % of cases RET mutations occur.  Addnl., activating mol. changes in VEGFR and MET pathways have also been implicated in MTC progression.  Clin. responses with cabozantinib in MTC could be obsd. in early clin. trials, and following confirmation of clin. benefit in a randomized phase III trial, cabozantinib gained FDA approval for first-line treatment of advanced MTC in 2012.  In prostate cancer models, MET expression increases with androgen ablation and clin. progression of bone and lymph node metastasis.  A phase II trial with cabozantinib also showed very promising response rates in patients with metastatic prostate cancer.  Therefore, randomized phase III studies are currently ongoing to validate the efficacy of cabozantinib in heavily pretreated prostate cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofpYohX76awrVg90H21EOLACvtfcHk0ljTKsdc0w0GqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVOqt7Y%253D&md5=e0adbd14c1da32af3e5ded5823f6ad32</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-54490-3_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-54490-3_12%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25BCllich%26aufirst%3DC.%26atitle%3DCabozantinib%253A%2520a%2520MET%252C%2520RET%252C%2520and%2520VEGFR2%2520Tyrosine%2520Kinase%2520Inhibitor%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2014%26volume%3D201%26spage%3D207%26epage%3D214%26doi%3D10.1007%2F978-3-642-54490-3_12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagel, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dralle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baudin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarzab, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasselli, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmuir, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, M. J.</span></span> <span> </span><span class="NLM_article-title">Vandetanib in Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer: a Randomized, Double-Blind Phase III trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1200/JCO.2011.35.5040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1200%2FJCO.2011.35.5040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=22025146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFGrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=134-141&author=S.+A.+Wellsauthor=B.+G.+Robinsonauthor=R.+F.+Gagelauthor=H.+Dralleauthor=J.+A.+Faginauthor=M.+Santoroauthor=E.+Baudinauthor=R.+Eliseiauthor=B.+Jarzabauthor=J.+R.+Vasselliauthor=J.+Readauthor=P.+Langmuirauthor=A.+J.+Ryanauthor=M.+J.+Schlumberger&title=Vandetanib+in+Patients+with+Locally+Advanced+or+Metastatic+Medullary+Thyroid+Cancer%3A+a+Randomized%2C+Double-Blind+Phase+III+trial&doi=10.1200%2FJCO.2011.35.5040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial</span></div><div class="casAuthors">Wells, Samuel A., Jr.; Robinson, Bruce G.; Gagel, Robert F.; Dralle, Henning; Fagin, James A.; Santoro, Massimo; Baudin, Eric; Elisei, Rossella; Jarzab, Barbara; Vasselli, James R.; Read, Jessica; Langmuir, Peter; Ryan, Anderson J.; Schlumberger, Martin I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-141</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC).  Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.  Patients and Methods Patients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo.  On objective disease progression, patients could elect to receive open-label vandetanib.  The primary end point was progression-free survival (PFS), detd. by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.  Results Between Dec. 2006 and Nov. 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100).  At data cutoff (July 2009; median follow-up, 24 mo), 37% of patients had progressed and 15% had died.  The study met its primary objective of PFS prolongation with vandetanib vs. placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001).  Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P = .001), and biochem. response (P < .001).  Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65).  A final survival anal. will take place when 50% of the patients have died.  Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%).  Conclusion Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnzd5Ld1n-AbVg90H21EOLACvtfcHk0ljTKsdc0w0GqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFGrsb0%253D&md5=99ea5fa9e2cd53b14f85b8a37e1e3c2b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.5040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.5040%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DDralle%26aufirst%3DH.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DBaudin%26aufirst%3DE.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DVasselli%26aufirst%3DJ.%2BR.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DLangmuir%26aufirst%3DP.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26atitle%3DVandetanib%2520in%2520Patients%2520with%2520Locally%2520Advanced%2520or%2520Metastatic%2520Medullary%2520Thyroid%2520Cancer%253A%2520a%2520Randomized%252C%2520Double-Blind%2520Phase%2520III%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D134%26epage%3D141%26doi%3D10.1200%2FJCO.2011.35.5040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elisei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licitra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarzab, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medvedev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreissl, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaron, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelkin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, S. I.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib in Progressive Medullary Thyroid Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">3639</span>– <span class="NLM_lpage">3646</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.48.4659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3646&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+M%C3%BCllerauthor=P.+Sch%C3%B6ffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+Progressive+Medullary+Thyroid+Cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0lgYtVuh_zTpjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%2BP.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520Progressive%2520Medullary%2520Thyroid%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3646%26doi%3D10.1200%2FJCO.2012.48.4659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elisei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habra, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newbold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianoukakis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyota, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzyzanowska, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutcus, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de las
Heras, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, S. I.</span></span> <span> </span><span class="NLM_article-title">Lenvatinib Versus Placebo in Radioiodine-Refractory Thyroid Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1406470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1056%2FNEJMoa1406470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=25671254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFWis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=621-630&author=M.+Schlumbergerauthor=M.+Taharaauthor=L.+J.+Wirthauthor=B.+Robinsonauthor=M.+S.+Broseauthor=R.+Eliseiauthor=M.+A.+Habraauthor=K.+Newboldauthor=M.+H.+Shahauthor=A.+O.+Hoffauthor=A.+G.+Gianoukakisauthor=N.+Kiyotaauthor=M.+H.+Taylorauthor=S.+B.+Kimauthor=M.+K.+Krzyzanowskaauthor=C.+E.+Dutcusauthor=B.+de+las%0AHerasauthor=J.+Zhuauthor=S.+I.+Sherman&title=Lenvatinib+Versus+Placebo+in+Radioiodine-Refractory+Thyroid+Cancer&doi=10.1056%2FNEJMoa1406470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lenvatinib versus placebo in radioiodine-refractory thyroid cancer</span></div><div class="casAuthors">Schlumberger, Martin; Tahara, Makoto; Wirth, Lori J.; Robinson, Bruce; Brose, Marcia S.; Elisei, Rossella; Habra, Mouhammed Amir; Newbold, Kate; Shah, Manisha H.; Hoff, Ana O.; Gianoukakis, Andrew G.; Kiyota, Naomi; Taylor, Matthew H.; Kim, Sung-Bae; Krzyzanowska, Monika K.; Dutcus, Corina E.; de las Heras, Begona; Zhu, Junming; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">621-630/1-621-630/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clin. activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).  In our phase 3, randomized, double-blind, multicenter study involving patients with progressive thyroid cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive lenvatinib (at a daily dose of 24 mg per day in 28-day cycles) and 131 patients to receive placebo.  At the time of disease progression, patients in the placebo group could receive open-label lenvatinib.  The primary end point was progression-free survival.  Secondary end points included the response rate, overall survival, and safety.  The median progression-free survival was 18.3 mo in the lenvatinib group and 3.6 mo in the placebo group (hazard ratio for progression or death, 0.21; 99% confidence interval, 0.14 to 0.31; P<0.001).  A progression-free survival benefit assocd. with lenvatinib was obsd. in all prespecified subgroups.  The response rate was 64.8% in the lenvatinib group (4 complete responses and 165 partial responses) and 1.5% in the placebo group (P<0.001).  The median overall survival was not reached in either group.  Treatment-related adverse effects of any grade, which occurred in more than 40% of patients in the lenvatinib group, were hypertension (in 67.8% of the patients), diarrhea (in 59.4%), fatigue or asthenia (in 59.0%), decreased appetite (in 50.2%), decreased wt. (in 46.4%), and nausea (in 41.0%).  Discontinuations of the study drug because of adverse effects occurred in 37 patients who received lenvatinib (14.2%) and 3 patients who received placebo (2.3%).  In the lenvatinib group, 6 of 20 deaths that occurred during the treatment period were considered to be drug-related.  Lenvatinib, as compared with placebo, was assocd. with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer.  Patients who received lenvatinib had more adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP3YOcsp5Eh7Vg90H21EOLACvtfcHk0lgYtVuh_zTpjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFWis70%253D&md5=4670427f7c296a58bd24f90e042b743d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1406470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1406470%26sid%3Dliteratum%253Aachs%26aulast%3DSchlumberger%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DM.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DRobinson%26aufirst%3DB.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DHabra%26aufirst%3DM.%2BA.%26aulast%3DNewbold%26aufirst%3DK.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DHoff%26aufirst%3DA.%2BO.%26aulast%3DGianoukakis%26aufirst%3DA.%2BG.%26aulast%3DKiyota%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DM.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DKrzyzanowska%26aufirst%3DM.%2BK.%26aulast%3DDutcus%26aufirst%3DC.%2BE.%26aulast%3Dde%2Blas%2BHeras%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DLenvatinib%2520Versus%2520Placebo%2520in%2520Radioiodine-Refractory%2520Thyroid%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D621%26epage%3D630%26doi%3D10.1056%2FNEJMoa1406470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Development of Sorafenib for the Treatment of Thyroid Cancer</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1517/17460441.2015.1006194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1517%2F17460441.2015.1006194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=25662396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFehtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=427-439&author=P.+T.+Whiteauthor=M.+S.+Cohen&title=The+Discovery+and+Development+of+Sorafenib+for+the+Treatment+of+Thyroid+Cancer&doi=10.1517%2F17460441.2015.1006194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of sorafenib for the treatment of thyroid cancer</span></div><div class="casAuthors">White, Peter T.; Cohen, Mark S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">427-439</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Although the prognosis for most differentiated thyroid cancers (DTCs) remains excellent, recurrence and insensitivity to radioactive iodine (RAI) lead to therapeutic challenges and poorer outcomes.  In defining the pathogenesis of DTC, multiple genetic alterations have been identified in key pathways focused around receptor tyrosine kinases (RTKs) and the MAPK cascade.  Sorafenib was specifically developed to target rapidly accelerated fibrosarcoma (RAF) kinase in the MAPK pathway.  It has been shown, however, to have potent inhibition of several key RTKs, RAF kinase and the V600E BRAF mutation, gaining FDA approval in Nov. 2013 for advanced RAI-refractory DTC.  Areas covered: The authors provide a review of the targeted RAF kinase discovery strategy as well as the preclin. and clin. development of sorafenib, leading to FDA approval of DTC.  The authors also provide some insight into the clin. use of sorafenib and look at important considerations for treatment.  Expert opinion: Sorafenib significantly improves progression-free survival in metastatic DTC patients who are RAI-refractory.  However, the overall survival benefit is still unproven and requires addnl. follow up.  Despite its cost and significant side-effect profile, which results in dose redns. in the majority of DTC patients, sorafenib should be considered for the treatment of RAI-refractory advanced DTC patients following evaluation of their individual risk-benefit stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ZRrHxZhzUrVg90H21EOLACvtfcHk0liGYpsemACNtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFehtr8%253D&md5=ec64129cfdfbf441102dba2f98878c73</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F17460441.2015.1006194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2015.1006194%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DP.%2BT.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26atitle%3DThe%2520Discovery%2520and%2520Development%2520of%2520Sorafenib%2520for%2520the%2520Treatment%2520of%2520Thyroid%2520Cancer%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2015%26volume%3D10%26spage%3D427%26epage%3D439%26doi%3D10.1517%2F17460441.2015.1006194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainor, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brubaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPietro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brose, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garralda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span> <span> </span><span class="NLM_article-title">Precision Targeted Therapy with BLU-667 for RET-Driven Cancers</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F2159-8290.CD-18-0338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=29657135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1altLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=836-849&author=V.+Subbiahauthor=J.+F.+Gainorauthor=R.+Rahalauthor=J.+D.+Brubakerauthor=J.+L.+Kimauthor=M.+Maynardauthor=W.+Huauthor=Q.+Caoauthor=M.+P.+Sheetsauthor=D.+Wilsonauthor=K.+J.+Wilsonauthor=L.+DiPietroauthor=P.+Flemingauthor=M.+Palmerauthor=M.+I.+Huauthor=L.+Wirthauthor=M.+S.+Broseauthor=S.+I.+Ouauthor=M.+Taylorauthor=E.+Garraldaauthor=S.+Millerauthor=B.+Wolfauthor=C.+Lengauerauthor=T.+Guziauthor=E.+K.+Evans&title=Precision+Targeted+Therapy+with+BLU-667+for+RET-Driven+Cancers&doi=10.1158%2F2159-8290.CD-18-0338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Precision Targeted Therapy with BLU-667 for RET-Driven Cancers</span></div><div class="casAuthors">Subbiah, Vivek; Gainor, Justin F.; Rahal, Rami; Brubaker, Jason D.; Kim, Joseph L.; Maynard, Michelle; Hu, Wei; Cao, Qiongfang; Sheets, Michael P.; Wilson, Douglas; Wilson, Kevin J.; Di Pietro, Lucian; Fleming, Paul; Palmer, Michael; Hu, Mimi I.; Wirth, Lori; Brose, Marcia S.; Ou, Sai-Hong Ignatius; Taylor, Matthew; Garralda, Elena; Miller, Stephen; Wolf, Beni; Lengauer, Christoph; Guzi, Timothy; Evans, Erica K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">836-849</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and papillary thyroid cancer.  No approved therapies have been designed to target RET; treatment has been limited to multikinase inhibitors (MKI), which can have significant off-target toxicities and limited efficacy.  BLU-667 is a highly potent and selective RET inhibitor designed to overcome these limitations.  In vitro, BLU-667 demonstrated ≥10-fold increased potency over approved MKIs against oncogenic RET variants and resistance mutants.  In vivo, BLU-667 potently inhibited growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR2.  In first-in-human testing, BLU-667 significantly inhibited RET signaling and induced durable clin. responses in patients with RET-altered NSCLC and MTC without notable off-target toxicity, providing clin. validation for selective RET targeting.  Significance: Patients with RET-driven cancers derive limited benefit from available MKIs.  BLU-667 is a potent and selective RET inhibitor that induces tumor regression in cancer models with RET mutations and fusions.  BLU-667 attenuated RET signaling and produced durable clin. responses in patients with RET-altered tumors, clin. validating selective RET targeting.  Cancer Discov; 8(7); 836-49. .copyright.2018 AACR.  See related commentary by Iams and Lovly, p. 797.  This article is highlighted in the In This Issue feature, p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9whHmxdlp0rVg90H21EOLACvtfcHk0liGYpsemACNtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1altLnE&md5=f910f4d236619a357cf42163583f5e7d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0338%26sid%3Dliteratum%253Aachs%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DRahal%26aufirst%3DR.%26aulast%3DBrubaker%26aufirst%3DJ.%2BD.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DMaynard%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DSheets%26aufirst%3DM.%2BP.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DK.%2BJ.%26aulast%3DDiPietro%26aufirst%3DL.%26aulast%3DFleming%26aufirst%3DP.%26aulast%3DPalmer%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DM.%2BI.%26aulast%3DWirth%26aufirst%3DL.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DGarralda%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWolf%26aufirst%3DB.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DGuzi%26aufirst%3DT.%26aulast%3DEvans%26aufirst%3DE.%2BK.%26atitle%3DPrecision%2520Targeted%2520Therapy%2520with%2520BLU-667%2520for%2520RET-Driven%2520Cancers%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D836%26epage%3D849%26doi%3D10.1158%2F2159-8290.CD-18-0338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subbiah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velcheti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuch, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busaidy, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabanillas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsi-Travali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhana, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span> <span> </span><span class="NLM_article-title">Selective RET Kinase Inhibition for Patients with RET-Altered Cancers</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1869</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdy137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1093%2Fannonc%2Fmdy137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=29912274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbot12lsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=1869-1876&author=V.+Subbiahauthor=V.+Velchetiauthor=B.+B.+Tuchauthor=K.+Ebataauthor=N.+L.+Busaidyauthor=M.+E.+Cabanillasauthor=L.+J.+Wirthauthor=S.+Stockauthor=S.+Smithauthor=V.+Lauriaultauthor=S.+Corsi-Travaliauthor=D.+Henryauthor=M.+Burkardauthor=R.+Hamorauthor=K.+Bouhanaauthor=S.+Winskiauthor=R.+D.+Wallaceauthor=D.+Hartleyauthor=S.+Rhodesauthor=M.+Reddyauthor=B.+J.+Brandhuberauthor=S.+Andrewsauthor=S.+M.+Rothenbergauthor=A.+Drilon&title=Selective+RET+Kinase+Inhibition+for+Patients+with+RET-Altered+Cancers&doi=10.1093%2Fannonc%2Fmdy137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selective RET kinase inhibition for patients with RET-altered cancers</span></div><div class="casAuthors">Subbiah V; Busaidy N L; Cabanillas M E; Velcheti V; Stock S; Tuch B B; Ebata K; Smith S; Lauriault V; Corsi-Travali S; Henry D; Brandhuber B J; Andrews S; Wirth L J; Burkard M; Hamor R; Bouhana K; Winski S; Wallace R D; Hartley D; Rhodes S; Reddy M; Rothenberg S M; Drilon A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1869-1876</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Alterations involving the RET kinase are implicated in the pathogenesis of lung, thyroid and other cancers.  However, the clinical activity of multikinase inhibitors (MKIs) with anti-RET activity in RET-altered patients appears limited, calling into question the therapeutic potential of targeting RET.  LOXO-292 is a selective RET inhibitor designed to inhibit diverse RET fusions, activating mutations and acquired resistance mutations.  Patients and methods:  Potent anti-RET activity, high selectivity, and central nervous system coverage were confirmed preclinically using a variety of in vitro and in vivo RET-dependent tumor models.  Due to clinical urgency, two patients with RET-altered, MKI-resistant cancers were treated with LOXO-292, utilizing rapid dose-titration guided by real-time pharmacokinetic assessments to achieve meaningful clinical exposures safely and rapidly.  Results:  LOXO-292 demonstrated potent and selective anti-RET activity preclinically against human cancer cell lines harboring endogenous RET gene alterations; cells engineered to express a KIF5B-RET fusion protein -/+ the RET V804M gatekeeper resistance mutation or the common RET activating mutation M918T; and RET-altered human cancer cell line and patient-derived xenografts, including a patient-derived RET fusion-positive xenograft injected orthotopically into the brain.  A patient with RET M918T-mutant medullary thyroid cancer metastatic to the liver and an acquired RET V804M gatekeeper resistance mutation, previously treated with six MKI regimens, experienced rapid reductions in tumor calcitonin, CEA and cell-free DNA, resolution of painful hepatomegaly and tumor-related diarrhea and a confirmed tumor response.  A second patient with KIF5B-RET fusion-positive lung cancer, acquired resistance to alectinib and symptomatic brain metastases experienced a dramatic response in the brain, and her symptoms resolved.  Conclusions:  These results provide proof-of-concept of the clinical actionability of RET alterations, and identify selective RET inhibition by LOXO-292 as a promising treatment in heavily pretreated, multikinase inhibitor-experienced patients with diverse RET-altered tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQnDC8BTRt7OdfST00W0BcfW6udTcc2eYew67J8X50irntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbot12lsA%253D%253D&md5=1acdc0949007df1a17f9ccbf227b8633</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdy137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdy137%26sid%3Dliteratum%253Aachs%26aulast%3DSubbiah%26aufirst%3DV.%26aulast%3DVelcheti%26aufirst%3DV.%26aulast%3DTuch%26aufirst%3DB.%2BB.%26aulast%3DEbata%26aufirst%3DK.%26aulast%3DBusaidy%26aufirst%3DN.%2BL.%26aulast%3DCabanillas%26aufirst%3DM.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DStock%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DCorsi-Travali%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DD.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DHamor%26aufirst%3DR.%26aulast%3DBouhana%26aufirst%3DK.%26aulast%3DWinski%26aufirst%3DS.%26aulast%3DWallace%26aufirst%3DR.%2BD.%26aulast%3DHartley%26aufirst%3DD.%26aulast%3DRhodes%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DM.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAndrews%26aufirst%3DS.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DDrilon%26aufirst%3DA.%26atitle%3DSelective%2520RET%2520Kinase%2520Inhibition%2520for%2520Patients%2520with%2520RET-Altered%2520Cancers%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3D1869%26epage%3D1876%26doi%3D10.1093%2Fannonc%2Fmdy137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakih, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olszanski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgensztern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reckamp, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seery, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolinakos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Multani, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1158%2F2159-8290.CD-18-0839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=30487236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOmsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=384-395&author=A.+Drilonauthor=S.+Fuauthor=M.+R.+Patelauthor=M.+Fakihauthor=D.+Wangauthor=A.+J.+Olszanskiauthor=D.+Morgenszternauthor=S.+V.+Liuauthor=B.+C.+Choauthor=L.+Bazhenovaauthor=C.+P.+Rodriguezauthor=R.+C.+Doebeleauthor=A.+Wozniakauthor=K.+L.+Reckampauthor=T.+Seeryauthor=P.+Nikolinakosauthor=Z.+Huauthor=J.+W.+Oliverauthor=D.+Troneauthor=K.+McArthurauthor=R.+Patelauthor=P.+S.+Multaniauthor=M.+J.+Ahn&title=A+Phase+I%2FIb+Trial+of+the+VEGFR-Sparing+Multikinase+RET+Inhibitor+RXDX-105&doi=10.1158%2F2159-8290.CD-18-0839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105</span></div><div class="casAuthors">Drilon, Alexander; Fu, Siqing; Patel, Manish R.; Fakih, Marwan; Wang, Ding; Olszanski, Anthony J.; Morgensztern, Daniel; Liu, Stephen V.; Cho, Byoung Chul; Bazhenova, Lyudmila; Rodriguez, Cristina P.; Doebele, Robert C.; Wozniak, Antoinette; Reckamp, Karen L.; Seery, Tara; Nikolinakos, Petros; Hu, Zheyi; Oliver, Jennifer W.; Trone, Denise; McArthur, Katherine; Patel, Rupal; Multani, Pratik S.; Ahn, Myung-Ju</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-395</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">RET fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLC).  The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial.  A recommended phase II dose of 275 mg fed daily was identified.  The most common treatment-related adverse events were fatigue (25%), diarrhea (24%), hypophosphatemia (18%), maculopapular rash (18%), and nonmaculopapular rash (17%).  In the phase Ib cohort of RET inhibitor-na.ovrddot.ive patients with RET fusion-pos. NSCLCs, the objective response rate (ORR) was 19% (95% CI, 8%-38%, n = 6/31).  Interestingly, the ORR varied significantly by the gene fusion partner (P < 0.001, Fisher exact test): 0% (95% CI, 0%-17%, n = 0/20) with KIF5B (the most common upstream partner for RET fusion-pos. NSCLC), and 67% (95% CI, 30%-93%, n = 6/9) with non-KIF5B partners.  The median duration of response in all RET fusion-pos. NSCLCs was not reached (range, 5 to 18+ months).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLZba-OIyH67Vg90H21EOLACvtfcHk0lg8TUsp-S70hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOmsLrN&md5=920590dca8e2475da2443d0721412b49</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0839%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFakih%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DOlszanski%26aufirst%3DA.%2BJ.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DRodriguez%26aufirst%3DC.%2BP.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DSeery%26aufirst%3DT.%26aulast%3DNikolinakos%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DOliver%26aufirst%3DJ.%2BW.%26aulast%3DTrone%26aufirst%3DD.%26aulast%3DMcArthur%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DR.%26aulast%3DMultani%26aufirst%3DP.%2BS.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DA%2520Phase%2520I%252FIb%2520Trial%2520of%2520the%2520VEGFR-Sparing%2520Multikinase%2520RET%2520Inhibitor%2520RXDX-105%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26spage%3D384%26epage%3D395%26doi%3D10.1158%2F2159-8290.CD-18-0839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moccia, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brescia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Falco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Admire, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8717</span>– <span class="NLM_lpage">8721</span>, <span class="refDoi"> DOI: 10.1002/anie.201501104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1002%2Fanie.201501104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8717-8721&author=B.+Frettauthor=F.+Carlomagnoauthor=M.+L.+Mocciaauthor=A.+Bresciaauthor=G.+Federicoauthor=V.+De+Falcoauthor=B.+Admireauthor=Z.+Chenauthor=W.+Qiauthor=M.+Santoroauthor=H.+Y.+Li&title=Fragment-Based+Discovery+of+a+Dual+pan-RET%2FVEGFR2+Kinase+Inhibitor+Optimized+for+Single-Agent+Polypharmacology&doi=10.1002%2Fanie.201501104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span></div><div class="casAuthors">Frett, Brendan; Carlomagno, Francesca; Moccia, Maria Luisa; Brescia, Annalisa; Federico, Giorgia; De Falco, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hong-yu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8717-8721</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is assocd. with several cancers.  A fragment-based chem. screen led to the identification of a novel RET inhibitor, Pz-1.  Modeling and kinetic anal. identified Pz-1 as a type II tyrosine kinase inhibitor that is able to bind the "DFG-out" conformation of the kinase.  Importantly, from a single-agent polypharmacol. standpoint, Pz-1 was shown to be active on VEGFR2, which can block the blood supply required for RET-stimulated growth.  In cell-based assays, 1.0 nM of Pz-1 strongly inhibited phosphorylation of all tested RET oncoproteins.  At 1.0 mg kg-1 day-1 per os, Pz-1 abrogated the formation of tumors induced by RET-mutant fibroblasts and blocked the phosphorylation of both RET and VEGFR2 in tumor tissue.  Pz-1 featured no detectable toxicity at concns. of up to 100.0 mg kg-1, which indicates a large therapeutic window.  This study validates the effectiveness and usefulness of a medicinal chem./polypharmacol. approach to obtain an inhibitor capable of targeting multiple oncogenic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcoWkpO70i7rVg90H21EOLACvtfcHk0lg8TUsp-S70hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtLnL&md5=05039c7074e7375de3884e0550d8c7ff</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.201501104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201501104%26sid%3Dliteratum%253Aachs%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DMoccia%26aufirst%3DM.%2BL.%26aulast%3DBrescia%26aufirst%3DA.%26aulast%3DFederico%26aufirst%3DG.%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DAdmire%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%2BY.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Dual%2520pan-RET%252FVEGFR2%2520Kinase%2520Inhibitor%2520Optimized%2520for%2520Single-Agent%2520Polypharmacology%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D8717%26epage%3D8721%26doi%3D10.1002%2Fanie.201501104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, H.</span></span> <span> </span><span class="NLM_article-title">Drug-Metabolizing Enzyme Systems I</span>. In  <i>Comprehensive Medicinal Chemistry III</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chackalamannil, S.</span>, <span class="NLM_string-name">Rotella, D.</span>, <span class="NLM_string-name">Ward, S.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">50</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2FB978-0-12-409547-2.12314-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=45-50&author=H.+Yamazakiauthor=S.+Chackalamannil&author=D.+Rotella&author=S.+Ward&title=Comprehensive+Medicinal+Chemistry+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-409547-2.12314-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-409547-2.12314-5%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DH.%26atitle%3DDrug-Metabolizing%2520Enzyme%2520Systems%2520I%26btitle%3DComprehensive%2520Medicinal%2520Chemistry%2520III%26aulast%3DChackalamannil%26aufirst%3DS.%26pub%3DElsevier%26date%3D2017%26spage%3D45%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lhTHPrdIdayaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anaganti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vecchio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billaud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span> <span> </span><span class="NLM_article-title">Disease Associated Mutations at Valine 804 in the RET Receptor Tyrosine Kinase Confer Resistance to Selective Kinase Inhibitors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6063</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1207810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fsj.onc.1207810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=15184865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVKlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6056-6063&author=F.+Carlomagnoauthor=T.+Guidaauthor=S.+Anagantiauthor=G.+Vecchioauthor=A.+Fuscoauthor=A.+J.+Ryanauthor=M.+Billaudauthor=M.+Santoro&title=Disease+Associated+Mutations+at+Valine+804+in+the+RET+Receptor+Tyrosine+Kinase+Confer+Resistance+to+Selective+Kinase+Inhibitors&doi=10.1038%2Fsj.onc.1207810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors</span></div><div class="casAuthors">Carlomagno, Francesca; Guida, Teresa; Anaganti, Suresh; Vecchio, Giancarlo; Fusco, Alfredo; Ryan, Anderson J.; Billaud, Marc; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6056-6063</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC50≤100 nM) towards constitutively active oncogenic RET kinases.  Here, we show that most oncogenic MEN2-assocd. RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition.  In contrast, MEN2-assocd. swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compds.  Substitution of valine 804 with the small amino- acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC50: 20 nM) than the wild-type kinase.  Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJql666y5D-bVg90H21EOLACvtfcHk0lhTHPrdIdayaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVKlt7c%253D&md5=39ec0aa2550048d7cd9a5536a6180fc0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207810%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DGuida%26aufirst%3DT.%26aulast%3DAnaganti%26aufirst%3DS.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DBillaud%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DDisease%2520Associated%2520Mutations%2520at%2520Valine%2520804%2520in%2520the%2520RET%2520Receptor%2520Tyrosine%2520Kinase%2520Confer%2520Resistance%2520to%2520Selective%2520Kinase%2520Inhibitors%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6056%26epage%3D6063%26doi%3D10.1038%2Fsj.onc.1207810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mologni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redaelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza-Menacho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambacorti-Passerini, C.</span></span> <span> </span><span class="NLM_article-title">Ponatinib is a Potent Inhibitor of Wild-Type and Drug-Resistant Gatekeeper Mutant RET Kinase</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2013.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.mce.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=23811235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2013&pages=1-6&author=L.+Mologniauthor=S.+Redaelliauthor=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+Gambacorti-Passerini&title=Ponatinib+is+a+Potent+Inhibitor+of+Wild-Type+and+Drug-Resistant+Gatekeeper+Mutant+RET+Kinase&doi=10.1016%2Fj.mce.2013.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span></div><div class="casAuthors">Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a mol. target in these tumors.  Vandetanib was recently approved for the treatment of medullary thyroid cancer.  However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants in chronic myeloid leukemia.  Ponatinib is a multi-target kinase inhibitor that was recently approved for treatment-refractory Philadelphia-pos. leukemia.  We show here potent inhibition of oncogenic RET by ponatinib, including the drug-insensitive V804M/L mutants.  Ponatinib inhibited the growth of RET+ and BCR-ABL+ cells with similar potency, while not affecting RET-neg. cells.  Both in biochem. and in cellular assays ponatinib compared favorably with known RET inhibitors, such as vandetanib, cabozantinib, sorafenib, sunitinib and motesanib, used as ref. compds.  We suggest that ponatinib should be considered for the treatment of RET+ tumors, in particular those expressing vandetanib-resistant V804M/L mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1KRyhCS6ULVg90H21EOLACvtfcHk0lhTHPrdIdayaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP&md5=f08de33f80af574f3ec843d26269ed98</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DPonatinib%2520is%2520a%2520Potent%2520Inhibitor%2520of%2520Wild-Type%2520and%2520Drug-Resistant%2520Gatekeeper%2520Mutant%2520RET%2520Kinase%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D377%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.mce.2013.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brägelmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bührmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tischler, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrugalla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richters, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leenders, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diebold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aerts, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahedi, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautschi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Drugging the Catalytically Inactive State of RET kinase in RET-Rearranged Tumors</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">eaah6144</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aah6144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1126%2Fscitranslmed.aah6144" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=28615362" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaah6144&author=D.+Plenkerauthor=M.+Riedelauthor=J.+Br%C3%A4gelmannauthor=M.+A.+Dammertauthor=R.+Chauhanauthor=P.+P.+Knowlesauthor=C.+Lorenzauthor=M.+Keulauthor=M.+B%C3%BChrmannauthor=O.+Pagelauthor=V.+Tischlerauthor=A.+H.+Scheelauthor=D.+Sch%C3%BCtteauthor=Y.+Songauthor=J.+Starkauthor=F.+Mrugallaauthor=Y.+Alberauthor=A.+Richtersauthor=J.+Engelauthor=F.+Leendersauthor=J.+M.+Heuckmannauthor=J.+Wolfauthor=J.+Dieboldauthor=G.+Pallauthor=M.+Peiferauthor=M.+Aertsauthor=K.+Gevaertauthor=R.+P.+Zahediauthor=R.+Buettnerauthor=K.+M.+Shokatauthor=N.+Q.+McDonaldauthor=S.+M.+Kastauthor=O.+Gautschiauthor=R.+K.+Thomasauthor=M.+L.+Sos&title=Drugging+the+Catalytically+Inactive+State+of+RET+kinase+in+RET-Rearranged+Tumors&doi=10.1126%2Fscitranslmed.aah6144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aah6144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aah6144%26sid%3Dliteratum%253Aachs%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DRiedel%26aufirst%3DM.%26aulast%3DBr%25C3%25A4gelmann%26aufirst%3DJ.%26aulast%3DDammert%26aufirst%3DM.%2BA.%26aulast%3DChauhan%26aufirst%3DR.%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DLorenz%26aufirst%3DC.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DB%25C3%25BChrmann%26aufirst%3DM.%26aulast%3DPagel%26aufirst%3DO.%26aulast%3DTischler%26aufirst%3DV.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DSch%25C3%25BCtte%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DStark%26aufirst%3DJ.%26aulast%3DMrugalla%26aufirst%3DF.%26aulast%3DAlber%26aufirst%3DY.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLeenders%26aufirst%3DF.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DDiebold%26aufirst%3DJ.%26aulast%3DPall%26aufirst%3DG.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DAerts%26aufirst%3DM.%26aulast%3DGevaert%26aufirst%3DK.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DGautschi%26aufirst%3DO.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DDrugging%2520the%2520Catalytically%2520Inactive%2520State%2520of%2520RET%2520kinase%2520in%2520RET-Rearranged%2520Tumors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26spage%3Deaah6144%26doi%3D10.1126%2Fscitranslmed.aah6144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesen, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allali-Hassani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finerty, P. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasney, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span> <span> </span><span class="NLM_article-title">Chemical Screening Methods to Identify Ligands that Promote Protein Stability, Protein Crystallization, and Structure Determination</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">15835</span>– <span class="NLM_lpage">15840</span>, <span class="refDoi"> DOI: 10.1073/pnas.0605224103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1073%2Fpnas.0605224103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=17035505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFymur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=15835-15840&author=M.+Vedadiauthor=F.+H.+Niesenauthor=A.+Allali-Hassaniauthor=O.+Y.+Fedorovauthor=P.+J.+Finertyauthor=G.+A.+Wasneyauthor=R.+Yeungauthor=C.+Arrowsmithauthor=L.+J.+Ballauthor=H.+Berglundauthor=R.+Huiauthor=B.+D.+Marsdenauthor=P.+Nordlundauthor=M.+Sundstromauthor=J.+Weigeltauthor=A.+M.+Edwards&title=Chemical+Screening+Methods+to+Identify+Ligands+that+Promote+Protein+Stability%2C+Protein+Crystallization%2C+and+Structure+Determination&doi=10.1073%2Fpnas.0605224103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination</span></div><div class="casAuthors">Vedadi, Masoud; Niesen, Frank H.; Allali-Hassani, Abdellah; Fedorov, Oleg Y.; Finerty, Patrick J., Jr.; Wasney, Gregory A.; Yeung, Ron; Arrowsmith, Cheryl; Ball, Linda J.; Berglund, Helena; Hui, Raymond; Marsden, Brian D.; Nordlund, Paer; Sundstrom, Michael; Weigelt, Johan; Edwards, Aled M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">15835-15840</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The 3D structures of human therapeutic targets are enabling for drug discovery.  However, their purifn. and crystn. remain rate detg.  In individual cases, ligands have been used to increase the success rate of protein purifn. and crystn., but the broad applicability of this approach is unknown.  The authors implemented two screening platforms, based on either fluorometry or static light scattering, to measure the increase in protein thermal stability upon binding of a ligand without the need to monitor enzyme activity.  In total, 221 different proteins from humans and human parasites were screened against one or both of two sorts of small-mol. libraries.  The first library comprised different salts, pH conditions, and commonly found small mols. and was applicable to all proteins.  The second comprised compds. specific for protein families of particular interest (e.g., protein kinases).  In 20 cases, including nine unique human protein kinases, a small mol. was identified that stabilized the proteins and promoted structure detn.  The methods are cost-effective, can be implemented in any lab., promise to increase the success rates of purifying and crystg. human proteins significantly, and identify new ligands for these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4duhcFpFn-bVg90H21EOLACvtfcHk0ljynmoit-F1BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFymur%252FN&md5=6515225c1613291deb7bb774d900f605</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0605224103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0605224103%26sid%3Dliteratum%253Aachs%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DNiesen%26aufirst%3DF.%2BH.%26aulast%3DAllali-Hassani%26aufirst%3DA.%26aulast%3DFedorov%26aufirst%3DO.%2BY.%26aulast%3DFinerty%26aufirst%3DP.%2BJ.%26aulast%3DWasney%26aufirst%3DG.%2BA.%26aulast%3DYeung%26aufirst%3DR.%26aulast%3DArrowsmith%26aufirst%3DC.%26aulast%3DBall%26aufirst%3DL.%2BJ.%26aulast%3DBerglund%26aufirst%3DH.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DMarsden%26aufirst%3DB.%2BD.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DSundstrom%26aufirst%3DM.%26aulast%3DWeigelt%26aufirst%3DJ.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26atitle%3DChemical%2520Screening%2520Methods%2520to%2520Identify%2520Ligands%2520that%2520Promote%2520Protein%2520Stability%252C%2520Protein%2520Crystallization%252C%2520and%2520Structure%2520Determination%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D15835%26epage%3D15840%26doi%3D10.1073%2Fpnas.0605224103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakaoku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagatoishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span> <span> </span><span class="NLM_article-title">A Secondary RET Mutation in the Activation Loop Conferring Resistance to Vandetanib</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">625</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-02994-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fs41467-018-02994-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=29434222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A280%3ADC%252BC1MrgslSgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=625&author=T.+Nakaokuauthor=T.+Kohnoauthor=M.+Arakiauthor=S.+Nihoauthor=R.+Chauhanauthor=P.+P.+Knowlesauthor=K.+Tsuchiharaauthor=S.+Matsumotoauthor=Y.+Shimadaauthor=S.+Mimakiauthor=G.+Ishiiauthor=H.+Ichikawaauthor=S.+Nagatoishiauthor=K.+Tsumotoauthor=Y.+Okunoauthor=K.+Yohauthor=N.+Q.+McDonaldauthor=K.+Goto&title=A+Secondary+RET+Mutation+in+the+Activation+Loop+Conferring+Resistance+to+Vandetanib&doi=10.1038%2Fs41467-018-02994-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A secondary RET mutation in the activation loop conferring resistance to vandetanib</span></div><div class="casAuthors">Nakaoku Takashi; Kohno Takashi; Shimada Yoko; Kohno Takashi; Tsuchihara Katsuya; Matsumoto Shingo; Mimaki Sachiyo; Ichikawa Hitoshi; Araki Mitsugu; Araki Mitsugu; Okuno Yasushi; Niho Seiji; Matsumoto Shingo; Yoh Kiyotaka; Goto Koichi; Chauhan Rakhee; Knowles Phillip P; McDonald Neil Q; Ishii Genichiro; Nagatoishi Satoru; Tsumoto Kouhei; McDonald Neil Q</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">625</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment.  The resistant tumor acquired a secondary mutation resulting in a serine-to-phenylalanine substitution at codon 904 in the activation loop of the RET kinase domain.  The S904F mutation confers resistance to vandetanib by increasing the ATP affinity and autophosphorylation activity of RET kinase.  A reduced interaction with the drug is also observed in vitro for the S904F mutant by thermal shift assay.  A crystal structure of the S904F mutant reveals a small hydrophobic core around F904 likely to enhance basal kinase activity by stabilizing an active conformer.  Our findings indicate that missense mutations in the activation loop of the kinase domain are able to increase kinase activity and confer drug resistance through allosteric effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9xn_VdnX4Cf69nzq6467DfW6udTcc2ebOZpQRE6DZmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrgslSgtg%253D%253D&md5=0c9d8b569d55d00076026f20a7679a52</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-02994-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-02994-7%26sid%3Dliteratum%253Aachs%26aulast%3DNakaoku%26aufirst%3DT.%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DAraki%26aufirst%3DM.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DChauhan%26aufirst%3DR.%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DTsuchihara%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DMimaki%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DIchikawa%26aufirst%3DH.%26aulast%3DNagatoishi%26aufirst%3DS.%26aulast%3DTsumoto%26aufirst%3DK.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DYoh%26aufirst%3DK.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DGoto%26aufirst%3DK.%26atitle%3DA%2520Secondary%2520RET%2520Mutation%2520in%2520the%2520Activation%2520Loop%2520Conferring%2520Resistance%2520to%2520Vandetanib%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D625%26doi%3D10.1038%2Fs41467-018-02994-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsden, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">7604</span>– <span class="NLM_lpage">7614</span>, <span class="refDoi"> DOI: 10.1021/jm0504858</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0504858" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCltbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7604-7614&author=A.+N.+Bullockauthor=J.+E.+Debreczeniauthor=O.+Y.+Fedorovauthor=A.+Nelsonauthor=B.+D.+Marsdenauthor=S.+Knapp&title=Structural+Basis+of+Inhibitor+Specificity+of+the+Human+Protooncogene+Proviral+Insertion+Site+in+Moloney+Murine+Leukemia+Virus+%28PIM-1%29+Kinase&doi=10.1021%2Fjm0504858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase</span></div><div class="casAuthors">Bullock, Alex N.; Debreczeni, Judit E.; Fedorov, Oleg Y.; Nelson, Adam; Marsden, Brian D.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7604-7614</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The kinase PIM-1 plays a pivotal role in cytokine signaling and is implicated in the development of a no. of tumors.  The three-dimensional structure of PIM-1 is characterized by an unique hinge region which lacks a second hydrogen bond donor and makes it particularly important to det. how inhibitors bind to this kinase.  We detd. the structures of PIM-1 in complex with bisindolylmaleimide (BIM-1) and established the structure-activity relationship (SAR) for this inhibitor class.  In addn., we screened a kinase targeted library and identified a no. of high affinity inhibitors of PIM-1 such as imidazo[1,2-b]pyridazines, pyrazolo[1,5-a]pyrimidines, and members of the flavonoid family.  In this paper we present an initial SAR of the identified scaffolds detd. on the basis of a thermostability shift assay, calorimetric binding data, and biochem. assays which may find applications for the treatment of PIM-1 dependent cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp28lXmrIarT7Vg90H21EOLACvtfcHk0liCHSF9prXvFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCltbjL&md5=762eab52382fe72eed93e00ce37b390e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm0504858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0504858%26sid%3Dliteratum%253Aachs%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DFedorov%26aufirst%3DO.%2BY.%26aulast%3DNelson%26aufirst%3DA.%26aulast%3DMarsden%26aufirst%3DB.%2BD.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DStructural%2520Basis%2520of%2520Inhibitor%2520Specificity%2520of%2520the%2520Human%2520Protooncogene%2520Proviral%2520Insertion%2520Site%2520in%2520Moloney%2520Murine%2520Leukemia%2520Virus%2520%2528PIM-1%2529%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7604%26epage%3D7614%26doi%3D10.1021%2Fjm0504858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kufareva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abagyan, R.</span></span> <span> </span><span class="NLM_article-title">Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7921</span>– <span class="NLM_lpage">7932</span>, <span class="refDoi"> DOI: 10.1021/jm8010299</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010299" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7921-7932&author=I.+Kufarevaauthor=R.+Abagyan&title=Type-II+Kinase+Inhibitor+Docking%2C+Screening%2C+and+Profiling+Using+Modified+Structures+of+Active+Kinase+States&doi=10.1021%2Fjm8010299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States</span></div><div class="casAuthors">Kufareva, Irina; Abagyan, Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7921-7932</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Type-II kinase inhibitors represent a class of chems. that trap their target kinases in an inactive, so-called DFG-out state, occupying a hydrophobic pocket adjacent to the ATP binding site.  These compds. are often more specific than those that target active DFG-in kinase conformations.  Unfortunately, the discovery of novel type-II scaffolds presents a considerable challenge, partially because the lack of compatible kinase structures makes structure-based methods inapplicable.  We present a computational protocol for converting multiple available DFG-in structures of various kinases (∼70% of mammalian structural kinome) into accurate and specific models of their type-II bound state.  The models, described as deletion-of-loop Asp-Phe-Gly-in (DOLPHIN) kinase models, demonstrate exceptional performance in various inhibitor discovery applications, including compd. pose prediction, screening, and in silico activity profiling.  Given the abundance of the DFG-in structures, the presented approach opens possibilities for kinome-wide discovery of specific mols. targeting inactive kinase states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp699dzZf5YRLVg90H21EOLACvtfcHk0liCHSF9prXvFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWisb%252FK&md5=64fb7b9f789940dd61c68015341af4a6</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm8010299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010299%26sid%3Dliteratum%253Aachs%26aulast%3DKufareva%26aufirst%3DI.%26aulast%3DAbagyan%26aufirst%3DR.%26atitle%3DType-II%2520Kinase%2520Inhibitor%2520Docking%252C%2520Screening%252C%2520and%2520Profiling%2520Using%2520Modified%2520Structures%2520of%2520Active%2520Kinase%2520States%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7921%26epage%3D7932%26doi%3D10.1021%2Fjm8010299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plaza-Menacho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnouin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Torres, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Rust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouilleron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span> <span> </span><span class="NLM_article-title">Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation in Trans</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2014.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2Fj.molcel.2014.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=24560924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFCku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=738-751&author=I.+Plaza-Menachoauthor=K.+Barnouinauthor=K.+Goodmanauthor=R.+J.+Mart%C3%ADnez-Torresauthor=A.+Borgauthor=J.+Murray-Rustauthor=S.+Mouilleronauthor=P.+Knowlesauthor=N.+Q.+McDonald&title=Oncogenic+RET+Kinase+Domain+Mutations+Perturb+the+Autophosphorylation+Trajectory+by+Enhancing+Substrate+Presentation+in+Trans&doi=10.1016%2Fj.molcel.2014.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans</span></div><div class="casAuthors">Plaza-Menacho, Ivan; Barnouin, Karin; Goodman, Kerry; Martinez-Torres, Ruben J.; Borg, Annabel; Murray-Rust, Judith; Mouilleron, Stephane; Knowles, Phillip; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">738-751</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To decipher the mol. basis for RET kinase activation and oncogenic deregulation, we defined the temporal sequence of RET autophosphorylation by label-free quant. mass spectrometry.  Early autophosphorylation sites map to regions flanking the kinase domain core, while sites within the activation loop only form at later time points.  Comparison with oncogenic RET kinase revealed that late autophosphorylation sites become phosphorylated much earlier than wild-type RET, which is due to a combination of an enhanced enzymic activity, increased ATP affinity, and surprisingly, by providing a better intermol. substrate.  Structural anal. of oncogenic M918T and wild-type RET kinase domains reveal a cis-inhibitory mechanism involving tethering contacts between the glycine-rich loop, activation loop, and αC-helix.  Tether mutations only affected substrate presentation but perturbed the autophosphorylation trajectory similar to oncogenic mutations.  This study reveals an unappreciated role for oncogenic RET kinase mutations in promoting intermol. autophosphorylation by enhancing substrate presentation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNqTC9t3FwObVg90H21EOLACvtfcHk0liCHSF9prXvFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFCku7c%253D&md5=ebac0e5fec3e9f67cfa18730b0a5e84e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2014.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2014.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DBarnouin%26aufirst%3DK.%26aulast%3DGoodman%26aufirst%3DK.%26aulast%3DMart%25C3%25ADnez-Torres%26aufirst%3DR.%2BJ.%26aulast%3DBorg%26aufirst%3DA.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DMouilleron%26aufirst%3DS.%26aulast%3DKnowles%26aufirst%3DP.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DOncogenic%2520RET%2520Kinase%2520Domain%2520Mutations%2520Perturb%2520the%2520Autophosphorylation%2520Trajectory%2520by%2520Enhancing%2520Substrate%2520Presentation%2520in%2520Trans%26jtitle%3DMol.%2520Cell%26date%3D2014%26volume%3D53%26spage%3D738%26epage%3D751%26doi%3D10.1016%2Fj.molcel.2014.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitayama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furitsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oritani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, Y.</span></span> <span> </span><span class="NLM_article-title">Constitutively Activating Mutations of C-Kit Receptor Tyrosine Kinase Confer Factor-Independent Growth and Tumorigenicity of Factor-Dependent Hematopoietic Cell Lines</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">790</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1182/blood.V85.3.790.bloodjournal853790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1182%2Fblood.V85.3.790.bloodjournal853790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=7530509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADyaK2MXjtlCqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1995&pages=790-798&author=H.+Kitayamaauthor=Y.+Kanakuraauthor=T.+Furitsuauthor=T.+Tsujimuraauthor=K.+Oritaniauthor=H.+Ikedaauthor=H.+Sugaharaauthor=H.+Mitsuiauthor=Y.+Kanayamaauthor=Y.+Kitamura&title=Constitutively+Activating+Mutations+of+C-Kit+Receptor+Tyrosine+Kinase+Confer+Factor-Independent+Growth+and+Tumorigenicity+of+Factor-Dependent+Hematopoietic+Cell+Lines&doi=10.1182%2Fblood.V85.3.790.bloodjournal853790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines</span></div><div class="casAuthors">Kitayama, Hitoshi; Kanakura, Yuzuru; Furitsu, Takuma; Tsujimura, Tohru; Oritani, Kenji; Ikeda, Hirokazu; Sugahara, Hiroyuki; Mitsui, Hideki; Kanayama, Yoshio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">790-8</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">The c-kit receptor tyrosine kinase (KIT) is activated upon ligand binding, thereby leading to a variety of signaling events that play a fundamental role in hematopoiesis.  In addn. to ligand-dependent activation, we have previously shown that KIT is constitutively activated in a ligand-independent manner by two-point mutations, Val-559 → Gly (G559) mutation in the juxtamembrane domain and Asp-814 → Val (V814) mutation in the phosphotransferase domain.  To investigate the biochem. consequence and biol. significance of these mutations, retroviral vectors encoding KITG559 or KITV814 were introduced into murine pro-B-type Ba/F3 cells and myeloid FDC-P1 cells, both of which require interleukin-3 (IL-3) for their growth and survival.  In the cells, KITG559 or KITV814 were found to be constitutively phosphorylated on tyrosine in the absence of stem cell factor (SCF) that is a ligand for KIT.  Chem. crosslinking anal. showed that a substantial fraction of the phosphorylated KITG559 underwent dimerization even in the absence of SCF, whereas the phosphorylated KITV814 did not, suggesting the distinct mechanisms underlying constitutive activation of KIT by G559 and V814 mutations.  Furthermore, the cells expressing either KITG559 or KITV814 were found to show a factor-independent growth, whereas the cells expressing wild-type KIT (KITWT) proliferated in response to SCF as well as IL-3.  Moreover, s.c. injection of Ba/F3 cells expressing KITG559 or KITV814 into nude mice resulted in prodn. of large tumors at all sites of the injection within 2 wk, and all nude mice quickly succumbed to leukemia and died.  These results suggest that, although the mechanisms underlying constitutive activation of KITG559 or KITV814 may be different, both of the activating mutations have a function to induce a factor-independent and tumorigenic phenotype.  Also, the data of this study raise the possibility that the constitutively activating mutations of c-kit may play a causal role in development of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraa_gnNjI0kbVg90H21EOLACvtfcHk0lgKFP5k5eD6wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtlCqur4%253D&md5=f932500323514ebe817c62f64b98bb90</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood.V85.3.790.bloodjournal853790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V85.3.790.bloodjournal853790%26sid%3Dliteratum%253Aachs%26aulast%3DKitayama%26aufirst%3DH.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DFuritsu%26aufirst%3DT.%26aulast%3DTsujimura%26aufirst%3DT.%26aulast%3DOritani%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DSugahara%26aufirst%3DH.%26aulast%3DMitsui%26aufirst%3DH.%26aulast%3DKanayama%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DConstitutively%2520Activating%2520Mutations%2520of%2520C-Kit%2520Receptor%2520Tyrosine%2520Kinase%2520Confer%2520Factor-Independent%2520Growth%2520and%2520Tumorigenicity%2520of%2520Factor-Dependent%2520Hematopoietic%2520Cell%2520Lines%26jtitle%3DBlood%26date%3D1995%26volume%3D85%26spage%3D790%26epage%3D798%26doi%3D10.1182%2Fblood.V85.3.790.bloodjournal853790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkaniga, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunaganti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span> <span> </span><span class="NLM_article-title">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1731</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01092</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01092" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Khur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1731-1760&author=W.+Yanauthor=N.+R.+Lakkanigaauthor=F.+Carlomagnoauthor=M.+Santoroauthor=N.+Q.+McDonaldauthor=F.+Lvauthor=N.+Gunagantiauthor=B.+Frettauthor=H.+Y.+Li&title=Insights+into+Current+Tropomyosin+Receptor+Kinase+%28TRK%29+Inhibitors%3A+Development+and+Clinical+Application&doi=10.1021%2Facs.jmedchem.8b01092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application</span></div><div class="casAuthors">Yan, Wei; Lakkaniga, Naga Rajiv; Carlomagno, Francesca; Santoro, Massimo; McDonald, Neil Q.; Lv, Fengping; Gunaganti, Naresh; Frett, Brendan; Li, Hong-yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1731-1760</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib.  Annually, it is estd. that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement.  In this Perspective, we discuss current development and clin. applications for TRK precision medicine by providing the following: (1) the biol. background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and anal. of their cocrystal structures, (3) an overview of TRK clin. trials, and (4) future perspectives for drug discovery and development of TRK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwUthQyJEzFrVg90H21EOLACvtfcHk0lgKFP5k5eD6wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Khur%252FO&md5=5ce2f8d295cf46f84b46f5890dad0160</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01092%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DW.%26aulast%3DLakkaniga%26aufirst%3DN.%2BR.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DGunaganti%26aufirst%3DN.%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.%2BY.%26atitle%3DInsights%2520into%2520Current%2520Tropomyosin%2520Receptor%2520Kinase%2520%2528TRK%2529%2520Inhibitors%253A%2520Development%2520and%2520Clinical%2520Application%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1731%26epage%3D1760%26doi%3D10.1021%2Facs.jmedchem.8b01092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+MAP+Kinase+by+Utilizing+a+Novel+Allosteric+Binding+Site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0lgKFP5k5eD6wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520MAP%2520Kinase%2520by%2520Utilizing%2520a%2520Novel%2520Allosteric%2520Binding%2520Site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Rust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibáñez, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, N. Q.</span></span> <span> </span><span class="NLM_article-title">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">33577</span>– <span class="NLM_lpage">33587</span>, <span class="refDoi"> DOI: 10.1074/jbc.M605604200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kjaerauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ib%C3%A1%C3%B1ezauthor=N.+Q.+McDonald&title=Structure+and+Chemical+Inhibition+of+the+RET+Tyrosine+Kinase+Domain&doi=10.1074%2Fjbc.M605604200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0li4bVDlWiiMlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIb%25C3%25A1%25C3%25B1ez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520Chemical%2520Inhibition%2520of%2520the%2520RET%2520Tyrosine%2520Kinase%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587%26doi%3D10.1074%2Fjbc.M605604200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geneste, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlumberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudkin, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuffenecker, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billaud, M.</span></span> <span> </span><span class="NLM_article-title">Oncogenic Activation of RET by Two Distinct FMTC Mutations Affecting the Tyrosine Kinase Domain</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1201199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1038%2Fsj.onc.1201199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=9242375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADyaK2sXlt1Sqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1997&pages=393-402&author=A.+Pasiniauthor=O.+Genesteauthor=P.+Legrandauthor=M.+Schlumbergerauthor=M.+Rosselauthor=L.+Fournierauthor=B.+B.+Rudkinauthor=I.+Schuffeneckerauthor=G.+M.+Lenoirauthor=M.+Billaud&title=Oncogenic+Activation+of+RET+by+Two+Distinct+FMTC+Mutations+Affecting+the+Tyrosine+Kinase+Domain&doi=10.1038%2Fsj.onc.1201199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain</span></div><div class="casAuthors">Pasini, Andrea; Geneste, Olivier; Legrand, Pierre; Schlumberger, Martin; Rossel, Mireille; Fournier, Laurence; Rudkin, Brian B.; Schuffenecker, Isabelle; Lenoir, Gilbert M.; Billaud, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-402</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Stockton</span>)
        </div><div class="casAbstract">Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are two dominantly inherited disorders caused by germline mutations of the RET proto-oncogene.  The RET gene codes for a receptor tyrosine kinase.  The majority of MEN2A and FMTC mutations are clustered in the extra-cellular cysteine-rich domain and result in constitutive activation of the tyrosine kinase through the formation of disulfide-bonded RET homodimers.  Recently, two novel point mutations have been identified in the germline of five distinct FMTC families.  Both mutations occur within the catalytic domain of the RET kinase and lead to the substitution of either glutamic acid 768 or valine 804 by an aspartic acid and a leucine resp.  The authors have introduced each FMTC mutation in two RET isoforms: RET51 the long isoform (1114 aa) and RET9 the short isoform (1072 aa) which differ in the C-terminal region of the protein.  The RET51 isoform carrying either E768D or V804L mutation was autophosphorylated, displayed a transforming activity upon expression in Rat1 fibroblasts and induced neuronal differentiation of PC12 cells.  However, the transforming capacity of these RET51-FMTC mutants was severalfold less potent compared to the same isoform carrying either the MEN2A mutation (C634R) or the MEN2B mutation (M918T).  In contrast, RET9 contg. mutations E768D or V804L was not autophosphorylated, exhibited a poor oncogenic potential in fibroblasts and did not promote neuritic outgrowth upon expression in PC12 cells.  Overall, these findings demonstrate that mutations E768D and V804L are gain-of-function mutations that confer to the long RET isoform the capacity to exert a biol. effect, although these mutations are more weakly activating than the MEN2A and MEN2B mutations.  These results may provide a biochem. basis as to why the phenotypic consequences of these mutations are restricted to thyroid C-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqela5Vlh60QrVg90H21EOLACvtfcHk0li4bVDlWiiMlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlt1Sqtbg%253D&md5=96747637bd386fed52375064de2af4f8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1201199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1201199%26sid%3Dliteratum%253Aachs%26aulast%3DPasini%26aufirst%3DA.%26aulast%3DGeneste%26aufirst%3DO.%26aulast%3DLegrand%26aufirst%3DP.%26aulast%3DSchlumberger%26aufirst%3DM.%26aulast%3DRossel%26aufirst%3DM.%26aulast%3DFournier%26aufirst%3DL.%26aulast%3DRudkin%26aufirst%3DB.%2BB.%26aulast%3DSchuffenecker%26aufirst%3DI.%26aulast%3DLenoir%26aufirst%3DG.%2BM.%26aulast%3DBillaud%26aufirst%3DM.%26atitle%3DOncogenic%2520Activation%2520of%2520RET%2520by%2520Two%2520Distinct%2520FMTC%2520Mutations%2520Affecting%2520the%2520Tyrosine%2520Kinase%2520Domain%26jtitle%3DOncogene%26date%3D1997%26volume%3D15%26spage%3D393%26epage%3D402%26doi%3D10.1038%2Fsj.onc.1201199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushijima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagao, M.</span></span> <span> </span><span class="NLM_article-title">cDNA Cloning and Characterization of Ret Activated in a Human Papillary Thyroid Carcinoma Cell Line</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(90)92335-W</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1016%2F0006-291X%2890%2992335-W" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=2334411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADyaK3cXktFyrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=1990&pages=402-408&author=Y.+Ishizakaauthor=T.+Ushijimaauthor=T.+Sugimuraauthor=M.+Nagao&title=cDNA+Cloning+and+Characterization+of+Ret+Activated+in+a+Human+Papillary+Thyroid+Carcinoma+Cell+Line&doi=10.1016%2F0006-291X%2890%2992335-W"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line</span></div><div class="casAuthors">Ishizaka, Yukihito; Ushijima, Toshikazu; Sugimura, Takashi; Nagao, Minako</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">402-8</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">Activated ret cDNAs (retTPC) were obtained from human papillary thyroid carcinoma cell line, TPC-1, and their structures were characterized.  The nucleotide sequence indicated that recombination had occurred just upstream of the kinase domain of the ret proto-oncogene and that the position, where the conserved sequence of the ret proto-oncogene starts in retTPC transcripts, was exactly the same as that of ret-II which was previously analyzed.  Furthermore, a unique 13-glycine stretch, which is also present in a small subunit of the calcium-dependent protease, calpain, was detected in the replaced sequence of retTPC.  The aberrant tyrosine kinase activity induced by the rearrangement of ret protooncogene could be involved in the development of papillary thyroid carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZAA0q8KYZNrVg90H21EOLACvtfcHk0li4bVDlWiiMlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktFyrtbc%253D&md5=81e59bfc46e5a8e6036c0d7da7683fcb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2890%2992335-W&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252890%252992335-W%26sid%3Dliteratum%253Aachs%26aulast%3DIshizaka%26aufirst%3DY.%26aulast%3DUshijima%26aufirst%3DT.%26aulast%3DSugimura%26aufirst%3DT.%26aulast%3DNagao%26aufirst%3DM.%26atitle%3DcDNA%2520Cloning%2520and%2520Characterization%2520of%2520Ret%2520Activated%2520in%2520a%2520Human%2520Papillary%2520Thyroid%2520Carcinoma%2520Cell%2520Line%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1990%26volume%3D168%26spage%3D402%26epage%3D408%26doi%3D10.1016%2F0006-291X%2890%2992335-W" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Franciscis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panariello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colantuoni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusco, A.</span></span> <span> </span><span class="NLM_article-title">Point Mutation of the RET Proto-Oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>207</i></span>,  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1995.1287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1006%2Fbbrc.1995.1287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=7864888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADyaK2MXjvVyqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=1995&pages=1022-1028&author=F.+Carlomagnoauthor=D.+Salvatoreauthor=M.+Santoroauthor=V.+de+Franciscisauthor=L.+Quadroauthor=L.+Panarielloauthor=V.+Colantuoniauthor=A.+Fusco&title=Point+Mutation+of+the+RET+Proto-Oncogene+in+the+TT+Human+Medullary+Thyroid+Carcinoma+Cell+Line&doi=10.1006%2Fbbrc.1995.1287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line</span></div><div class="casAuthors">Carlomagno, Francesca; Salvatore, Domenico; Santoro, Massimo; de Franciscis, Vittorio; Quadro, Loredana; Panariello, Luigi; Colantuoni, Vittorio; Fusco, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1022-8</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a tyrosine-kinase receptor specifically expressed in tissues of neuroectodermal origin.  Recently specific point mutations of RET have been demonstrated to be responsible for the Multiple Endocrine Neoplasia type 2A and 2B and Familial Medullary Thyroid Carcinoma syndromes, characterized by the occurrence of medullary thyroid carcinomas.  Here we report that a human medullary thyroid carcinoma cell line, the TT cell line, harbours a MEN2A-type mutation, specifically a cysteine to triptophan substitution at the level of the RET codon 634.  This mutation is heterozygous and both normal and mutated alleles are expressed.  We suggest that the TT cell line could be a useful cell system to investigate the role played by the RET oncogene in the transformation and differentiation of human thyroid C-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0Ot8w4LkPbbVg90H21EOLACvtfcHk0li4bVDlWiiMlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjvVyqs74%253D&md5=580b07bb815deef0181f8d378e6d9ca0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1995.1287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1995.1287%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSalvatore%26aufirst%3DD.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3Dde%2BFranciscis%26aufirst%3DV.%26aulast%3DQuadro%26aufirst%3DL.%26aulast%3DPanariello%26aufirst%3DL.%26aulast%3DColantuoni%26aufirst%3DV.%26aulast%3DFusco%26aufirst%3DA.%26atitle%3DPoint%2520Mutation%2520of%2520the%2520RET%2520Proto-Oncogene%2520in%2520the%2520TT%2520Human%2520Medullary%2520Thyroid%2520Carcinoma%2520Cell%2520Line%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D207%26spage%3D1022%26epage%3D1028%26doi%3D10.1006%2Fbbrc.1995.1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makinoshima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchihara, K.</span></span> <span> </span><span class="NLM_article-title">Identification of a Lung Adenocarcinoma Cell Line with CCDC6-RET Fusion Gene and the Effect of RET Inhibitors in Vitro and in Vivo</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1111/cas.12175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1111%2Fcas.12175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=23578175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFGmsbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=896-903&author=M.+Suzukiauthor=H.+Makinoshimaauthor=S.+Matsumotoauthor=A.+Suzukiauthor=S.+Mimakiauthor=K.+Matsushimaauthor=K.+Yohauthor=K.+Gotoauthor=Y.+Suzukiauthor=G.+Ishiiauthor=A.+Ochiaiauthor=K.+Tsutaauthor=T.+Shibataauthor=T.+Kohnoauthor=H.+Esumiauthor=K.+Tsuchihara&title=Identification+of+a+Lung+Adenocarcinoma+Cell+Line+with+CCDC6-RET+Fusion+Gene+and+the+Effect+of+RET+Inhibitors+in+Vitro+and+in+Vivo&doi=10.1111%2Fcas.12175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo</span></div><div class="casAuthors">Suzuki, Makito; Makinoshima, Hideki; Matsumoto, Shingo; Suzuki, Ayako; Mimaki, Sachiyo; Matsushima, Koutatsu; Yoh, Kiyotaka; Goto, Koichi; Suzuki, Yutaka; Ishii, Genichiro; Ochiai, Atsushi; Tsuta, Koji; Shibata, Tatsuhiro; Kohno, Takashi; Esumi, Hiroyasu; Tsuchihara, Katsuya</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">896-903</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Rearrangements of the proto-oncogene RET are newly identified potential driver mutations in lung adenocarcinoma (LAD).  However, the absence of cell lines harboring RET fusion genes has hampered the investigation of the biol. relevance of RET and the development of RET-targeted therapy.  Thus, we aimed to identify a RET fusion pos. LAD cell line.  Eleven LAD cell lines were screened for RET fusion transcripts by reverse transcription-polymerase chain reaction.  The biol. relevance of the CCDC6-RET gene products was assessed by cell growth, survival and phosphorylation of ERK1/2 and AKT with or without the suppression of RET expression using RNA interference.  The efficacy of RET inhibitors was evaluated in vitro using a culture system and in an in vivo xenograft model.  Expression of the CCDC6-RET fusion gene in LC-2/ad cells was demonstrated by the mRNA and protein levels, and the genomic break-point was confirmed by genomic DNA sequencing.  Mutations in KRAS and EGFR were not obsd. in the LC-2/ad cells.  CCDC6-RET was constitutively active, and the introduction of a siRNA targeting the RET 3' region decreased cell proliferation by downregulating RET and ERK1/2 phosphorylation.  Moreover, treatment with RET-inhibitors, including vandetanib, reduced cell viability, which was accompanied by the downregulation of the AKT and ERK1/2 signaling pathways.  Vandetanib exhibited anti-tumor effects in the xenograft model.  Endogenously expressing CCDC6-RET contributed to cell growth.  The inhibition of kinase activity could be an effective treatment strategy for LAD.  LC-2/ad is a useful model for developing fusion RET-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozFPtfC_fKsLVg90H21EOLACvtfcHk0lg4u6C70kctDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFGmsbfN&md5=f226982ebc36869700c45b23ee6bfac7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fcas.12175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.12175%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DMakinoshima%26aufirst%3DH.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DMimaki%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DK.%26aulast%3DYoh%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DG.%26aulast%3DOchiai%26aufirst%3DA.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DEsumi%26aufirst%3DH.%26aulast%3DTsuchihara%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520a%2520Lung%2520Adenocarcinoma%2520Cell%2520Line%2520with%2520CCDC6-RET%2520Fusion%2520Gene%2520and%2520the%2520Effect%2520of%2520RET%2520Inhibitors%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DCancer%2520Sci.%26date%3D2013%26volume%3D104%26spage%3D896%26epage%3D903%26doi%3D10.1111%2Fcas.12175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitagliano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellone, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span> <span> </span><span class="NLM_article-title">Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1897</span>– <span class="NLM_lpage">1902</span>, <span class="refDoi"> DOI: 10.1210/jc.2002-021278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=10.1210%2Fjc.2002-021278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=12679489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFCltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=1897-1902&author=F.+Carlomagnoauthor=D.+Vitaglianoauthor=T.+Guidaauthor=F.+Basoloauthor=M.+D.+Castelloneauthor=R.+M.+Melilloauthor=A.+Fuscoauthor=M.+Santoro&title=Efficient+Inhibition+of+RET%2FPapillary+Thyroid+Carcinoma+Oncogenic+Kinases+by+4-amino-5-%284-chloro-phenyl%29-7-%28t-butyl%29pyrazolo%5B3%2C4-d%5Dpyrimidine+%28PP2%29&doi=10.1210%2Fjc.2002-021278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Comment: Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)</span></div><div class="casAuthors">Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Basolo, Fulvio; Castellone, Maria Domenica; Melillo, Rosa Marina; Fusco, Alfredo; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1897-1902</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Inappropriate activation of the RET receptor tyrosine kinase causes development of papillary and medullary thyroid cancer.  We have previously shown that pyrazolopyrimidine is a potent inhibitor of the RET kinase.  Here, we show that 4-amino-5-(4-chloro-phenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2), another pyrazolopyrimidine, blocks the enzymic activity of the isolated RET kinase and RET/PTC1 oncoprotein at IC50 in the nanomolar range.  PP2 blocked in vivo phosphorylation and signaling of the RET/PTC1 oncoprotein.  PP2 prevented serum-independent growth of RET/PTC1-transformed NIH3T3 fibroblasts and of TPC1 and FB2, two human papillary thyroid carcinoma cell lines that carry spontaneous RET/PTC1 rearrangements.  Finally, PP2 blocked invasion of type 1 collagen matrix by TPC1 cells.  Thus, pyrazolopirimidines hold promise for the treatment of human cancers sustaining oncogenic activation of RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaaPru7feflrVg90H21EOLACvtfcHk0lg4u6C70kctDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFCltLc%253D&md5=4e207efc7c20be1fa2bc3439ff2ef257</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1210%2Fjc.2002-021278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2002-021278%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DVitagliano%26aufirst%3DD.%26aulast%3DGuida%26aufirst%3DT.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DCastellone%26aufirst%3DM.%2BD.%26aulast%3DMelillo%26aufirst%3DR.%2BM.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DEfficient%2520Inhibition%2520of%2520RET%252FPapillary%2520Thyroid%2520Carcinoma%2520Oncogenic%2520Kinases%2520by%25204-amino-5-%25284-chloro-phenyl%2529-7-%2528t-butyl%2529pyrazolo%255B3%252C4-d%255Dpyrimidine%2520%2528PP2%2529%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2003%26volume%3D88%26spage%3D1897%26epage%3D1902%26doi%3D10.1210%2Fjc.2002-021278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OH4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OH4','PDB','2OH4'); return false;">PDB: 2OH4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3WZE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3WZE','PDB','3WZE'); return false;">PDB: 3WZE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVU','PDB','2IVU'); return false;">PDB: 2IVU</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i19"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01336">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_38837"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01336?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01336</a>. <ul class="NLM_list-list_type-label"><li><p class="inline">Molecular formula string of NPA101.3 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_001.csv">CSV</a>)</p></li><li><p class="inline">Additional data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Supplementary Methods, Tables S1–S4, and Figures S1–S14 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_003.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_001.csv">jm9b01336_si_001.csv (0.33 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_002.pdb">jm9b01336_si_002.pdb (189.35 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01336/suppl_file/jm9b01336_si_003.pdf">jm9b01336_si_003.pdf (1.25 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">VEGFR2 DFG-out crystal structure, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2OH4">2OH4</a>; amino acid sequence of RET, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVU">2IVU</a>; Sorafenib in the VEGFR2 DFG-out crystal structure, PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3WZE">3WZE</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01336&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-9%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01336%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01336" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677adc51ee65d1c3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
